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The present thesis focuses on relapse-preventive efforts during psychotherapy to 
sustain long-term remission in depressed individuals being at high risk for relapse and 
recurrence. Relapse prevention in the context of this thesis includes providing of continuation 
and maintenance treatments as well as enhancing transfer of therapy achievements into time 
after termination of therapy. The first study determined current evidence on psychological and 
pharmacological continuation and maintenance treatments in individuals suffering from 
persistent depressive disorder within a systematic review and meta-analysis, showing that 
only a few studies are available in this field. Therefore, we piloted a telephone-based 
continuation therapy for high-risk depressed individuals to assess feasibility and acceptance of 
this low-intensity intervention within the second study, applying an exploratory mixed-
methods approach combining qualitative and quantitative data to obtain in-depth 
understanding of the intervention’s new components. If several preconditions including low 
level of depressive symptoms and effective coping strategies are ensured, the intervention is 
considered feasible and accepted. The third study explored relapse-preventive efforts during 
psychotherapy, which focus on the implementation of strategies into patient’s daily routines. 
For this purpose, we developed an observer-based rating instrument called the KERI-D 
(Coding System to Assess Interventions of Relapse Prevention in Depression), which showed 
sufficient inter-rater and retest reliabilities, and moreover, first evidence of content validity 








Diese Dissertation fokussiert auf psychotherapeutische Behandlungsmöglichkeiten, 
die darauf abzielen rückfallgefährdeten Depressionspatienten auf lange Sicht ein Leben in 
Remission zu ermöglichen. Rückfallprophylaxe in diesem Kontext schliesst sowohl das 
Bereitstellen und die Inanspruchnahme von Erhaltungstherapien und Rezidivprophylaxe ein, 
als auch den verbesserten Transfer vom in der Therapie Erlernten in den (behandlungsfreien) 
Alltag. Die erste Studie schätzt in Form eines systematischen Reviews und einer Meta-
Analyse die aktuelle Befundlage zu psychologischen und pharmakologischen 
Erhaltungstherapien und Rezidivprophylaxe bei Personen mit persistierender Depression ein, 
wobei nur wenige Studien in diesem Bereich existieren. Daher wurde innerhalb der zweiten 
Studie eine telefongestützte Erhaltungstherapie für Depressionspatienten mit erhöhtem 
Rückfallrisiko pilotiert. Die Akzeptanz und Machbarkeit der neuen Komponenten dieser 
Behandlung wurde, basierend auf der Kombination von qualitativen und quantitativen Daten, 
durch beteiligte Patienten und Therapeuten eingeschätzt. Die Intervention scheint 
durchführbar und akzeptiert zu sein, wenn gewisse Rahmenbedingungen wie tiefer 
Symptomstatus und wirkungsvolle Copingstrategien sichergestellt werden. Die dritte Studie 
hat rückfallprophylaktische Behandlungsbausteine untersucht, die auf die Implementierung 
des in der Psychotherapie Erlernten in den Alltag des Patienten fokussieren. Dazu haben wir 
ein Ratinginstrument entwickelt (KERI-D: Kodierbogen zur Erfassung 
Rückfallprophylaktischer Interventionen bei Depression), welches zufriedenstellende 
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Depressive disorders are associated with a high risk of relapse and recurrence [1], 
especially if kept untreated [2]. Reasons for the recurrent and persistent nature of depression 
are focus of scientific inquiry for decades, including factors associated with the patient (e.g., 
genetic vulnerability, cognitions) [1] and factors located within the health care system (e.g., 
availability and application of evidence-based treatments) [3]. Several interventions for 
depression treatment (e.g., antidepressant medication, psychotherapy, and their combination) 
were developed and evaluated for their feasibility and effectiveness within large and well 
conducted trials to date [4]. However, most of these studies address episodic forms of 
depression during the acute treatment phase. Despite promising short-term results of such 
acute phase interventions we are confronted with the problem that studies also show that 30-
50% of depressive disorders are turning chronic during the course of an individual’s lifetime 
[5]. This allows for discussion whether or not the current treatment concepts can prevent 
relapse and recurrence in the long-term.  
Whilst providing interventions during the acute treatment phase is currently the way of 
care which is mostly provided, long-term continuation and maintenance treatment might be 
required for individuals who are at high risk for relapse or recurrence of symptoms [6]. 
Continuation treatments are provided to currently remitted patients or to patients who 
previously responded to treatment, and maintenance treatments are given only during 
recovery, which is defined as remission lasting longer than six months [7, 8]. Most studies to 
date investigate pharmacological long-term treatments assuming relapse preventive effects in 
high-risk individuals. At the same time, patients report on severe side-effects resulting in 
discontinuing antidepressant medication without the doctor’s agreement, which in turn 
increases likelihood of relapse [9]. Psychological long-term interventions can meet this 





adverse events [10]. Moreover, as individuals with recurrent or persistent depression 
commonly take antidepressant medication, psychotherapy might support relevance and 
continuous intake of drugs.  
As outlined above, several attempts to meet the recurrent and persistent character of 
depression had been made in the past, mostly focusing on short-term acute phase treatments 
and pharmacological interventions. With respect to high relapse and recurrence rates, this 
thesis will address relapse-preventive efforts of treatments for depressive disorders to sustain 
remission and recovery in the long-term. All three studies presented in this thesis take the 
potential recurrent or persistent character of depression into account by investigating the form 
and impact of continuation and maintenance treatments in high-risk individuals. Moreover, 
relapse-preventive elements implemented during psychotherapy, which encourage the patient 
to transfer therapy achievements into time after termination of treatment or to long-term 
treatments will be considered.  
Core concepts of relapse prevention and current evidence on according treatment 
options in several forms of depressive disorder are presented in chapter 2. Specific research 
questions underlying the aim of the three studies of this thesis will be presented in chapter 3, 
followed by displaying each of the studies in chapter 4. Study 1 illustrates the current 
evidence on the general effectiveness of continuation and maintenance treatments for 
individuals suffering from persistent depressive disorder by means of a systematic review and 
meta-analysis. Study 2 addresses the question if a telephone-based continuation 
psychotherapy is feasible and accepted by therapists and their patients suffering from 
recurrent or persistent depression. Finally, study 3 focuses on relapse-preventive efforts 
initiated by therapists during psychotherapy, which might contribute to the relapse-preventive 





2 Theoretical background 
2.1  Depression is a recurrent and persistent disorder  
Depressive disorders are associated with a high risk of relapse and recurrence [1] 
especially if kept untreated [2]. Moreover, relapse and recurrence rates remain high even with 
evidence-based treatments [11, 12]. Studies indicate that approximately 50% of individuals 
who recovered from an initial depressive episode will experience one or more further episodes 
in the future, and that such recurrent episodes will usually begin within five years after the 
initial episode had occurred [13, 14]. Moreover, it is estimated that individuals with a history 
of depressive disorder will experience between five and nine episodes in their lifetime [15, 
16]. Regarding persistent forms of depression, the mean duration of illness is between 17 and 
30 years [17, 18], and lifetime prevalence is estimated to range from 3% to 6% in the Western 
world [19–21]. Thus, research focusing on the prevention of relapse and recurrence of 
depression was identified as a top priority [22].  
The one big question researchers have been interested in for decades is “Why do 
individuals relapse?”, and obviously, there are several different factors discussed to be 
accountable for the recurrent or persistent character of this illness. The most pessimistic 
explanation strikes the illness itself and states that depressive disorders are recurrent or 
persistent by nature [1]. This hypothesis assumes that affected individuals may have an 
underlying (genetic) vulnerability, and that those individuals with high vulnerability might be 
predisposed to experience recurrent depressive episodes. Greater family history of 
psychopathology, more comorbidities and more severe initial episodes of depression might 
also reflect a genetic vulnerability in individuals affected by recurrent and chronic forms of 
depression besides environmental influences [23]. In this regard, the diagnosis of a 
“Depressive Personality Disorder” (DPD) has been discussed for many years to account for 





recurrent or chronic course [24]. Due to a conceptual overlap with the already established 
diagnosis of dysthymia, DPD was not considered a distinct diagnosis in the Diagnostic and 
Statistical Manual of Mental Disorders [13, 25], although there is open discussion if DPD 
could better account for underlying depressive cognitive and intrapsychic symptoms than 
dysthymia [26]. However, with the presence of permanent depressive personality traits it 
might be assumed that treatment would be likely to not be beneficial as these attitudes are part 
of a subject’s character and therefore unchangeable. 
Other explanations for the recurrent or persistent character of depressive disorders are 
mostly located within the health care system [3]. Studies show that subjects affected by 
depressive symptoms seek professional medical help with a delay of eight years on average 
after the first occurrence of their problems [27]. It is assumed that affected people wait for 
such a long time despite their distress due to fear of stigmatization and lack of knowledge 
about depression and its treatment options [28]. As a consequence, depressive symptoms 
might persist over the years and likelihood of successful later treatment might diminish.  
Even once subjects enter the health care system it is still not guaranteed that they 
receive adequate treatment, and on several steps within the system problems might occur. 
Most patients usually seek help first from their general practitioner (GP), and studies show 
that GPs often fail to detect depressive symptoms accurately [29], considering more often a 
somatic cause for symptoms by neglecting possible mental health problems [30]. If depression 
is diagnosed correctly, GPs tend to increasingly prescribe antidepressant medication [31] 
although clinical guidelines contain distinct treatment options depending on severity of 
current depressive episode and development and kind of current and past symptomatology [6]. 
Moreover, most patients would prefer to receive psychotherapy to solve the cause of their 
depression, while antidepressants are regarded to be addictive [32].  
One relevant issue in this context is lack of professional networking, which likely 





physicians are rarely referring their patients to mental health professionals (psychotherapists 
or psychiatrists) because they often have limited knowledge regarding mental health providers 
located nearby and the range of effective treatments [33]. All of these reasons for lacking 
adequate and timely treatment might contribute to the likelihood that depression is turning 
recurrent or chronic over time.  
However, even if a patient actually is referred to a mental health professional in time, 
it is still not guaranteed that he will receive adequate treatment, considering that only a 
marginal amount of psychotherapists ground their treatments on evidence-based techniques 
recommended by clinical guidelines [34]. Finally, assuming a patient does receive state of the 
art treatment – can we know for sure that this treatment will help the patient to recover from 
depression in the long-term? In research and clinical practice we are currently confronted with 
the problem that we are considered to have effective evidence-based treatments, but at the 
same time studies show that 30-50% of depressive disorders are turning persistent during the 
course of an individual’s lifetime [5]. This allows for discussion whether or not the current 
treatment concepts can prevent relapse and recurrence in the long-term. 
This thesis tries to contribute to the discussion whether or not we have adequate 
treatment concepts for depressive disorders in order to sustain remission in the long-term, and 
if and in what way there is room for improvement of these treatments. Recurrent and 
persistently depressed individuals in particular are at high risk for further relapse and 
recurrence, which is why the major part of this thesis will focus on this patient population. 
 
2.1.1  Recurrent and persistent forms for depression 
The majority of individuals with depression will experience more than one lifetime 
major depressive episode [5]. Long-term depression can take several courses over time, with 





individuals rarely or never remitting from episodes at all [13]. In research literature a clear 
distinction between these two forms is made. 
Recurrent depression, referred to as “recurrent depression with full inter-episode 
recovery” in the diagnostic classification system DSM-5 [13], is characterized by more than 
one episode of major depressive disorder and full remission between episodes. Although 
individuals experience several episodes over their lifetime, they also experience months or 
even years without any depressive symptoms, so that this form of depression is not considered 
to be persistent. 
By contrast, persistent forms of depression are newly referred to as “persistent 
depressive disorder” (PDD) in the DSM-5 [13], and contain four diagnostic subgroups 
characterized by an illness duration of at least two years: (1) dysthymia, (2) chronic major 
depression, (3) recurrent major depression with incomplete remission between episodes, and 
(4) double depression [35]. Dysthymia is defined as a condition with mild depressive 
symptoms persisting for at least two years. Chronic major depression refers to a more severe 
condition that meets full criteria for a major depressive episode continuously for a minimum 
of two years. Individuals who have recovered to the point at which they no longer meet full 
criteria for a major depressive episode but continue to experience significant symptoms for at 
least two years are referred to as suffering from recurrent major depression with incomplete 
remission between episodes. The superimposition of a major depressive episode on 
antecedent dysthymia is referred to as double depression [20].  
Both PDD and recurrent depression are associated with severe impairments as for 
instance increased loss of physical wellbeing, more frequent suicide attempts, less social, 
psychological and emotional functioning, more hospitalizations, and longer treatment duration 
compared to non-persistent or non-recurrent forms of depression [1, 17, 36, 37]. Those 
individuals are therefore in urgent need for treatments that focus on diminishing these 





2.1.2  Treatment phases 
One opportunity to minimize likelihood of relapse and recurrence in depressive 
disorders is to provide relapse-preventive treatment. Considering an entire treatment period 
there are three treatment phases conceivable [38]: acute phase, continuation phase and 
maintenance phase treatments (see figure 1). Interventions during the acute phase aim to 
reduce depressive symptoms and to maintain the individual’s functional level - also beyond 
termination of acute treatment. Following response to acute treatment, long-term continuation 
and maintenance treatment might be required for individuals who are at high risk for relapse 
or recurrence of symptoms [6]. Whilst continuation treatments are provided to currently 
remitted patients or to patients who previously responded to treatment, maintenance 
treatments are given only during recovery, which is defined as remission lasting longer than 
six months [7, 8]. All three types of interventions intend to prevent patients from experiencing 
relapse (return of depressive symptoms before full remission has been achieved) or recurrence 
(appearance of another episode of depression after full remission) [8].  
 
  
Figure 1. Treatment phases depending on response and remission status of the patient.  






With regard to pharmacological treatment, clinical guidelines recommend to continue 
ADM with the same dose received during acute treatment, considering a tapering down of 
ADM by the end of continuation and maintenance treatment phase [6]. By contrast, 
psychotherapeutic continuation and maintenance treatments are not considered a simple 
extension of acute therapy [39], but rather contain the generalization of skills a patient 
acquired during acute treatment to daily routine situations. This usually manifests in a less 
frequent therapeutic setting, i.e., longer intervals between sessions are considered meaningful.  
As relapse-preventive efforts can be located throughout the entire treatment period, 
this thesis will give insight into all three treatment phases described above, predominantly 
focusing on psychotherapeutic efforts to prevent relapse and recurrence. The next chapter will 
give an overview on current evidence on pharmacological and psychological treatment 
options in major depressive disorder (MDD) and PDD, highlighting the relevance and need 
for further research of psychological treatments.  
 
2.2  Effectiveness of pharmacological and psychological treatments for 
major depressive disorder 
2.2.1  Acute phase treatments for MDD 
Extensive research was done in this field, mostly in so called “relapse-preventive 
trials”. These trials provide patients with a specific amount of treatment, usually between 6 
and 12 weeks [6], intending to reduce depressive symptoms by the end of the intervention, 
and to sustain response or remission also beyond terminating acute phase treatment. Studies 
indicate that pharmacological treatment is effective in reducing depressive symptoms 
compared to placebo [40], and that, on average, pharmacological agents do not substantially 
differ in their effectiveness [41]. Studies also show that pharmacological treatment is only 





symptoms re-emerge after discontinuation of ADM [42]. Moreover, receiving ADM is 
associated with experiencing adverse events, mostly in the form of side effects (e.g., 
headache, insomnia), which often lead the patient to stop taking the drugs [9].  
With regard to psychological treatment, acute phase psychotherapy is proven to be 
effective in reducing symptoms even beyond termination of acute phase psychotherapy, with 
most studies investigating the effects of cognitive therapy (CT) or cognitive-behavioral 
therapies (CBT) [12, 43]. In their meta-analysis, Vittengl and colleagues [12] found acute 
phase CBT superior to acute phase ADM, showing that 39% of participants receiving CBT 
had a relapse or recurrence compared to 61% of participants receiving ADM over a mean of 
68 weeks after terminating treatment.  
Additionally, the authors were interested in possible add-on effects of either of these 
treatments. The combination of ADM and CBT resulted in significantly less relapses or 
recurrences compared to ADM alone within 56 weeks after terminating treatment. By 
contrast, the combination of ADM and CBT did not differ from CBT alone regarding relapse 
and recurrence during follow-up, but only three studies contributed data, limiting conclusions 
of this comparison [12]. In recent years interventions also target ‘third wave' cognitive and 
behavioral therapies which include strategies addressing mindfulness exercises and 
acceptance of unwanted thoughts and feelings. A recent meta-analysis found that these 
therapies were superior to treatment as usual regarding clinical response rates at end of 
intervention [44]. The authors noted that this result is based on a small amount of included 
studies (n = 4), with limitations in methodological quality, and lack of follow-up data.  
 
2.2.2  Continuation and maintenance phase treatments in MDD 
Clinical guidelines recommend to continue treatment to maintain remission and 





continuation and maintenance treatments (between four months and two years), but agree that 
the treatment, which proved to be effective during acute treatment, should be continued and 
maintained in the following phases, and that patient’s preference on type of treatment should 
be taken into account. Studies indicate that pharmacological continuation and maintenance 
treatments are effective in reducing depressive symptoms compared to placebo [42, 46], 
indicating no substantial differences between pharmacological agents.  
With regard to psychological continuation and maintenance treatments, CBT did not 
differ from other active treatments (e.g., ADM) by end of continuation/maintenance 
treatment, but showed better outcomes (i.e., fewer relapses and recurrences) compared to 
ADM during 114 weeks of follow-up on average [12]. Moreover, compared to non-active 
controls (e.g., assessment only), participants receiving continued or maintained CBT had 
fewer relapses and recurrences by the end of intervention and at follow-up. In recent years, 
the Mindfulness-Based Cognitive Therapy (MBCT) obtained attention in reducing relapse and 
recurrence in depressed individuals currently in partial or full remission [47, 48], teaching the 
patient to deal with negative feelings and thoughts as a part of their lives through becoming 
aware of negative cognitive patterns. The meta-analysis of Piet and Hougaard [47] showed 
that for individuals with recurrent depression (with full inter-episode recovery) MBCT 
significantly reduced risk of relapse and recurrence compared to treatment as usual or placebo 
control, if participants had experienced at least three or more depressive episodes. By 
contrast, MBCT did not differ from continued/maintained ADM based on two studies. 
Although MBCT seems to be a promising approach in preventing relapse and recurrence, 
there is open discussion if MBCT is actually a continuation treatment program. MBCT studies 
include remitted patients but without requiring the patients to have received an acute phase 
treatment beforehand, so it remains unclear how patients remitted. Also, MBCT programs 
offer eight sessions of group therapy providing the main concept of MBCT to participants, 





and maintenance interventions intend to maintain the already gained during acute treatment, 
MBCT programs might be considered a different approach.  
The body of research indicates that acute, continued and maintained interventions are 
effective in individuals with major depressive disorder, including individuals with recurrent 
depression with full inter-episode recovery. Still, it remains challenging to completely 
understand the mechanisms of relapse and recurrence prevention in the short- and long-term 
[49].  
 
2.2.3  Mechanisms of change 
Whilst pharmacological treatments are considered to mainly target symptoms on a 
physiological level, psychological treatments intend to target origin and maintenance of 
depression by challenging attitudes and changing behavior. The exact therapeutic mechanisms 
of pharmacological treatments are still critically discussed [50]. However, most ADMs seem 
to increase the concentration of monoamine neurotransmitters in the synaptic cleft [51]. 
Depending on the type of active ingredient, ADMs can have mood-enhancing, anxiolytic or 
sedative effects and are able to increase or decrease inner drive. 
Regarding psychological treatments, process-outcome researchers are interested in 
how therapy works, i.e., finding specific mechanisms during psychotherapy potentially 
underlying patients symptom change [52]. Recently, Lemmens and colleagues [53] reviewed 
35 studies identifying psychological mediators in psychotherapy for depression. Considering 
only high quality studies (n = 17), behavioral concept of CBT and worry were the most often 
found significant mediators regarding outcome change (depression severity), followed by 
dysfunctional attitudes, negative (automatic) thoughts, mindfulness skills, attributional style, 
rumination, and therapeutic alliance. Most of these found mechanisms are theorized processes 





studies addressed CBT interventions. The authors of this review were careful with final 
conclusions due to unsatisfactory methodological quality of included studies. For instance, 
only two studies could accurately assess the temporal association between change in the 
mediator and change in outcome on a session-by-session basis, and none of the studies 
manipulated the mediator experimentally to test for causal processes [53]. Next to 
methodological recommendations the authors conclude that there is a need for improving 
theory behind processes of change followed by developing valid mediator measures using 
multiple sources of information (e.g., self-report, independent raters, behavioral measures).  
This thesis will have a closer look on therapeutic processes, which might be involved 
in patients´ symptom change. This is addressed by the development of a new observer-based 
instrument to assess relapse-preventive efforts during psychotherapy (study 3), aiming to 
contribute to sustained remission in the long-term.  
 
2.3  Effectiveness of pharmacological and psychological treatments for 
persistent depressive disorder (PDD) 
The previous chapter demonstrated that there are indeed effective acute and 
continuation/maintenance treatments (ADMs, psychotherapy) for individuals suffering from 
major depressive disorder or recurrent depressive disorder (with full inter-episode recovery). 
As these patients experience remission and recovery, treatment might be different from that 
provided to individuals who suffer from PDD, as these patients experience constant 
depressive symptoms for at least two years. This chapter will point out current evidence on 








2.3.1  Acute phase treatments for PDD 
Meta-analyses agree that pharmacological treatments show better outcomes 
(response/remission rates) compared to psychotherapy in purely dysthymic patients [43, 54–
56], and they found selective-serotonin-reuptake-inhibitors (SSRIs) to be specifically 
effective in dysthymic patients. Generally, ADM is superior to placebo regarding response 
and remission rates [56, 57], and especially the drugs fluoxetine, paroxetine, sertraline, 
moclobemide, impipramine, and amisulpride are considered efficacious and acceptable [56]. 
One meta-analysis found no differences regarding response rates between SSRIs and tricyclic 
antidepressants (TCAs), but SSRIs were more acceptable in terms of dropout rates compared 
to TCAs [57].  
Evidence regarding the effectiveness of psychological treatments or combined 
treatment of ADMs and psychotherapy is rather inconclusive, especially due to marked 
heterogeneity between trials in terms of kind of psychotherapy and specific combination with 
an antidepressant agent and diagnostic subgroup. Two kinds of psychotherapy are mostly 
researched in PDD: interpersonal therapy (IPT) and the Behavioral Analysis System of 
Psychotherapy (CBASP). While IPT is mostly provided for dysthymic patients, CBAPS is 
mostly provided for patients with a chronic major depressive disorder in studies [56]. Two 
meta-analyses found indicators that combined treatment of ADM and psychotherapy might be 
superior to a stand-alone treatment in regard to response/remission rate [54, 56]. By contrast, 
von Wolff and colleagues [58] found combined treatment equally effective as ADM alone, 
although participants receiving combined treatment reported better quality of life at end of 
intervention compared to participants receiving ADM alone. 
Besides proposed benefits of acute treatment in PDD, pharmacological and 
psychological interventions might also be associated with adverse events (side effects, 





one treatment over the other might be based on suggested differences regarding adverse 
events. A recent meta-analysis identified 60 studies addressing pharmacological, 
psychological and combined treatments in PDD and concluded that adverse events were 
insufficiently considered in evaluated studies [59]. Whilst pharmacological and combined 
studies mostly reported adverse events, the majority of psychotherapeutic studies did not. 
Generally, psychotherapeutic studies often fail to report adverse events [60, 61], which should 
be considered when comparing outcomes of ADMs and psychotherapy studies.  
Research clearly indicates that pharmacological treatment is effective and accepted in 
PDD, and it might be an advantage to provide additional psychotherapy. Yet, given the high 
rates of relapse and recurrences following response to acute treatment, long-term continuation 
and maintenance therapy are of great importance [49]. 
 
2.3.2  Continuation and maintenance phase treatments for PDD 
Although the vast majority of evidence addresses acute treatments for PDD, some studies 
have been conducted to address the effectiveness of continuation and maintenance treatments 
[62–70]. The majority of studies investigating continuation and maintenance treatments in 
PDD focus on long-term ADM, include different pharmacological agents and show their 
superiority compared to placebo regarding relapse and recurrence rates [62–64, 66, 71].  
CBASP [72] is a program especially developed for psychotherapeutic treatment of 
PDD and has been subject of scientific inquiry in recent years. The program itself combines 
techniques from IPT and CBT programs, focusing on early traumatic events and relationships, 
which might have let to specific behaviors such as interpersonal avoidance. Most results on 
the effectiveness of CBASP are based on one study involving 681 outpatients receiving either 
nefazodone  (ADM) or CBASP (psychotherapy) or both during the acute [73] and 





received either ADM or placebo [62], or either CBASP or assessment only  [65]. The 
continuation phase study found no differences between the three treatment arms, i.e., CBASP 
alone, nefazodone alone, and combination of CBASP and nefazodone were equally effective 
[67]. By contrast, participants receiving nefazodone during 52 weeks of maintenance 
treatment showed fewer relapses and recurrences compared to participants receiving placebo 
[62], and also, receiving CBASP during this treatment phase was associated with fewer 
relapses and recurrences compared to assessment only [65]. This multi-center study attracted 
much attention as it found promising effects of long-term psychotherapy that were 
comparable to the effects of stand-alone pharmacological treatment, which was the state of 
the art treatment until then. However, this study was also criticized because of a missing 
untreated control group and use of an ADM (nefazodone) which was withdrawn from the 
market in 2004 in some countries due to the rare incidence of hepatoxicity [74]. 
Despite the relevance of providing continuation and maintenance treatments in 
individuals being at high risk of relapse and recurrence [6], only a few studies address those 
treatment phases, and these studies differ in their methods and found results. Thus, we 
conducted a systematic review and meta-analysis on the effectiveness of pharmacological and 
psychological continuation and maintenance treatments in PDD patients. This topic is 
addressed by study 1 of this thesis, and was conducted in cooperation with the Cochrane 
Collaboration. This organization is a global independent network of researchers and 
professionals, aiming to provide the best and most current evidence on different kinds of 
treatments. Cochrane holds a comprehensive database of systematic reviews1, and monitors 










2.4  Enhancing relapse-preventive efforts throughout and beyond therapy 
2.4.1  Methods for assessing and evaluating relapse-preventive efforts  
As outlined in the previous chapters, there is a vast amount of research on relapse-
preventive effects of different kinds of treatments in different forms of depressive disorder. 
The majority of these studies focus on the general effect of acute, continuation or maintenance 
treatments following the question whether outcomes differ substantially between treatment 
arms and over time. Outcomes typically addressed in studies are rates of relapse/recurrence, 
level of depressive symptoms or dropout, often measured within a pre-post design [53]. 
Usually, studies in this field of outcome research do not assess by which means 
psychotherapy produces its effects [75]. Thus, researchers assume that such treatments 
generally help to minimize likelihood of relapse and recurrence, but without assessing the 
specific mechanisms potentially underlying symptom change in patients. Process-outcome 
studies measure different kinds of processes of both the therapist (e.g., specific techniques) 
and the patient (e.g., motivation) throughout therapy that might lead to patient change [76]. 
Studies try to investigate possible mediators that drive the effects of treatment, and that 
relapse prevention trials ideally need a session-by-session assessment to evaluate temporal 
changes [53]. 
To conduct such relapse prevention trials, usually a considerable number of therapists 
are involved, and in order to conclude afterwards that a specific treatment has been effective it 
is necessary for all therapists to provide the treatment in the same way. Otherwise, one cannot 
know whether the individual therapist and his/her specific attitudes drive the main effects, or 
if the treatment concept and sessions including strategies and exercises are responsible for the 
measured effects (very likely, both aspects including their interaction is the most realistic 
explanation). In psychotherapy research, this issue is addressed by treatment integrity, which 





[77]. Adherence is defined as the degree to which a therapist provides interventions as 
determined in the treatment manual, whereas competence is defined as the extent to which a 
therapist implements such techniques in a skillful manner [77]. Researchers wonder whether 
level of treatment integrity might have an impact on intervention effectiveness [78], with the 
idea that better implementation of treatment might lead to better outcomes in patients, 
possibly minimizing relapse and recurrence in the long-term. However, a meta-analysis 
addressing this question found no significant associations between adherence/competence and 
treatment outcome, which the authors attributed to the variety of applied methods (rating 
instruments, number of rated sessions, etc.), or to little influence of therapists’ adherence and 
competence on patients’ symptom change [79].  
Indeed, a variety of reliable and validated instruments assessing therapist’s adherence 
and competence during psychotherapy are available. These instruments usually target the core 
aspects of a treatment concept. For instance, if a scale is intended to measure adherence to a 
CBT intervention, it will probably measure if and to what degree a therapist addresses 
recognition of cognitive errors or distancing oneself from beliefs during the sessions, as these 
aspects are considered main components of CBT interventions. The most influential 
adherence scale is the Collaborative Study Psychotherapy Rating Scale [CSPRS; 80], and the 
most influential competence scale is the validated and frequently applied Cognitive Therapy 
Scale [CTS; 81]. Both scales use an observer-based format, i.e., independent observers 
evaluate the therapist’s behavior by watching videotaped therapy sessions and rating the 
occurrence and degree of specific components. Having trained observers evaluate therapists´ 
behavior is considered more objective than relying on therapists´ self-reports of the accuracy 
of delivering the treatment [82].  
Available adherence and competence scales focus on processes in-session and within 
the acute phase treatment period, aiming to ensure accurate implementation of core treatment 





follow-up, resulting in a relapse-preventive effect of treatment. Interestingly, established 
treatment manuals for acute psychotherapy in cognitive and interpersonal therapies (Ellis and 
Dryden, 1997; Hollon et al., 2002; Beck et al., 2010; Schramm and Berger, 2010; Hautzinger, 
2013) include specific recommendations for relapse prevention techniques which exceed core 
concepts represented in adherence and competence scales. More specifically, elements that 
can be rehearsed in the final treatment phase include: early detection of depressive symptoms, 
anticipating critical situations and adequate coping skills, maintaining antidepressant 
activities, activating resources, reinforcing helpful cognitions, planning the future, 
summarizing the achievements of therapy, sensitizing the patient to potential relapses, and 
preparing transition from therapy to time after therapy termination. Although a variety of 
relapse prevention strategies seem to be recommended and commonly used in clinical 
practice, available scales assessing adherence and competence during psychotherapy do not 
fully cover the adequate implementation of relapse-prevention techniques beyond core 
treatment elements (e.g., central cognitions in CT).  
The above mentioned scales target relapse prevention elements only to a marginal 
degree, i.e., through items such as ‘Encouragement of self-monitoring’ or ‘relapse 
prevention,´ and these scales focus rather on the application of certain behaviors during 
treatment than on preparing for their application after discontinuing treatment. Especially for 
inpatients who receive acute treatment in hospital, strategies learned in this sheltered 
environment might not work properly in everyday life. We consider the transition of therapy 
gains between treatment phases as well as between therapy and life after termination of 
therapy a relevant aspect, which might be relapse-preventive next to core treatment concepts 
as explained above. Thus, we were aware of potential relapse preventive strategies that are 
currently not covered by existing instruments in research. Consequently, we intended to 
develop a measure to assess specific relapse prevention elements initiated by the therapist, 





as anticipating critical situations and adequate coping skills or sensitizing the patient to 
potential relapses and recurrences in the long run. By this, we want to contribute to enhancing 
relapse-preventive efforts throughout and beyond psychotherapy, as described in study 3 of 
this thesis. 
 
2.4.2  Challenges in providing and receiving continued treatment 
Individuals who seek acute treatment are in urgent need for help and it is likely that 
providers will try to offer immediate treatment, and that health insurances will try to cover 
costs for this treatment. This is somewhat different regarding continuation treatments. First of 
all, continued treatment should be offered only to patients who responded to or remitted after 
a previous acute treatment [6, 45], which means patients are reporting a better health status. 
Thus, health insurances are probably less willing to cover the costs for treatment of an already 
remitted patient, and moreover, the patient might be eager to live without any therapeutic help 
at this point. Continuing treatment despite feeling well again might not be first choice of 
patients, which raises the question of how accepted continued treatments actually are. 
Acceptance of a treatment is usually reported by dropout rates, i.e., how many patients 
terminated therapy prematurely [83]. Generally, dropout rates tend to vary between 30% and 
50% in studies addressing individual psychotherapy [83], and were found to be around 25% in 
a meta-analyses regarding individual and group CBT for unipolar depression in routine 
clinical practice [84]. In the same meta-analysis, authors reported that only 70% of 
investigators reported on the extent of dropout, and even if dropout was reported, intention-to-
treat (ITT) analyses were rarely used compared to completer analyses [84].  
Regarding acceptance of continuation treatments, we are especially interested in 
dropout rates between the acute and the continuation treatment - therefore studies that offer 





treatment phases, but also include non-responders to acute treatment into these dropout rates, 
keeping the reader uninformed on how many patients were actually eligible and have actively 
refused to enter continuation treatment for other reasons. One multi-center trial (of high 
methodological quality) on the comparative effectiveness of sertraline and imipramine in 
chronically depressed patients reported 24% dropout between the acute and continuation 
treatment phase, and a continuation phase completion rate of 86% [68]. Whilst reasons for 
dropout within one treatment phase are usually reported (e.g., ‘intervention ineffective’, 
‘adverse events’), reasons why patients are not willing to continue treatment are mostly 
unknown yet.  
As already mentioned, low level of patients´ motivation due to stable current health 
status might be an explanation, but also that patients have to organize possible continuation 
treatment on their own because the health care system commonly does not provide distinct 
continuation programs or does not cover additional therapies beyond achieved remission [3]. 
The latter point addresses costs of continuation treatment, which request additional financial 
resources (compared to acute treatment only) but can increase treatment effectiveness, for 
instance in collaborative care programs in patients with PDD [85]. Moreover, it is assumed 
that the costs of lower workplace performance due to depression exceed the costs for treating 
the illness, which in turn can prevent the deterioration of patients´ workplace performance 
[86, 87].  
There is not only the problem of funding evidence-based continuation treatments, but 
also in facilitating access to them. Despite available psychotherapeutic treatments, patients 
tend to make use of treatments delayed, or even never, also because of fear of stigmatization 
[33]. One study assessed perceived barriers to receiving psychological depression treatment, 
and found that higher scores on stigma, emotional concerns, misfit of therapy to needs, and 
time constraints predicted fewer reports of attending psychotherapy one year later [88]. Time 





psychotherapy in patients being at high risk of relapse. For instance, the majority of patients 
suffering from PDD receive pharmacological treatment as it proved to be effective during 
acute, continuation and maintenance treatment phases (see previous chapters). Receiving a 
prescription of an antidepressant medication and taking pills each day might be “easier” for 
the patient in terms of expenditures (time, costs, etc.) compared to psychotherapy, although 
psychotherapy might have equal effects, a lower risk of side effects, and better long-term 
behavioral change compared to pharmacological treatments [10].  
As low level of mood, interest and energy are key symptoms of depression, the above 
mentioned barriers have to be taken into account when conceptualizing continuation 
treatments. This raises the question of how we can increase the likelihood that patients enter 
and maintain continuation therapies, and by this increase likelihood of sustained remission. 
 
2.4.3  Opportunities in providing and receiving continued treatment 
To optimize patients’ access to continuation treatment, several recommendations on 
system level can be made: better interdisciplinary cooperation between providers, establishing 
knowledge on evidence-based treatment options in providers, and developing low-intensity, 
easily accessible and flexible treatments [3]. Stepped care programs are considered to 
contribute to better access to treatment by a cooperative system in which providers can up- or 
downgrade level of treatment intensity depending on health status of the individual [89]. 
Multi-center trials in different countries investigated this complex system of treatment in 
depression, and they vary in results regarding effectiveness compared to care as usual [85, 
90–92], leaving open discussion upon access, effectiveness and efficiency of stepped care 
programs [89].  
Another opportunity to provide treatment to a wide range of patients, especially 





low-intensity treatments, which are associated with fewer financial expenses due to less 
intense treatment and innovative delivery options [93]. Such treatments include less or even 
no direct therapeutic involvement compared to traditional (face-to-face) settings, for instance 
due to use of new technologies such as CBT provided over the internet or other mobile 
devices, and might involve highly qualified mental health professionals (e.g., 
psychotherapists) or non-professions (e.g., peer supporters). A systematic review regarding 
low-intensity psychological interventions to reduce relapse in depression found differing 
degrees of clinical effectiveness and cost-effectiveness of evaluated interventions [93]. 
Despite inconclusive results on average, the authors highlighted one study that implemented a 
relapse prevention intervention to improve adherence to ADM in recovered patients who were 
at high risk of relapse, providing two face-to-face and three telephone sessions as well as 
personalized mailings [94]. Although relapse/recurrence rates did not differ between 
participants in the program and those receiving care as usual over 12 months follow-up, 
adherence to ADM was greater compared to care as usual. The authors assumed that more 
intensive treatment might be required to reduce relapse and recurrence in high-risk patients 
[94]. Rodgers and colleagues [93] defined low-intensity treatments in their review by 
therapeutic contact of less than six hours and required studies to provide interventions that not 
only involved reducing depressive symptoms, but also intended to improve self-management 
of depression and prevention of relapse and recurrence in the long-term. Therefore, many 
studies addressing treatments delivered through remote technologies were probably excluded 
from the review due to more than six hours of contact. 
Currently, the majority of studies in this field investigate the efficacy of guided or 
unguided internet-based interventions during the acute phase of major depression treatment. 
Meta-analyses demonstrate that CBT provided over the internet (iCBT) is superior to control 
groups (waiting list, usual care) in reducing depressive symptoms at posttreatment, but not 





[97]. Meta-analyses also demonstrate that guided internet interventions lead to greater 
symptom reduction and fewer dropouts compared to unguided interventions [98, 99]. 
Moreover, iCBT seems to be equally effective to face-to-face CBT in reducing depressive 
symptoms [100–102], and iCBT might be equally effective regarding adherence although 
completion rates in face-to-face CBT were higher compared to iCBT [103].  
Some studies also address the relapse-preventive character of internet-based 
interventions, indicating that iCBT is associated with fewer relapses compared to control 
group after 24 months follow-up [104], and also indicating that iCBT is at least as effective as 
group-based face-to-face CBT also during three years of follow-up [105]. One trial compared 
iCBT with e-mail therapy and found that the majority of participants showed only minimal 
depressive symptoms over 3.5 years of follow-up comparable across treatment conditions, 
indicating that individuals with mild to moderate major depression might benefit from such 
internet interventions in the long-term [106].  
By contrast, evidence regarding internet-based interventions in individuals with 
persistent depressive symptoms is limited. One study reanalyzed data of participants who 
received iCBT for their depression, and compared outcomes of participants showing chronic 
symptoms (more than two years) with non-chronic participants [107]. Chronicity of 
symptoms did not predict treatment outcome (level of depressive symptoms at posttreatment), 
and neither did both groups differ regarding their change in depressive symptoms from pre- to 
posttreatment, but chronically depressed patients achieved full recovery less often. Another 
study provided two patients with CBASP over the internet (‘CBASP@home’) in order to 
maintain gained therapeutic successes over three months after patients had terminated a 12 
week inpatient CBASP program [108]. For each of the nine sessions, the patient completes 
the ‘situational analysis’, which is a key procedure of the CBASP program, and receives 
feedback from his/her psychotherapist via a secured sever. This study describes two case 





patient in transferring the gains from inpatient treatment to everyday life situations, and by 
this, preventing relapse and improving approaches of long-term care for PDD patients [108].  
 
2.4.4  Telephone-based interventions 
Whilst internet-based interventions are mostly provided as stand-alone interventions 
that require little or no contact between patient and therapist, one might wonder if 
development of a sound therapeutic relationship is possible in this context, as visual and 
auditory cues are missing [109]. Delivering psychotherapy by telephone might approach this 
challenge, as all auditory information is maintained, and moreover, since it might be 
considered a valuable further approach to providing many patients with treatment, due to its 
low-intensity character in terms of low costs, overcoming barriers and practicability in 
everyday life [110]. While a personal contact between patient and therapist is guaranteed, 
delivering telephone therapy is more suitable in terms of arranging the time and place of 
therapy than traditional face-to-face settings. Telephone therapy as a stand-alone treatment in 
depressive disorders has been investigated only within the field of acute depression so far, and 
is associated with reducing depressive symptoms compared to control groups [111], and 
shows comparable effectiveness (e.g., with regard to level of depressive symptoms) as well as 
lower dropout rates than face-to-face settings in CBT [112–114]. Moreover, therapeutic 
alliance in telephone-based CBT for acute depression was found to be equal to face-to-face 
CBT [115]. Studies also indicate a relative cost-effectiveness of telephone-based 
interventions, with 36% lower costs per sessions compared to face-to-face settings [116].  
Besides evidence on effectiveness, little attention has been paid to the patients’ 
perspectives of new technologies in mental health care. One study assessed patient acceptance 
and resistance to telephone-based care (mostly CBT), and found wide heterogeneity between 





limitations of the medium alone. Moreover, they highlight the relevance of perceived 
‘adequacy of fit’ between CBT and telephone delivery, assuming that dissatisfied participants 
might have had a discrepancy between medium telephone and their individual constructs of 
what therapy represents. However, the majority of participants accepted telephone for the 
delivery of CBT components [117].  
As outlined above, there is some evidence that telephone might be an adequate 
medium for delivering CBT to acutely depressed individuals. Evidence on persistently or 
recurrently depressed individuals as well as evidence on continuation and maintenance 
treatments delivered by telephone is even more limited. A recent study provided an eight 
week self-help intervention which also included a weekly 15-minute telephone support to 
recurrently depressed individuals currently in full or partial remission or recovery [118]. 
Participants receiving this intervention (added to care as usual) showed fewer relapses or 
recurrences and a greater reduction in depressive symptoms over 12 months compared to 
participants receiving care as usual only. Participants in this study were not required to have 
terminated an acute treatment beforehand and thus, the provided intervention is not 
considered a continuation treatment per definition. However, this intervention included 
working on specific relapse and recurrence prevention strategies and a personal prevention 
plan, which are key components of continuation treatments [39].  
To our knowledge, there is only one study available which investigated a telephone-
based psychotherapeutic intervention during the continuation treatment phase. This program 
was offered to individuals with substance abuse disorders who had completed an intensive 
four week outpatient program before entering the telephone-based twelve-week continuation 
treatment [119]. Participants in the telephone condition received an initial face-to-face session 
followed by one 15-minute phone call each week, having the opportunity to join a weekly 
support group during the first four weeks of treatment. The telephone condition showed 





during follow-up, compared to more intense face-to-face standard interventions [120]. The 
authors were also interested in the moderating effect of a composite risk factor, which was 
calculated based on the amount of addictive substances and response to previous acute 
treatment. They found that participants with low to moderate risk-scores showed better 
outcomes in the telephone condition, while participants with higher risk-scores showed better 
outcomes in face-to-face conditions [119]. The authors conclude that although mechanisms of 
change in telephone-based interventions are not yet known, patients who achieved 
stabilization might benefit from such a continuation program, which is focused on goals, more 
convenient compared to face-to-face settings due to flexibility in time and location, and has 
less interference with responsibilities as employment or child care.  
The above outlined studies, although limited in number and methodological quality, 
indicate that telephone might be an adequate medium for delivering continued 
psychotherapeutic care to depressed patients who responded to or remitted after a previous 
intensive treatment. There is more research needed to confirm effectiveness of telephone-
based interventions compared to face-to-face settings regarding clinical outcome measures. In 
case of equal effects, telephone-based interventions might be associated with lower costs and 
more flexibility in time and location compared to face-to-face settings, and by using this 
technology, representing considerable potential for overcoming several barriers to providing 
and receiving care [121], and as a consequence, preventing relapse and recurrence. 
With respect to limited evidence in low-threshold long-term interventions for 
individuals being at high risk of relapse, we developed a telephone-based continuation 
treatment for patients with recurrent or persistent depression who previously responded to an 
acute psychotherapy, and evaluated the feasibility and acceptance of this program within a 







2.5  Summary  
The previous chapters outline that several effective pharmacological and psychological 
treatments exist to prevent relapse and recurrence of depression. The majority of these studies 
focus on effects of the entire treatment program as measured by reliable change between pre- 
and posttreatment, and most of these studies were conducted during the acute treatment phase 
of major depressive disorder. However, relapse and recurrence rates tend to remain high even 
after successful acute therapy. Whilst providing several short-term treatments with intervals 
of (more or less) well-being in-between is one way of care, the question is whether this 
treatment concept corresponds to the needs of a chronically impaired patient. This thesis 
assumes that long-term care in terms of continuation and maintenance treatments might be the 
more appropriate way of approaching the recurrent and persistent character of depressive 
disorders. But effects of continued and maintained treatments, especially in severely 
depressed individuals, are quite inconclusive due to a limited number of available studies and 
marked heterogeneity between these studies. All three studies presented in this thesis address 
relapse-preventive efforts of treatments for depressive disorders to sustain remission and 
recovery in the long-term. Each of the studies takes the potential recurrent or persistent 
character of depression into account, indicating that all treatment phases should focus 
intensively on relapse-preventive strategies, and that continuation and maintenance treatments 
might be offered to individuals being at higher risk of relapse.  
 
3  Specific research questions 
As introduced in the theoretical background, researchers are interested in finding 
answers to the question of why individuals suffering from depression frequently experience 
relapse and recurrence despite receiving evidence-based treatments. Besides biological 





within the health care system might also contribute to the course of depressive symptoms. 
This thesis addresses the latter approach, by optimizing access to and investigating effects of 
interventions for depressive disorders within different treatment phases (see figure 2) to 
sustain remission and recovery in the long-term.  
 
Figure 2. Graphic representation of the three studies presented in this thesis. 







Study 1 illustrates the current evidence on the general effectiveness of continuation 
and maintenance treatments for individuals suffering from persistent depressive disorder 
(PDD) by means of a systematic review and meta-analysis. This study addresses a) whether 
psychotherapy and antidepressant medication (ADM) are more effective than no treatment or 
placebo, respectively, and b) whether both treatments are considered equally effective in 
direct comparison and as add-on treatments (i.e., combination of psychotherapy and ADM 
compared to each treatment alone). We were interested in relapse/recurrence and dropout 
rates as primary outcomes, but also in several secondary outcomes including quality of life 
and adverse events, each at the end of the intervention and during follow-up. As we already 
expected to find a limited amount of available studies in this field, we conducted a subsequent 
study, which aims at developing telephone-based continuation therapy for PDD patients who 
had previously responded to acute psychotherapy, to help patients sustain remission in the 
long-term.  
Study 2 addresses the question if such a program is feasible and accepted by therapists 
and their patients suffering from recurrent or persistent depression. As use of technology is 
considered a promising approach to provide many people with mental health care [110], we 
were especially interested in the acceptance of the telephone in this context, combined with 
evaluation of the impact of length and frequency of therapeutic phone calls. Moreover, we 
wanted to determine how implementation of the continuation concept was realized, because 
continuation therapy is no simple extension of acute therapy, but rather supports patients in 
transferring already learned strategies to everyday life situations and over time. As delivering 
continued care in high-risk patients by telephone is a new treatment concept, we decided to 
first determine feasibility and acceptance of this program with the help of qualitative means 
within a pilot study.  
Finally, study 3 focuses on therapist behavior during psychotherapy, which might 





This study explores if there are relapse-preventive efforts other than those implemented in 
existing adherence and competence scales [80, 81] that can be observed during video-taped 
psychotherapy sessions. For this purpose, we developed a new measure for assessing relapse 
preventive elements during psychotherapy (‘the KERI-D’), which aims at fostering the 
transfer from therapy to life after termination of therapy. We were interested in the degree of 
inter-rater and retest reliabilities and in content validity as measured by clinical and scientific 
experts, as well as in associations of KER-D subscales with clinical outcome data.  
In the following chapters, all three studies are described in detail without further 
comments in-between. Main results, limitations, and contributions to relapse prevention are 
first discussed separately for each study, followed by a general discussion of all three studies 
reviewing relevance and scope regarding the prevention of relapse and recurrence and 





4 Empirical studies 
4.1 Comparative effectiveness of continuation and maintenance 
treatments for persistent depressive disorder (Cochrane review)2 
4.1.1 Abstract 
Background. Given the high rates of relapse and recurrence of persistent depressive disorder 
(PDD) following response to acute treatment, long-term continuation and maintenance 
therapies are frequently needed. 
Objectives. To summarize empirical evidence on the effectiveness of psychological, 
pharmacological and combined continuation and maintenance treatments for PDD. 
Search methods. Search of the Cochrane Depression, Anxiety and Neurosis Review Group’s 
specialized register of randomized controlled trials (CCDANCTR), PsycINFO, PSYNDEX, 
MEDLINE, EMBASE, CENTRAL, and grey literature up to December 2016. We also 
searched reference lists of included studies and contacted the first author of all included 
studies. 
Selection criteria. We included randomized (RCTs) and non-randomized controlled trials 
(NRCTs) in adults with formally diagnosed PDD, receiving pharmacological, psychological, 
or combined continuation and maintenance interventions. 
Data collection and analysis. Data were extracted independently by two reviewers. The 
primary efficacy outcome was relapse/recurrence rate of depression. The primary acceptance 
outcome was dropping out due to any reason other than relapse/recurrence. Random effects 
meta-analyses were performed using risk ratio (RR) for dichotomous outcomes and mean 
differences (MD) for continuous outcomes. 
                                                          





Main results. We included 10 studies (seven RCTs, three NRCTs) involving 840 participants 
in this review, from which five studies investigated continuation treatments and five studies 
investigated maintenance treatments. The most common comparison was antidepressant 
medication versus pill placebo. Participants taking antidepressant medication were 
significantly less likely to relapse or to suffer from a recurrent episode compared to 
participants in the placebo group at end of intervention (RR = 0.41, 95% CI = 0.21 to 0.79; 
participants = 383; studies = 4; I2 = 54%). Overall dropout rates (four RCTs, N = 386) did not 
differ significantly between participants in the medication and placebo group (RR = 0.90, 
95% CI 0.39 to 2.11). All other comparisons were addressed in no or very few studies. 
However, regarding psychological treatments the few studies indicate that continued or 
maintained psychotherapy could be a useful intervention compared to no treatment or 
antidepressant medication. Overall, the included studies were at low to moderate risk of bias. 
Authors’ conclusions. Antidepressants seem to be superior to placebo in continuation and 
maintenance treatment regarding relapse/recurrence. For all other comparisons the body of 
evidence was too small to draw final conclusions, although continued or maintained 
psychotherapy might be effective compared to no treatment. A need for conducting more 
psychological interventions is obvious. Further studies should address health related quality of 
life and adverse events more precisely, as well as assessing follow-up data.  
 
4.1.2 Plain language summary 
Long-term treatment for people with persistent depression 
Why is this review important? 
Depressive disorders that persists for at least two years cause considerable problems. Even 
after successful treatment, they frequently recur. Common treatments are antidepressant drugs 





Long-term treatments should prevent the recurrence of depressive symptoms. 
Who will be interested in this review? 
People with persisting depression (> two years), friends, families, and carers. General 
practitioners, psychiatrists, clinical psychologists, psychological therapists, and pharma-cists. 
What questions does this review aim to answer? 
In adults with persistent depression who improved with acute treatment: 
Is receiving continued antidepressant medicine, psychological treatment, or a combination of 
both more effective in preventing recurrence of depression compared to placebo (a pre-tended 
treatment) or care as usual? Is receiving continued antidepressant medicine, psychological 
treatment, or a combination of both equally accepted as receiving placebo or usual care? Is 
one treatment more effective or more accepted than another? 
Which studies does the review include? 
We searched medical databases and other sources to find all relevant studies completed up to 
December 2016. The studies had to compare antidepressant treatment, psychological 
treatment, or a combination of both, with each other, with placebo, or with care as usual for 
preventing recurrence of depression in adults diagnosed with persistent depression. We 
included 10 studies involving 840 participants. Five studies compared antidepressant 
medicine with placebo. The other comparisons were only addressed in zero to two studies. 
What does the evidence from the review tell us? 
The risk of depression returning in participants receiving a placebo (instead of antidepressant 
medicine) was 34%. In comparison to that, participants remaining on antidepressant 
medicines had a significantly lower risk for recurrence of 14%. The continued treatment 
lasted between four months and two years. Antidepressant were as well accepted as placebo. 
As studies on the long-term effects of medication are lacking, recommendations on the 





The benefits of psychological therapies or combined treatment remained unclear, due to the 
small number of studies. Overall, the included studies were of moderate or high 
methodological quality. 
What should happen next? 
This review provides evidence that continued antidepressant medication (compared to pill 
placebo) can reduce the risk of depression recurring in adults with persistent depression. 
However, only a few studies have been done. Further studies should especially address 
psychological and combined long-term treatments. 
 
4.1.3 Background 
Description of the condition 
Persistent forms of depression that last for two years or longer represent a substantial 
proportion of depressive disorders [17, 123–125]. Within the literature, four subtypes can be 
distinguished: (1) dysthymia, (2) chronic major depression, (3) recurrent major depression 
with incomplete remission between episodes, and (4) double depression [35]. Dysthymic 
disorder is defined as a condition with mild depressive symptoms persisting for at least two 
years. Major depressive episode, chronic type, refers to a more severe condition that meets 
full criteria for major depression continuously for a minimum of two years. Patients who have 
recovered to the point at which they no longer meet full criteria for a major depressive 
episode but continue to experience significant symptoms for at least two years are referred to 
as recurrent major depression with incomplete remission between episodes. The 
superimposition of a major depressive episode on antecedent dysthymia is referred to as 
double depression [20]. In the DSM-5 [13], the new diagnostic category of persistent 






The mean length of persistent depression is between 17 and 30 years [17, 18], and the 
lifetime prevalence for persistent depressive disorders is estimated to range from 3% to 6% in 
the Western world [19–21]. In comparison to acute forms of depression, persistent depressive 
disorders are associated with longer treatment duration, increased loss of physical wellbeing, 
increased comorbidity, more severe impairments in social, psychological and emotional 
functioning, increased health care utilization, and more frequent suicide attempts and 
hospitalizations [17, 36]. Thus, persistent depression is likely to make a large contribution to 
the high burden of disease that is associated with unipolar depression according to disability-
adjusted life years (DALYs) [126]. 
 
Description of the intervention 
Overall, a large number of different interventions exist for the treatment of unipolar 
depression, including psychological, pharmacological, and combined psychological and 
pharmacological therapies. Evidence from randomized controlled trials as well as meta-
analyses suggests that these interventions are effective in the acute treatment of depression, 
including persistent forms of depression [43, 54–58, 73, 127]. Still, there is also evidence that 
a relevant amount of patients does not respond to treatment, does not reach complete 
remission and develops persisting residual symptoms in the long run [128]. It is estimated that 
probably half of the people suffering from depressive disorders are developing a chronic 
course [5]. 
Moreover, acute phase treatments often fail to prevent relapse (which is defined as the 
return of symptoms of depression before a full remission has been achieved) and recurrence 
(which is defined as the appearance of another new episode of depression after full remission 
of a previous episode has been achieved) in major depression. For example, after scheduled 
termination of acute phase cognitive therapy (CT), relapse/recurrence rates were found to be 





depression-specific psychological therapies and even higher doses of pharmacotherapy were 
used after the acute-phase treatment, relapse and recurrence rates were still found to be high 
[12]. Besides, there are studies showing that 30 to 50% of patients considered to be remitted 
still have to deal with residual depressive symptoms [129].  
Thus, following response to acute treatment, long-term continuation and maintenance 
therapy is required to protect patients from relapse or recurrence of symptoms. Continuation 
treatments are defined as treatments given to currently remitted patients (remission is defined 
as depressive symptoms dropping below case level) or to patients that previously responded to 
an antidepressant treatment. Maintenance therapy is given during recovery (which is defined 
as remission lasting longer than six months) [8, 45]. The German National Clinical Practice 
Guideline for Unipolar Depression [6] recommends a combination of pharmacotherapy and 
psychological therapy as acute phase treatment for patients suffering from persistent forms of 
depression. Additionally, a continued psychological therapy and/or pharmacotherapy is 
recommended to prevent relapse and recurrence. Specifically, the type of treatment which was 
successful in the acute phase is recommended to be continued [6, 45, 130]. However, the 
recommendations concerning the continuation of therapy are based on unipolar depressive 
patients in general, specific recommendations regarding patients with persistent depressive 
disorders are lacking. 
Hence, a systematic search of evidence regarding the effectiveness of 
pharmacological, psychological and combined pharmacological and psychological therapies 
as continuation and maintenance treatments for patients suffering from persistent forms of 








How the intervention might work 
Acute treatments aim to reduce depressive symptoms and re-establish psychosocial 
functioning. In comparison, continuation and maintenance treatments aim to maintain (or 
improve) the psycho-functional status reached by acute treatment, and to reduce the likelihood 
of relapse and recurrence in the long-term [6]. Therefore, continuation and maintenance 
treatments are considered to be more than a pure extension of acute treatments, because 
continuation/maintenance treatments differ in frequency and content over the course of the 
illness in comparison to acute treatments. 
Psychological continuation and maintenance interventions are offered usually less 
frequently than acute psychological therapy, aiming to monitor symptoms and to integrate 
techniques and strategies into daily life in the long-term [6]. Different programs targeting the 
prevention of relapse and recurrence focus on a range of effect mechanisms. Cognitive 
therapy (CT) approaches focus on the generalization of skills achieved during acute therapy 
[131] or the cognitive content of negative thinking [38]. Mindfulness-Based Cognitive 
Therapy (MBCT) was especially developed to reduce relapse and recurrence in depression 
[47, 48] and teaches people to deal with negative feelings and thoughts as a part of their lives 
through becoming aware of negative cognitive patterns. Maintenance Interpersonal 
Psychotherapy (IPT) aims to complement skills gained in the acute phase therapy and teaches 
patients to take responsibility in the prevention of future episodes by recognizing and 
preventing stressing environmental and social circumstances [49]. Still, it remains challenging 
to completely understand the mechanisms of preventing relapse and recurrence [49].  
The exact therapeutic mechanisms of antidepressants are still critically discussed [50]. 
Most antidepressants seem to increase the concentrations of monoamine neurotransmitters 
(e.g., serotonin or noradrenaline) in the synaptic cleft [51]. However, the effect of most 
antidepressants fully develops after some weeks, indicating that neurophysiological changes 





presence of a constant level of active ingredients, are necessary for permanent improvement. 
Depending on the type of active ingredient, antidepressants can have mood-enhancing, 
anxiolytic or sedative effects and are able to increase or decrease inner drive. Moreover, the 
placebo effect is of particular importance in the treatment of depression. There are studies 
assuming that the more severe the depressive symptoms are, the greater the benefit of 
antidepressants seem to be compared to placebo [132, 133]. However, a recent meta-analysis 
performed on patient-level data regarding the response to antidepressant medication showed 
that initial depression severity and outcomes were similarly related in treatment and placebo 
groups [134].  
A number of studies have shown that the risk of relapse or recurrence of depression is 
associated with residual symptoms following acute treatment phases. These findings lead to 
the therapeutic goal of sustained remission and recommendations of international treatment 
guidelines to continue antidepressant medication after acute phase treatment [45, 130].  
 
Why it is important to do this review   
Research focusing on the prevention of recurrence of depression was identified as a 
top priority in the recent project “Depression: asking the right questions” [22]. The high 
prevalence and the severe personal, societal and economic consequences of persistent 
depressive disorder [17] underline the need for adequate treatment strategies. Growing 
evidence indicates that persistent depressive disorder responds well to several acute 
interventions such as combined psychological and pharmacological treatments, although the 
number of randomized controlled trials is still limited [127]. Yet, given the high rates of 
relapse and recurrences of depression following response to acute treatment, long-term 





The effectiveness of continuation and maintenance therapies for depression has been 
supported by several randomized controlled trials [65, 135–140]. A meta-analysis on relapse 
prevention with antidepressant drug treatment of depressive disorders [42] showed that 
continued antidepressant medication produced a robust reduction in relapse. Another meta-
analysis [12] summarizes the findings of long-term effects of cognitive behavioral therapy 
(CBT). Patients who responded to acute treatment and continued to receive CBT showed a 
significant reduction in relapse and recurrence rates in comparison to inactive as well as 
active controls. 
Although the vast majority of evidence addresses acute treatments for persistent 
depressive disorder or long-term treatments for acute depressive episodes, some studies have 
been performed to address the effectiveness of long-term treatments of persistent depressive 
disorder [62–70]. Until now, no systematic review on the comparative effectiveness of 
continuation and maintenance treatments for persistent depressive disorder is available. 
In summary, this systematic review may be of high relevance due to the following 
reasons: Persistent depressive disorders have a high prevalence and serious personal, societal, 
and economic consequences. No evidence synthesis is available on continuation and 
maintenance treatments of persistent depressive disorders. High quality evidence synthesis is 
needed for clinical guideline recommendations and their implementation in clinical practice. 
 
Objectives 
To assess the effects of pharmacological and psychological continuation and 
maintenance treatments for persistent depressive disorder, in comparison with each other; 
placebo (drug/attention placebo/non-specific treatment control); and treatment as usual. In 
addition, to assess the effects of combined psychological and pharmacological continuation 







Criteria for considering studies for this review 
Types of studies 
Randomized controlled trials (RCTs), and non-randomized controlled trials (NRCTs) 
were included in the systematic review. NRCTs were considered in this review as we 
expected a limited number of RCTs. No restrictions regarding other design characteristics 
were applied. There were no cross-over or cluster RCTs eligible for inclusion in this review, 
however future versions of this review could consider including these trials. 
 
Types of participants 
We considered participants from the age of 18 years of any gender and ethnicity for 
inclusion. Participants who have a diagnosis of persistent depressive disorder or have had this 
diagnosis before their last previous acute treatment were included. The diagnosis of 
depression needed to rely on a formal classification system, such as the International 
Classification of Diseases (ICD) [141] or the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) [13]. Participants needed to be either currently remitted from persistent 
depressive disorder or needed to have at least partially responded to an acute intervention (at 
least 25% symptom reduction from baseline) at the beginning of the continuation or 
maintenance treatment. Participants described as "treatment resistant" were included if they 
fulfilled the formerly mentioned criteria. As the distinction between subtypes of persistent 
depressive disorder (chronic major depression, dysthymia, double depression, or recurrent 
depression without a complete remission between episodes) is controversial, inclusion was 
primarily driven by the duration of the existing depressive disorder. Consequently, studies 





recurrent depression without a complete remission between episodes were included if the 
target disorders are or have been of at least two years' duration. Studies reporting to 
investigate "chronically depressed" participants without fulfilling these criteria (e.g., less than 
two years duration) were excluded. 
Studies focusing exclusively on persistently depressed participants with a specific 
concurrent mental or somatic disorder were excluded – as we assume that the interventions in 
these kinds of studies (primarily) address the comorbid condition and are not focused 
exclusively on persistent depression. Studies that did not define specific concurrent mental or 
somatic conditions as inclusion criteria but reported on comorbidities in addition to the 
persistent depressive disorder were included. No restrictions based on setting were made. 
Studies, in which both participants with persistent and acute forms of depression were 
included, were only considered, if data were reported separately for the persistent subgroup 
(or if 80% or more of the total sample has a diagnosis of persistent depression). If 
randomization was based on the total sample, studies were included and categorized as non-
randomized controlled trials. 
 
Types of interventions 
Experimental intervention 
Pharmacological, psychological, and combined continuation and maintenance 
interventions were considered. Continuation treatments were defined as treatments given to 
currently remitted individuals or to individuals that previously responded to an antidepressant 
treatment, whereas maintenance treatments were defined as treatments given to people who 
are currently recovered. Continuation/maintenance treatments needed to be started within one 
year after termination of an acute treatment. We considered all interventions that satisfied 





reported data on interventions that were clearly labeled as “continuation” or “maintenance” 
treatments were considered.  
We considered pharmacological interventions including the oral administration of 
classified antidepressants: tricyclic antidepressants, selective serotonin reuptake inhibitors, 
monoamine oxidase inhibitors, alpha2-receptor-antagonists, selective noradrenalin dopamine 
reuptake inhibitors, melatonin receptor agonists and serotonin 5 HT2C receptor antagonists, 
as well as  non-classified antidepressants (Trazodone), lithium, Hypericum perforatum, and 
antipsychotic drugs, as these drugs can be used (alone or in combination) in treating different 
forms of depression [6].  
Psychological therapies had to fulfil the following criteria: The intervention must be 
based on a scientific theory (described in detail and/or manualized and/or referenced). At least 
one contact between therapist and participant either face-to-face or via telecommunication 
technologies (e.g., online therapy) must take place. Thus, for example, the general 
dissemination of information material in form of leaflets in waiting rooms will not be 
considered as a psychological therapy. The intervention must consider the personal needs of 
the participant or a group of participants and must be individually tailored in an interpersonal 
process. Thus, group therapies will be included. Concerning psychological therapies, we 
considered behavior therapy/behavior modification, cognitive behavioral therapy, third wave 
cognitive behavioral therapies, psychodynamic therapies, humanistic therapies, integrative 
therapies, systemic therapies, and other psychologically-oriented interventions (based on the 
definition of the Cochrane Common Mental Disorders Group) for inclusion. Combined 
interventions included the administration of one or more pharmacological agents combined 
with one or more psychological therapy.  
Somatic (e.g., electroconvulsive therapy, vagus nerve stimulation, acupuncture), non-





management) interventions were not considered as including too many different interventions 
was likely to result in large clinical and methodological heterogeneity. 
Comparator intervention 
Both controlled and comparative effectiveness studies were included. The comparators 
were: pharmacological placebo (participants received placebo pills), attention-
placebo/nonspecific control (participants received a treatment that involved nonspecific 
psychosocial factors or assessment only), treatment as usual (TAU), (other) psychological 
therapy, (other) pharmacological treatment, (other) combined psychological/pharmacological 
therapy. 
 
Types of outcome measures 
Primary outcomes 
1. Relapse or recurrence rate of depression, preferentially defined as a) fulfillment of 
formal diagnostic criteria for depression (DSM, ICD), or as b) exceeding a cut-off on a 
depression symptom rating scale used by the authors, specifically i) the Hamilton Depression 
Rating Scale (HAM-D) [142], ii) the Montgomery -Åsberg Depression Rating Scale 
(MADRS) [143], iii) the Beck-Depression-Inventory (BDI) [144], iv) the Inventory of 
Depressive Symptomatology (IDS) [145], v) the Patient Health Questionnaire (PHQ) [146], or 
vi) any other depression symptom scale. Due to the long tradition of depression research, 
most instruments used in clinical trials are usually psychometrically sound. Such measures 
were preferred throughout the review (either referenced and/or sufficient psychometric quality 
reported). 2. Dropout due to any reason. 
Secondary outcomes 
3. Symptom severity of depression at the end of treatment (metric outcome of 





Life [WHOQOL] [147]). 5. Dropout due to adverse events. 6. Experiencing any adverse 
event. 7. Serious adverse events. 
Definition of adverse events and side effects are inconsistent [148, 149]. In this 
review, adverse events are defined as any negative event occurring during or after treatment in 
relation a patient whereas side effects are defined as any adverse event that can be attributed 
to a lege artis invervention. Adverse events leading to serious consequences like death, mortal 
danger, hospitalization or disability are referred as serious adverse events [150].  
The primary outcome time point was ‘end of intervention’ (regardless of the duration 
of the intervention). Additionally, outcome was planned to be evaluated at the time point ‘one 
year after the end of intervention’ providing that enough data would be available. If one-year-
data were not available, we planned to use data that ranged between 6 and 18 months after the 
end of intervention with a preference for the time that was closest to one year after the end of 
intervention. However, just one study provided follow-up data 12 weeks after end of 
intervention. If more than one diagnostic definition and/or depression symptom rating scale 
was available (concerning outcome 1. Relapse or recurrence rate of depression), the presented 
hierarchy was used to select measures (priority starting with a) fulfillment of formal 
diagnostic criteria, continuing with b) i) (HAM-D), b)ii) (MADRS) etc.).  
 
Search methods for identification of studies   
Electronic searches 
1. The Cochrane Common Mental Disorders Group maintains a specialized register of 
randomized controlled trials (RCTs), the CCMD-CTR (description in Appendix A, see p. 
192). The CCMD-CTR was searched for study records using the following controlled search 
terms (condition only): ("chronic depression" or “dysthymia” or "dysthymic disorder" or 
"persistent depressive disorder" or "recurrent depression") 2. The CCMD-CTR was searched 





depress*" or "double depress*" or dysthymi* or (depress* NEAR2 recurr*) or "persistent 
depressive disorder"):ti,ab,kw,ky,mh,mc,emt [Key: ti=title; ab=abstract; kw=keywords; 
ky=additional keywords; mh=MeSH terms; mc=MeSH checkwords;emt=EMTREE terms]. 
Records were screened for continuation and maintenance trials. 3. As the review includes both 
RCTs and NRCTs, complementary searches were conducted on the following bibliographic 
databases using relevant subject headings and search syntax’, appropriate to each resource: 
OVID PsycINFO (search strategy listed in Appendix A, see p. 192), PSYNDEX, OVID 
MEDLINE, OVID EMBASE, CENTRAL (Cochrane Library). 
Databases were searched from 1970 onwards (EMBASE from 1980) until December 
2016; no other restriction on language or publication status was applied to the searches. 
Records retrieved from the CCMD-CTR and PsycINFO searches were screened prior to 
running other database searches and the search strategies were validated to prevent the 
retrieval of too many irrelevant references (for example, following the first search we 
considered including the specific terms for 'maintenance' or 'continuation' of treatments for 
persistent depressive disorder appropriate). 
 
Searching other resources 
The following sources of grey literature were searched: ProQuest Dissertations and 
Theses Database (http://www.proquest.com/; retrieved August 11, 2015), Depression. The 
treatment and management of depression in adults [45], S3 Guideline/National Clinical 
Practice Guideline. Unipolar Depression [6], Canadian Network for Mood and Anxiety 
Treatments (CANMAT). Clinical guidelines for the management of major depressive disorder 
in adults [151], Open Grey (http://www.opengrey.eu/; retrieved August 11, 2015). 
As all relevant journals are included in the bibliographic databases being searched no 
further handsearches in journals were conducted. The reference lists of all included studies 





original electronic searches (for example, unpublished or in-press citations). A cited reference 
search was also conducted on the Web of Science. The first author of all included studies was 
contacted for information on unpublished or ongoing studies or to request additional trial data. 
 
Data collection and analysis 
Selection of studies 
Two review authors [KM, SL, RM, or AJ] independently screened titles and abstracts 
for inclusion of all the potential studies identified as a result of the search and coded them as 
'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve' (ineligible). We retrieved 
the full-text study reports/publications and two review authors [KM, SL, or RM] 
independently screened the full-texts and determined studies for inclusion. Reasons for 
exclusion of the ineligible studies were recorded. We resolved any disagreement through 
discussion or, if required, we consulted a fourth person [AJ]. We identified and excluded 
duplicate records and we collated multiple reports that relate to the same study so that each 
study rather than each report was the unit of interest in the review. We recorded the selection 
process in sufficient detail to complete a PRISMA flow diagram. 
 
Data extraction and management 
We used a data collection form, which has been piloted on at least one study in the 
review, to extract study characteristics and outcome data. Two independent review authors 
[KM, SL, or RM] extracted study characteristics and outcome data from included studies. We 
extracted the following study characteristics: study design, time of randomization, total 
duration of study, location, study setting, and date of study (year), number of participants (N), 
mean age, age range, % female, diagnostic subgroup, mean age of onset, length of current/last 





previous to continuation/maintenance treatment, primary and secondary outcomes specified 
and collected, and time points reported, funding of the trial. 
We noted in the 'Characteristics of included studies' table (see Appendix B, see p. 196) 
if outcome data were not reported in a usable way. We resolved disagreements by consensus 
or by involving a third person [KM, SL, or RM]. One review author [SL] transferred data into 
the Review Manager file [152]. We double-checked that data were entered correctly by 
comparing the data presented in the systematic review with the study reports. A second 
review author [KM] spot-checked study characteristics for accuracy against the trial report. 
 
Main comparisons 
Seven main comparisons were chosen from the list of possible comparisons based on 
clinical importance and expected frequency of the comparisons in clinical trials: 
1. pharmacological continuation and maintenance therapies versus placebo 
2. pharmacological continuation and maintenance therapies versus treatment as usual 
(TAU) 
3. psychological continuation and maintenance therapies versus attention 
placebo/nonspecific control 
4. psychological continuation and maintenance therapies versus treatment as usual 
(TAU) 
5. psychological continuation and maintenance therapies versus pharmacological 
continuation and maintenance therapies 
6. combined psychological and pharmacological continuation and maintenance therapies 
versus pharmacological continuation and maintenance therapies alone 
7. combined psychological and pharmacological continuation and maintenance therapies 






Assessment of risk of bias in included studies   
Two review authors [KM, SL, or RM] independently assessed risk of bias for each 
study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of 
Interventions [153]. We resolved any disagreements by discussion or by involving another 
author [KM, SL, or RM]. We assessed the risk of bias according to the following domains: 
random sequence generation, allocation concealment, blinding of participants and personnel, 
blinding of outcome assessment, incomplete outcome data, selective outcome reporting, other 
bias. We judged each potential source of bias as high, low or unclear and provided a 
supporting quotation from the study report together with a justification for our judgment in 
the 'Risk of bias' table. We summarized the risk of bias judgments across different studies for 
each of the domains listed. Where information on risk of bias related to unpublished data or 
correspondence with a trialist, we noted this in the 'Risk of bias' table. The ROBINS-I tool 
[154] for assessing the quality of non-randomized studies in meta-analyses was used to assess 
the quality of non-randomized controlled trials. We included no cluster-randomized trials, 
however in future versions of this review recruitment bias, baseline imbalance, loss of 
clusters, incorrect analysis, and comparability with individually randomized trials in cluster-
randomized trials should be considered [153]. The risk of bias was considered in sensitivity 
analyses. Moreover, we took the risk of bias into account when interpreting the treatment 
effects. 
 
Measures of treatment effect 
Dichotomous data 
In order to increase clinical applicability of the findings, the relative risk of 
relapse/recurrence was calculated for the primary outcomes, as they are more likely to help 
clinicians to make informed decisions in specific clinical situations. For rare outcomes 





None of the included studies in this review used time-to-event data, however in future 
versions of this review primary studies should consider pooled hazard ratios for calculations. 
Continuous data  
We analyzed continuous data as mean differences (MD). In this review, all studies 
used the same rating scale for depression severity (HAM-D), however if in future versions of 
the review there are different scales used across the studies, standardized mean differences 
(SMD) should be analyzed. We entered data presented as a scale with a consistent direction of 
effect. We undertook meta-analyses only where this was meaningful, i.e., if the treatments, 
participants and the underlying clinical question were similar enough for useful pooling. We 
planned to narratively describe skewed data reported as medians and interquartile ranges – if 
effect size calculation is not possible. This procedure was not necessary in this review, 
however in future versions of this review this could be considered. 
 
Unit of analysis issues 
Cross- over and cluster-randomized trials 
As we expected a small number of overall available studies, data from cross-over trials 
and cluster-randomized trials were planned for inclusion in the analysis, regardless of the 
level of randomization. None of the studies in this review was either a cross-over or a cluster-
randomized trial. However, in future versions of this review, cluster-randomized trials should 
include direct effect estimates of the primary studies, only if they were obtained from analyses 
that accounted for the clustering in the data (e.g., using a multilevel model). Otherwise, the 
effect estimates should be approximated using an inflated standard error that incorporates the 
design effect [153]. Concerning cross-over trials, only the first comparison (pre-crossover) 
meeting our inclusion criteria should be used from cross-over trials. 





Concerning studies with multiple treatment groups, for each of the main objectives 
addressed in our review, only data from the comparison of interest were considered. If the 
study provided more than one comparison of interest for one of the main objectives, we 
planned to divide the number of participants in the arm used several times by the number of 
arms for all analyses to avoid including participants more than once in the analysis. However, 
this procedure was not necessary to implement in our analyses but should be considered in 
future versions of this review. 
 
Dealing with missing data 
In case of missing or unclear data, we contacted corresponding authors or study 
sponsors in order to obtain key study characteristics and missing numerical outcome data 
when possible (e.g., when a study was identified as abstract only). We documented all 
requests and correspondences. For all studies, we planned to calculate effect sizes using the 
intention-to-treat principle, i.e., analyzing all subjects allocated to the respective study arm. 
For the primary outcome, all randomized participants were included in the analyses (when 
possible) irrespective of how the authors of the primary studies defined their intention-to-treat 
(ITT) sample. For all other outcomes the definition of the intention-to-treat sample provided 
by the authors were followed. In case, no ITT data were available, we used the data provided. 
 
Assessment of heterogeneity   
Statistical heterogeneity between study results were tested for significance using 
Cochran's Q-test and quantified using the I² statistic [155]. Results were visually displayed as 
forest plots. We expected considerable clinical heterogeneity between studies. I² values in the 
range of 0% to 40%: might not be important, 30% to 60%: may represent moderate 





considerable heterogeneity. Based on this classification, we considered I² values in the range 
of 50 to 100% as relevant statistical heterogeneity that is to be further explored. As 
“thresholds for the interpretation of I² can be misleading, since the importance of 
inconsistency depends on several factors” [153], this was only a rough orientation. Therefore, 
we decided on a case-by-case-basis if the determined heterogeneity needed to be further 
explored. 
 
Assessment of reporting bias  
Possible reporting biases and small-study effects were tested using visual examination 
of funnel plots (when useful). Egger's test [156] was planned for test of publication bias but 
could not be applied in this review, as it requires at minimum 10 studies per comparison. 
 
Data synthesis 
All analyses were performed by applying a random effects model [157]. We used 
random effect models rather than fixed effect ones, because we assumed that the included 
studies would not be functionally equivalent and would show considerable clinical 
(concerning population, intervention) and methodological (concerning quality) heterogeneity. 
Results are visually displayed as forest plots. If it was not possible to combine studies via 









In order to identify possible treatment effect moderators, a priori defined subgroup 
analyses (in case of categorical predictors) or meta-regression analyses (in case of metric 
predictors) were planned for the primary outcomes. Due to the little amount of included 
studies we were not able to undertake these analyses. However, in future versions of this 
review, differences between subgroups should be tested formally [158–160], and all meta-
regression analyses should be performed using the restricted maximum likelihood estimate 
method, a recommended random effects approach that accounts for residual between-trial 
heterogeneity [161].  
The following variables were planned to be considered in subgroup analyses: Subtype 
of persistent depressive disorder (dysthymia vs. other): A possibly moderating effect of 
subtype would suggest that a distinction between these subtypes might be used for allocation 
of patients to treatments (differential indication). On the other hand, a possible homogeneity 
of effects across subtypes may suggest that a distinction is of little relevance in the day-to-day 
practice. Dysthymia will be tested against other subtypes as dysthymia is assumed to be the 
most frequently mentioned subtype. Mean age of onset: The age of onset is known as a 
relevant predictor, it should be assessed if patients with early onset need different treatments. 
Applied intervention (cognitive behavioral therapies vs. other, SSRIs vs. other): As 
experience shows, cognitive behavioral approaches/SSRIs are the most frequent forms of 
psychological therapies/antidepressants to be studied. Therefore, we decided to test these 
approaches vs. other approaches. Evidence on the best available treatments (in case of 
considerable differences) is indispensable for guideline recommendations. Duration of 
continuation/maintenance treatment (weeks): For guideline recommendations and clinical 
practice, it is indispensable to know, if different treatment durations result in different 
outcomes, e.g., if longer treatments lead to better outcomes. 
In case of considerable heterogeneity between study results that cannot be explained by the a 





meta-regression analyses should be performed to identify sources of heterogeneity. A priori 
and a posteriori analyses should be clearly labeled as such. 
 
Sensitivity analysis 
Sensitivity analyses were performed excluding studies with a high or unclear risk of 
bias (separately for each of the seven domains according to the risk of bias-tool of the 
Cochrane Handbook, when possible) and/or outlying findings. Results were contrasted to 
those acquired with data from all studies in order to control for possible effects of study 
quality on pooled effects. Additional sensitivity analysis were planned: 1) excluding trials 
without a randomization on person level (second phases of cross-over trials, NRCTs, and 
cluster-randomized trials) and 2) excluding trials without (re-)randomization immediately 
before the continuation/maintenance phase in order to control for possible design effects. 
However, due to the small number of included studies we were not able to apply additional 
analyses, but this procedure should be considered for future versions of this review. 
 
Summary of findings table 
Summary of findings tables were provided for one comparison: effectiveness of 
pharmacotherapy versus placebo for persistent depressive disorder. Summary of findings 
tables include a summary of the quality of evidence, the magnitude of effects of the according 
intervention and a summary of available data on the primary outcomes (relapse/recurrence 
and dropout due to any reason). Findings were expressed as measures of risk ratio and 








Description of studies 
Results of the search 
We conducted searches between December 2015 and December 2016, retrieving 4489 
rec-ords from the CCDANCTR studies and references registers. Following this, we ran a 
cross-search on OVID MEDLINE, EMBASE and PsycINFO, together with a search on 
CENTRAL (Cochrane Library), retrieving an additional 929 records after exclusion of 
duplicates. Screening several sources of grey literature (Open Grey, ProQuest, ICTRP, 
clinicaltrials.gov), reference lists of relevant systematic reviews and studies, and 
correspondence with authors of included studies yielded additional 732 records. After 
removal of duplicates, two review authors (SL, KM, RM, or AJ) independently screened 5418 
records by title and abstract and excluded 4899 records as they did not meet inclusion criteria 
or were untraceable. Each of the remaining 519 full-texts was checked independently by two 
out of three review authors (SL, KM, or RM) for eligibility. We included 17 publications for 
the qualitative synthesis, and out of this pool we used 10 studies for the quantitative synthesis. 
The PRISMA flow diagram displays the details of the selection process (figure 3). 
Included studies3 
Qualitative analysis: We included 17 publications, describing five continuation and 
five maintenance studies in the qualitative analysis. Three publications (Keller 1998b, Keller 
2000, Marin 1994) described the acute phases of the included continuation and maintenance 
studies, one publication was a study protocol (Rush 1998) and three publications (Berndt 
2000, Kocsis 1997, Kocsis 2002) provided additional analyses on the studies of Keller 1998 
and Koran 2001. Thus, these seven publications were used to extract data missing in the main 
                                                          
3 For reasons of clarity and comprehensibility, from now on the included studies will be addressed by the form 
‚First author, year of publication‘, e.g., Koran 2001. The respective complete references can be found in 





publications. Apart from that, they are not further addressed here. The quantitative syntheses 
is based on 10 studies described below. 
 
 
Figure 3. Study flow diagram 
 
Quantitative analysis: We included 10 studies (following five acute treatment studies) 





between the different continuation/maintenance treatment studies that followed one acute 
treatment study. However, these studies focus on different comparisons and were not included 
in the same analyses. One exception are the studies of Kocsis 1996 and Miller 2001. These 
two studies focused on the same comparison (desipramine versus placebo) during the 
maintenance phase, but analyzed different diagnostic subgroups. Whilst Miller 2001 analyzed 
solely dysthymic participants, Kocsis 1996 included additionally participants with a chronic 
major depressive episode and double depression. Both studies share the group of dysthymic 
participants, although just partially as Miller 2001 included also dysthymic participants not 
involved in Kocsis 1996. Two studies (Harrison 1986; Hellerstein 2001) investigated solely 
continuation treatments. The other eight studies (Koran 2001; Keller 1998; Gelenberg 2003; 
Kocsis 2003; Klein 2004; Kocsis 1996; Miller 2001; Kocsis 1995) followed three acute 
treatment studies, and investigated both continuation and maintenance treatments. For an 
overview of included studies and corresponding acute treatment studies see table 1. 
  
Comparisons 
We predefined seven relevant comparisons: 
1) Pharmacological continuation and maintenance therapies versus placebo. Five of ten 
studies included comparisons of an antidepressant medication with a pharmacological placebo 
(Keller 1998; Harrison 1986; Gelenberg 2003; Kocsis 1996; Miller 2001). Two of these five 
studies (Kocsis 1996; Miller 2001) compared desipramine vs. placebo in the maintenance 
phase, but used different subgroups for analyses (see table 1).  
2) Pharmacological continuation and maintenance therapies versus treatment as usual 






3) Psychological continuation and maintenance therapies versus attention 
placebo/nonspecific control. One study (Klein 2004) compared psychotherapy versus 
assessment only. 
4) Psychological continuation and maintenance therapies versus treatment as usual 
(TAU). There were no studies comparing psychological therapies versus TAU. 
5) Psychological continuation and maintenance therapies versus pharmacological 
continuation and maintenance therapies. One study with three treatment arms (Kocsis 
2003) compared pharmacological, psychological and combined continuation therapy. 
6) Combined psychological and pharmacological continuation and maintenance 
therapies versus pharmacological continuation and maintenance therapies alone. The 
study of Kocsis 2003 with three treatment arms (see above) as well as the study of Hellerstein 
2001 provided data on this comparison. 
7) Combined psychological and pharmacological continuation and maintenance 
therapies versus psychotherapeutic continuation and maintenance therapies alone. The 
study of Kocsis 2003 with three treatment arms (see above) provided data on this comparison. 
8) Pharmacological continuation and maintenance therapies versus other 
pharmacological continuation and maintenance therapies (post hoc). This comparison 
was not predefined, but as two studies (Koran 2001 and Kocsis 1995) provided data on this 






Table 1 Overview of included studies 
Related acute phase 










Imipramine Continuation (16 weeks) NRCT 




Placebo Maintenance (76 weeks) RCT 
chronic major depressive disorder, 
double depression 
Harrison 1986 Harrison 1986 Phenelzine 
Placebo 






Continuation (16 weeks) NRCT 
chronic major depressive disorder, double depression, 






Maintenance (52 weeks) RCT 
chronic major depressive disorder, double depression, 





Maintenance (52 weeks) RCT 
chronic major depressive disorder, double depression, 






Fluoxetine + Group Psychotherapy 









Maintenance (104 weeks) RCT 





Maintenance (104 weeks) RCT dysthymia 







Two studies used a randomized controlled parallel group design to investigate the 
continuation treatment phase (Harrison 1986, Hellerstein 2001). Three studies (Koran 2001, 
Kocsis 2003, Kocsis 1995) investigated a continuation treatment within a non-randomized 
controlled trial, i.e., the patients continued to receive the same treatment being effective 
during acute treatment. Each of these three studies was followed by maintenance treatments 
applying a randomized controlled parallel group design (Keller 1998; Gelenberg 2003; Klein 
2004; Kocsis 1996; Miller 2001). Continuation treatments lasted between 16 and 26 weeks, 
maintenance treatments between 52 and 104 weeks. All 10 studies involved preceded acute 
treatments in their study design (see table 1). 
Sample Size 
Study size varied largely. The two studies investigating solely a continuation treatment 
randomized 12 participants (Harrison 1986) and 40 participants (Hellerstein 2001). Two 
studies randomized between 329 participants (Kocsis 2003) and 386 participants (Koran 
2001) for the continuation phase and re-randomized between 82 participants (Klein 2004) and 
161 participants (Keller 1998) for the subsequent maintenance phase. Another study (Kocsis 
1995) randomized 73 participants to the continuation phase and re-randomized between 27 
participants (Miller 2001) and 53 participants (Kocsis 1996) to the subsequent maintenance 
phase. 
Setting 
Two studies were multicenter (Harrison 1986, Hellerstein 2001) and five were 
singlecenter studies (Koran 2001; Keller 1998; Kocsis 2003; Gelenberg 2003; Klein 2004). 





continued singlecenter during the maintenance phase (Kocsis 1996, Miller 2001). All studies 
were conducted in the US and used an outpatient setting for treatment. 
Inclusion criteria 
All studies required the participants to meet DSM criteria for persistent depressive 
disorder by the time of entering the study, i.e., start of acute treatment. Two continuation 
treatment studies included dysthymic participants only (Harrison 1986; Hellerstein 2001), 
whereby the latter one focused on early onset dysthymic participants. Whilst Koran 2001 and 
Keller 1998 included participants with either a chronic depressive episode or double 
depression, Kocsis 2003, Gelenberg 2003 and Klein 2004 additionally included participants 
with recurrent depression with incomplete interepisode remission. Kocsis 1995 analyzed 
participants with either dysthymia or double depression in the continuation treatment phase. 
The subsequent maintenance treatment phase (Kocsis 1996; Miller 2001) included 
participants with either chronic major depressive disorder, dysthymia or double depression, 
whereby Miller 2001 analyzed only dysthymic participants.  
All studies used explicit response or remission criteria for entry into continuation or 
maintenance phases. Participants were required to show at least clinical response or partial 
remission, scoring below 15 on the Hamilton Rating scale (HAM-D) (Kocsis 2003; Gelenberg 
2003; Klein 2004) or to range between a score of seven and 12 on the HAM-D (Kocsis 1996; 
Miller 2001). Harrison 1986 required the participants to reach a score of 1 or 2 (“very much 
improved” or “much improved”) on the Clinical Global Impression (CGI). Koran 2001 and 
Keller 1998 required participants to fulfil both a HAM-D score of 15 or less and a CGI score 
of less than 3 (i.e., no more than mild depression). One study additionally defined specific 
remission criteria based on the Longitudinal Interval Follow-up Evaluation (LIFE) for 
participants with double depression (Koran 2001), scoring with 1 (no symptoms) or 2 (some 





decrease of symptoms compared to acute phase baseline scores (Koran 2001; Keller 1998; 
Kocsis 2003; Gelenberg 2003; Klein 2004; Miller 2001), and one study with at least 40% 
reduction of symptoms (Hellerstein 2001).   
For the studies investigating continuation treatments, participants had to achieve the 
defined response or remission criteria directly at the end of acute treatment (Kocsis 2003; 
Hellerstein 2001) or had to maintain the specific score for the last four weeks before entering 
the continuation phase (Koran 2001). For the studies investigating maintenance treatments, 
participants had to continue their response or remission throughout the end of continuation 
treatment for being eligible to enter the maintenance phase (Keller 1998; Gelenberg 2003; 
Klein 2004; Kocsis 1996; Miller 2001). Participants included in the studies had to be aged 
between 21 and 65 (Koran 2001; Keller 1998; Hellerstein 2001) or between 18 and 75 years 
(Kocsis 2003; Gelenberg 2003; Klein 2004).  
Patients’ characteristics 
Whilst one study (Harrison 1986) reported that the majority of included participants 
were in their thirties or fourties, all other studies provided mean age scores of participants 
varying between 36 and 45 years of age. Harrison 1986 included predominantly female 
participants (83%), while the proportion of women varied between 50% and 66% in all other 
studies. Distribution of diagnostic subgroups differed among the included studies, whereby 
eight studies treated participants of several diagnostic subgroups, and two studies analyzed 
solely dysthymic participants (Hellerstein 2001, Miller 2001). The number of participants 
with double depression varied between 23% and 63% (Koran 2001; Keller 1998; Harrison 
1986; Kocsis 2003; Gelenberg 2003; Klein 2004; Kocsis 1995; Kocsis 1996). Six studies 
treated participants with a chronic depressive episode (Koran 2001; Keller 1998; Kocsis 2003; 
Gelenberg 2003; Klein 2004; Kocsis 1996), of which the amount varied between 11% and 





with incomplete interepisode remission (Kocsis 2003; Gelenberg 2003; Klein 2004), of which 
the amount varied between 22% and 29%. Three studies treated also participants with 
dysthymia, of which the amount varied between 37% and 40% (Harrison 1986; Kocsis 1995; 
Kocsis 1996). 
Data on the mean age of onset were provided in six studies, the mean age of onset 
ranged from 12.3 to 29.5 years. The mean length of the current/previous episode (data 
provided in five studies: Gelenberg 2003; Keller 1998; Klein 2004; Kocsis 2003; Koran 2001) 
was 73.2 to 105.6 months. Four studies (Hellerstein 2001; Keller 1998; Klein 2004; Koran 
2001) provided data on the number of previous episodes and reported a mean number of 1.3 
to 3.0 episodes. 
Exclusion criteria 
All five studies described criteria for excluding participants prior to study entry, i.e., 
before starting the acute treatment of the study program. Six studies excluded participants 
who failed to respond to either at least one adequate trial of antidepressant medication (Koran 
2001; Keller 1998; Harrison 1986) or who failed to respond to three or more previous trials of 
antidepressant medication and/or at least two trials of empirical supported psychotherapy 
(Kocsis 2003; Gelenberg 2003; Klein 2004). All studies (except Harrison 1986) excluded 
participants with serious medical illness, DSM diagnosed axis I disorders (if principal), 
personality disorders, present psychotic symptoms, or immediate suicidal risk. Five studies 
excluded participants who took concomitant (psychoactive) medication or who had received 
electroconvulsive therapy (ECT) either within three months (Koran 2001; Keller 1998) or 
three years prior to study entry (Kocsis 2003; Gelenberg 2003; Klein 2004). Hellerstein 2001 
excluded participants who parallel underwent another psychotherapy, and Koran 2001 and 
Keller 1998 excluded participants who started another psychotherapy within the previous 






Types of intervention 
Antidepressant drugs and drug placebo interventions 
Continuation treatment: One continuation treatment study included the comparison of 
an active antidepressant drug with a pill placebo (Harrison 1986). In this study, the 
monoamine oxidase inhibitor (MAOIs) phenelzine was used as active treatment for 26 weeks. 
Participants in the active group received on average 51mg of phenelzine daily. Participants in 
the placebo group discontinued phenelzine treatment over a period of 14 days by reducing the 
daily dose by 15mg every 2 to 3 days. Two continuation treatment studies included a direct 
comparison of two antidepressant medications. Koran 2001 compared sertraline (SSRI) with a 
dose between 50mg and 200mg per day to imipramine (TCA) with a dose between 50mg and 
300mg per day during 16 weeks of treatment. The dose could be adapted by 50mg per day a 
week depending on the participant’s symptoms and side effects. The second study (Kocsis 
1995) compared two tricyclic antidepressants during 16 to 20 weeks of treatment. Participants 
received the same final dose achieved during acute treatment (300mg of imipramine or 200mg 
of desipramine per day). Two continuation treatment studies included comparisons of 
antidepressant medication alone versus the combined treatment of medication and 
psychotherapy. Kocsis 2003 investigated three active treatment arms, including nefazodone 
(SNDRI) alone, psychotherapy alone (Cognitive Behavioral Analysis System of 
Psychotherapy), and their combination over 16 weeks. In both medication arms, participants 
received between 300mg and 600mg nefazodone per day. Hellerstein 2001 compared 
fluoxetine (SSRI) alone with the combined treatment of fluoxetine and a group psychotherapy 






Maintenance treatment: Four maintenance treatment studies included the comparison 
of an active antidepressant drug with a pill placebo (Keller 1998; Gelenberg 2003; Kocsis 
1996; Miller 2001). Of these four, two studies (Kocsis 1996, Miller 2001) analyzed the same 
comparison (desipramine vs. placebo) but with focus on different diagnostic subgroups. All 
studies used antidepressants of different classes. In Keller 1998, the participants in the active 
treatment group received a flexible daily dose of 50 to200mg of the selective serotonin 
reuptake inhibitor (SSRI) sertraline hydrochloride for 76 weeks. Participants in the placebo 
arm reduced the sertraline dose by 50mg every week and received placebo substitution. 
Gelenberg 2003 used nefazodone, a serotonin-norepinephrine-dopamine reuptake inhibitor 
(SNDRI) at the same dose being effective during the previous continuation phase (300mg and 
600mg per day) over 52 weeks. Participants in the placebo arm received identical (but 
inactive) tablets without any stepwise reduction between continuation and maintenance phase. 
Kocsis 1996 and Miller 2001 used the tricyclic antidepressant (TCA) desipramine over 104 
weeks as maintenance treatment. Participants in the active group maintained the dose (75-
350mg/day) of the previous continuation phase. Participants in the placebo arm reduced their 
dose by 25% per week during the first month of maintenance treatment and subsequently 
started a treatment with identical placebo pills. 
Types of psychological therapies 
Three studies were identified that investigated psychotherapeutic treatments, two 
continuation treatment studies and one maintenance treatment study. Kocsis 2003 examined 
the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) (McCullough 2000) 
during the 16 week-continuation phase. Participants received six sessions of manualized 
CBASP, both in the CBASP and the combined treatment arm. The continuation treatment 
study of Hellerstein 2001 compared a fluoxetine (SSRI) only group with a group receiving 





phase. The latter group received treatment according to an unpublished manual of Cognitive-
Interpersonal Group Psychotherapy for Chronic Depression (CIGP-CD), combining cognitive 
and interpersonal approaches. Up to 10 participants formed a group with weekly meetings of 
90 minutes. Klein 2004 investigated the comparison of CBASP versus assessment only in the 
52 week-maintenance phase which followed the study of Kocsis 2003 (see above). 
Participants in the CBASP group received one session every four weeks for a total of up to 13 
sessions, and were evaluated by an independent evaluator every four weeks. Participants in 
the assessment only group attended the project coordinator and the independent evaluator also 
every four weeks, hence received some attention but no active treatment.  
Process evaluation of psychological treatments 
Information on process evaluation was inferable from one continuation treatment 
study (Hellerstein 2001) and one maintenance treatment study (Klein 2004). 
Hellerstein 2001 involved two clinical psychology PhD students with extensive 
psychotherapy training for conducting the group therapy in the continuation treatment phase. 
On a weekly basis, these two students met a senior psychiatrist supervisor during two months 
for reviewing how to conduct the treatment with the CIGP-CD treatment manual. By the start 
of the study, sessions with the participants were audiotaped and supervised weekly for 
adherence to the manual. Information on the CBASP sessions in the maintenance treatment 
study was inferable from the main publication (Klein 2004). Additional information was 
received from the publication of the acute treatment phase (Keller 2000). The CBASP 
sessions were all videotaped and conducted by psychotherapists with at least two or five years 
of experience (dependent on last degree achieved). The therapists underwent a two-day 
training workshop with James P. McCullough (founder of CBASP) including an evaluation of 
two videotaped pilot cases before starting treatment with study participants. Throughout the 





reviewing videotapes by designated supervisors at each site. These supervisors were directly 
supervised by James P. McCullough. Treatment adherence was measured using a CBASP 
specific rating scale developed by McCullough (McCullough 2000). In case of nonadherence, 
an immediate meeting with the respective therapist was scheduled and opportunities for 
improvement were discussed.  
 
Types of outcome measures 
Primary outcomes 
The primary efficacy outcome were rates of relapse or recurrence of depression, 
defined by either exceeding a specific score on the HAM-D or on the severity of the CGI, by 
fulfilling DSM criteria for a major depressive episode (MDD), and/or by clinical judgement 
of the research team during a predefined range of time.  
Two continuation studies applied criteria for relapse, either scoring below a satisfactory 
response during four weeks (Koran 2001) or scoring three or more on the CGI during two 
weeks (Harrison 1986). In the maintenance treatment study of Keller 1998, participants had to 
fulfill DSM criteria for a MDD during three consecutive weeks, a CGI rating of three or more, 
and an increase of at least four points on the HAM-D (compared to maintenance baseline) to 
be diagnosed as having a recurrence. One week later, a senior investigator had to determine 
the diagnosis within a clinical interview to confirm relapse. Two other maintenance treatment 
studies (Kocsis 1996; Miller 2001) defined a participant’s recurrence by a score of 12 or more 
on the HAM-D and a score below 60 on the GAS on three consecutive ratings within four 
weeks. Also, if a participant fulfilled these criteria on just one rating but was considered to 
need urgently alternative treatment, the participant was rated as being recurred.  
One continuation treatment study (Kocsis 2003) and two maintenance treatment 





followed the same acute treatment study (Keller 2000). This three studies required the 
participants to score 16 or higher on the HAM-D, to fulfill DSM criteria for a MDD on two 
consecutive visits and to undergo a clinical interview with a senior investigator confirming 
recurrence. These three studies also applied another definition in case a participant scored 16 
or more on the HAM-D but did not fulfill MDD criteria or discontinued before a second visit 
for clarification. Then, senior investigators reviewed the data of such participants at the end of 
study, discussed and decided  if and at what time a MDD had occurred and if the participant 
could be considered to have recurred. Two studies did not address relapse or recurrence as an 
outcome (Hellerstein 2001, Kocsis 1995). 
The primary safety/acceptability outcome was dropout due to any reason other than 
recurrence. Nine studies reported overall dropout rates. Most of the studies also reported 
reasons for dropout (see section “secondary outcomes”). One study (Miller 2001) did not 
report any dropout rates. 
Secondary outcomes 
Metric outcomes of depression severity scales and quality of life measures were 
reviewed as secondary efficacy outcomes. In six studies changes in severity of depressive 
symptoms from pre- to posttreatment on the HAM-D were reported (Koran 2001; Keller 
1998; Harrison 1986; Gelenberg 2003; Klein 2004; Hellerstein 2001). Three studies included 
quality of life measures (Koran 2001; Keller 1998; Hellerstein 2001). The continuation 
treatment study of Koran 2001 reported data on the Quality of Life Enjoyment and 
Satisfaction Questionnaire (Q-LES-Q), a self-report measure obtaining the degree of 
enjoyment and satisfaction in different areas of daily functioning. In the subsequent 
maintenance treatment study, Keller 1998 used the 36-item short-form health survey (SF-36), 
and reported data on three subscales (social functioning, role limitations owing to emotional 





2002). In Hellerstein 2001, the Satisfaction With Life Scale (SWLS), a self-report measure of 
subjective life satisfaction, was used. Only in this study follow-up outcome data (both for the 
HAM-D and the SWLS scores) 12 weeks after end of intervention were reported. 
Measures of safety, i.e., dropout due to adverse events and the occurrence of any or 
severe adverse events were also reviewed. Five of ten studies reported dropout due to adverse 
events other than recurrence, and all of these studies compared antidepressant medication with 
placebo or another medication (Keller 1998; Koran 2001; Harrison 1986; Gelenberg 2003; 
Kocsis 1995). Reasons for such dropout were either side effects, insufficient response, 
intercurrent illness or dispute with staff. Two studies reported the occurrence of any adverse 
events, including side effects (e.g., headache, insomnia, sexual problems) for the majority of 
participants (Keller 1998) and side effects (especially sleep disturbances and sexual problems) 
for all participants in the medication arm (Harrison 1986), although no data were reported for 
the placebo group in the latter study. 
Excluded studies   
The major reason for exclusion of studies was the non-fulfilment of the diagnosis 
“persistent depressive disorder” (see study flow diagram; figure 3, p. 55). Some studies 
involved participants with recurrent depressive disorder with complete interepisode remission 
(e.g., Jarrett 2013), other studies involved in fact also chronic forms of depression, but the 
percentage of chronic forms was less than 80% (e.g., Thase 2001) or no separate analyses of 
diagnostic subgroups of persistent depression were provided (e.g., Petersen 2010), 
respectively. Other studies were excluded because they did not apply clear response or 
remission criteria for participants to be eligible for entering continuation/maintenance 
treatment, i.e., all participants from the acute phase could take part in the following treatment 







Risk of bias in included studies   
Of the 10 studies included, seven were randomized controlled trials (RCTs) and three 
were non-randomized controlled trials (NRCTs). These three NRCTs were continuation 
treatment studies (Koran 2001; Kocsis 2003; Kocsis 1995), and were labelled as NRCTs for 
this review as the acute phase responders were not re-randomized for the continuation 
treatment. The RCTs were rated with the Risk of Bias-Tool on a three point scale 
(low/high/unclear risk) (see figure 4 and 5). The NRCTs were rated with the ROBINS-I tool 
(Sterne 2016), using a five point scale (low/moderate/serious/critical/unclear risk) (see figure 
6 and 7).  
 
Figure 4. Risk of bias graph RCTs 
Review authors' judgements about each risk of bias item presented as percentages across all included 
seven RCTs. Blank space in rows containing no information indicate missing information on the RoB 







Figure 5. Risk of bias summary RCTs 
Review authors' judgements about each risk of bias item for each included RCT (seven studies). Blank 








Figure 6. Risk of bias graph NRCTs 
Review authors' judgement about each risk of bias item presented as percentages across all included 






Figure 7. Risk of bias summary NRCTs 
Review authors' judgements about each risk of bias item for each included NRCT (three studies). 
 
Risk of Bias in RCTs (7 studies) 
Random sequence generation (selection bias). The random sequence generation was 
described in none of the included RCTs. Hence this domain was rated as unclear risk of bias 
in all seven RCTs. 
Allocation (selection bias). All seven RCTs have an unclear risk of bias concerning allocation 
as there were no information on the allocation process. 
Blinding of participants and personnel (performance bias). Five studies (Keller 1998; 





personnel were blinded (low risk). Two studies (Hellerstein 2001; Klein 2004) were 
psychotherapy studies. Therefore, participants and personnel were aware of the treatment 
condition (high risk). 
Blinding of outcome assessment (detection bias). In two studies (Gelenberg 2003; Klein 
2004), the outcome assessors were independent and blind to the treatment condition (low 
risk), in two other studies (Keller 1998; Harrison 1986) there was no information on this 
domain (unclear risk) and in three studies (Hellerstein 2001; Kocsis 1996; Miller 2001) the 
assessors were study clinicians not blinded to the treatment condition (high risk). 
Incomplete outcome data (attrition bias). In five studies (Harrison 1986; Gelenberg 2003; 
Klein 2004; Kocsis 1996; Miller 2001), the risk concerning incomplete outcome data was 
low. In these studies, the number of participants with missing data was low (below five 
percent), there was no missing data or the (main) outcome was reported for all included 
participants. Two studies (Keller 1998; Hellerstein 2001) had a high risk of bias as the 
number of participants with missing data was very high, and we considered the used 
imputation methods (LOCF; last observation carried forward) as rather inadequate for this 
context (see discussion section).  
Selective reporting (reporting bias). Five studies (Keller 1998; Harrison 1986; Gelenberg 
2003; Klein 2004; Hellerstein 2001) had an unclear risk concerning this domain. There was 
no study protocol for the continuation or maintenance treatment available. Nevertheless, the 
risk of bias was not rated as “high” as outcomes in relevant domains were reported and there 
was no specific indication for selective reporting. In two other studies (Kocsis 1996; Miller 
2001) the risk was assessed as “high” as results were not reported for all applied measures. 
Other potential sources of bias. To operationalize the domain of other relevant sources of 





adherence, allegiance bias/conflict of interest, and attention bias. Then, ratings from these 
three subdomains were summarized to one overall rating of „other potential sources of bias“ 
for each RCT. If one of these three subdomains indicated a high risk of bias, we assessed the 
overall rating as “high”. In the case that two (or three) domains indicated an unclear risk and 
one (or no) domain indicated a low risk, the overall rating was “unclear”. The overall rating 
was “low risk” if two or three domains indicated a low risk and no or one domain indicated an 
unclear risk. Three studies (Keller 1998; Gelenberg 2003; Hellerstein 2001) were assessed as 
having a high risk, especially because conflict of interest was considered very likely 
(pharmaceutical sponsoring). One study (Harrison 1986) had an unclear risk as information on 
the three subdomains were mostly lacking. Three studies (Klein 2004; Kocsis 1996; Miller 
2001) had a low risk as there was – for example – serum level control to ensure the treatment 
adherence. Moreover, the investigators ensured that all groups received the same amount of 
attention and there were – in case of sponsoring from a pharmaceutical company – also other, 
independent authors involved in the publication. 
 
Risk of bias in NRCTs (3 studies) 
Bias due to confounding (mostly: group allocation). Two studies (Koran 2001, Kocsis 2003) 
were assessed as having a low risk in this domain as participants were randomized before the 
acute treatment. In one study (Kocsis 1995) there was no information on how participants 
were allocated to the groups in the acute treatment phase (unclear risk). 
Bias in selection of participants into the study. Two studies (Koran 2001, Kocsis 2003) 
included all eligible participants and described the process of inclusion and the study flow 
clearly. In the study of Kocsis 1995, participants from three different acute phase treatment 
protocols with different treatment durations and medication were included, thus the risk in 





Bias in classification of interventions. The intervention status was well defined in all three 
NRCTs, for example the planned and actual dose of the pharmacological intervention and the 
number of psychotherapy sessions was described, indicating a low risk. 
Bias due to departures from intended interventions. In all three NRCTs, there was no 
indication for departures from intended interventions, e.g., plasma level checks were 
performed and the dose range of medication or the number of psychotherapy sessions, 
respectively, were within the planned range. Therefore, the risk was rated as low.  
Bias due to missing data. In the studies of Koran 2001 and Kocsis 2003, the number of 
participants with missing data was low (less than 5% for the main outcome) and comparable 
across the intervention groups. The risk was assessed as moderate for the study of Kocsis 
1995, as the proportions of participants with missing data differed substantially across the 
groups, but reasons for dropout were reported. 
Bias in measurement of outcomes. The assessment methods were reliable, comparable across 
treatment groups and performed by trained independent raters in the studies of Koran 2001 
and Kocsis 2003. In the study of Kocsis 1995, the frequency of ratings differed across 
treatment groups and participants as well as raters were aware of the treatment (serious risk). 
Bias in selection of the reported result. In the study of Koran 2001, the outcomes correspond 
to the ones named in the methods section. The study protocol focused solely on the acute 
phase of the study, and not all measures described in the protocol were reported in the 
publication of the continuation treatment study (moderate risk). For the study reported by 
Kocsis 2003, no study protocol was available, but all measures reported in the methods 
section were also reported in the results section (moderate risk). In the study reported by 






Effects of interventions   
For all comparisons, intention-to-treat (ITT) data were analyzed when possible. Six 
studies reported ITT data for all outcome measures included in this review. In the other four 
studies, data for 2% to 10% of the ITT sample were missing for single outcome measures at 
end of intervention. Missing data were not replaced, calculations are based on the data 
provided in the publications. Data on the dropout rate (overall dropout and dropout due to 
adverse events) are consistently based on the complete ITT sample. The only study with 
follow-up data (Hellerstein 2001) provided data on depression severity at follow-up for the 
complete ITT sample and data on quality of life at follow-up for 85% of the participants of the 
ITT sample. Risk ratios (RR) and their 95% confidence intervals (CI) were calculated. When 
the overall results were significant, the number needed to treat to benefit (NNTB) was also 
calculated. Mean differences (MD) are presented for continuous data.4 
1 Pharmacological continuation and maintenance therapies versus placebo 
Five studies provided data on this comparison. Keller 1998 compared sertraline (N = 
77) with placebo (N = 84), Harrison 1986 compared phenelzine (N = 5) with placebo (N = 7), 
and Gelenberg 2003 compared nefazodone (N = 76) with placebo (N = 84). Both Kocsis 1996 
and Miller 2001 compared desipramine with placebo, analyzing different diagnostic 
subgroups: Kocsis 1996 (desipramine: N = 28; placebo: N = 25), Miller 2001 (desipramine: N 
= 14; placebo: N = 13). As Kocsis 1996 and Miller 2001 evaluated partially overlapping 
groups (see above), only the data of the larger group (Kocsis 1996) were considered here. The 




                                                          
4 In the following, graphic representations of effects (forest plots) are only displayed if more than one study 






Participants taking antidepressant medication had significant less relapses or 
recurrences compared to the placebo group at end of intervention, with moderate degree of 
heterogeneity between these four studies (figure 8). This translates to a NNTB of six. The four 
included studies were all RCTs. Three of them were maintenance treatment studies 
(Gelenberg 2003; Keller 1998; Kocsis 1996), while Harrison 1986 was a continuation 
treatment study. All studies used different antidepressants from varying classes. 
 
Figure 8. Forest plot of comparison: Medication versus placebo, outcome: Relapse/recurrence. 
 
Four studies provided overall dropout rates at the end of intervention. The four 
included studies were all RCTs. Three of them were maintenance treatment studies 
(Gelenberg 2003; Keller 1998; Kocsis 1996), while Harrison 1986 was a continuation 
treatment study. We found no significant differences between medication and placebo. 
Heterogeneity was substantial (I² = 64%) (figure 9). Two studies (Gelenberg 2003; Kocsis 
1996) reported less dropouts in the medication arm, while the other two studies (Keller 1998; 
Harrison 1986) reported less dropouts in the placebo group.  
 







Means and standard deviations (SDs) were available from three RCTs. Two of them 
were maintenance treatment studies (Gelenberg 2003; Keller 1998), while Harrison 1986 was 
a continuation treatment study. Participants in the medication arms showed a significantly 
lower symptom severity on the HAM-D at end of intervention compared to the placebo 
groups. Heterogeneity was moderate to substantial (figure 10).   
 
Figure 10. Forest plot of comparison: Medication versus placebo, outcome: Depression severity. 
 
One RCT (Keller 1998) provided quality of life measures at end of intervention and 
reported three subscales of the SF-36. In this maintenance treatment study, participants in the 
medication arm reported both higher social functioning (MD = 10.80, 95% CI = 3.04 to 
18.56; participants = 161) and less limitations owing to emotional problems (MD = 20.70, 
95% CI = 7.43 to 33.97; participants = 161). No significant difference was found for the 
subscale of role limitations owing to physical health problems. Three RCTs provided data on 
dropout due to adverse events at end of intervention and indicated no significant difference 
between medication and placebo (figure 11). Two of them were maintenance treatment 







Figure 11. Forest plot of comparison: Medication versus placebo, outcome: Dropout due to adverse 
event. 
 
One RCT (Keller 1998) provided data on experiencing any adverse event (physical 
problems like headache or insomnia) at end of intervention. In this maintenance treatment 
study no significant difference between medication and placebo were found (OR = 1.47, 95% 
CI = 0.70 to 3.09; participants = 161). The continuation treatment study of Harrison 1986 
(RCT) also provided data on adverse events, but solely for the medication group. In the 
medication group all participants suffered from adverse events. 
No data on serious adverse events available. 
 
2 Pharmacological continuation and maintenance therapies versus treatment as usual 
(TAU). None of the included studies provided data on this comparison. 
 
3 Psychological continuation and maintenance therapies versus attention 
placebo/nonspecific control 
One maintenance treatment study (RCT) provided data on the comparison 
psychotherapy versus assessment only (Klein 2004, N = 82). 
Primary outcomes 
Rates of relapse/recurrence were significantly lower in the psychotherapy arm (RR = 





There were no significant differences between the overall dropout rates of the two groups (RR 
= 0.87, 95% CI = 0.41 to 1.81; participants = 82). 
Secondary outcomes 
The depression severity was significantly lower in the psychotherapy group at end of 
intervention (MD = -4.00, 95% CI = -7.05 to -0.95; participants = 82).  
No data on quality of life available. No data on dropout due to adverse events available. No 
data on experiencing any adverse events available. No data on serious adverse events 
available. 
 
4 Psychological continuation and maintenance therapies versus treatment as usual 
(TAU). None of the included studies provided data on this comparison. 
 
5 Psychological continuation and maintenance therapies versus pharmacological 
continuation and maintenance therapies 
One continuation treatment study (Kocsis 2003, N = 179) provided data on the 
comparison psychotherapy versus medication, applying a non-randomized controlled trial 
(NRCT). 
Primary outcomes 
Concerning relapse/recurrence rates, there were no significant differences between the 
two treatment arms (RR = 1.22, 95% CI = 0.43 to 3.49; participants = 176). There were no 
significant differences in dropout rates between the two treatment arms, although a tendency 
favoring psychotherapeutic treatment is observable (RR = 0.56, 95% CI = 0.30 to 1.03; 







No data on depression severity scales available. No data on quality of life available. 
No data on dropout due to adverse events available. No data on experiencing any adverse 
events available. No data on serious adverse events available. 
 
6 Combined psychological and pharmacological continuation and maintenance therapies 
versus pharmacological continuation and maintenance therapies alone 
Two continuation treatment studies provided data on this comparison: Kocsis 2003 
(NRCT) compared nefazodone (N = 91) to nefazodone combined with CBASP (N = 150), 
while Hellerstein 2001 (RCT) compared fluoxetine only (N = 19) to a combination of 
fluoxetine and group psychotherapy (N = 20). 
Primary outcomes 
Kocsis 2003 (NRCT) provided data on relapse/recurrence rates, showing no 
significant difference between participants taking medication only (nefazodone) or medication 
combined with psychotherapy (CBASP) (RR = 1.23, 95% CI = 0.44 to 3.44; participants = 
238). Both studies provided overall dropout rates at end of intervention and found no 
significant differences between medication only and the combined treatment. No 
heterogeneity was found between studies (RR = 1.43, 95% CI = 0.90 to 2.29; participants = 
280; I2 = 0%) (figure 12). 
 








Continuous data were available from the RCT of Hellerstein 2001. Participants in the 
combined treatment group showed a significantly lower symptom severity on the HAM-D at 
end of intervention compared to the medication only group (MD = 2.80, 95% CI = 0.38 to 
5.22; participants = 39). This study also provided follow-up data 12 weeks after the end of 
intervention. No significant differences between both treatment conditions were found (MD = 
0.90, 95% CI = -3.26 to 5.06; participants = 39). Hellerstein 2001 (RCT) provided quality of 
life measures at end of intervention (MD = -0.50, 95% CI = -1.63 to 0.63; participants = 35) 
and at follow-up 12 weeks after end of intervention (MD = 0.60, 95% CI = -0.56 to 1.76; 
participants = 33), using the Satisfaction with Life Scale (SWLS). There were no significant 
differences between both treatment conditions at either time point. No data on dropout due to 
adverse events available. No data on experiencing any adverse events available. No data on 
serious adverse events available. 
 
7 Combined psychological and pharmacological continuation and maintenance therapies 
versus psychotherapeutic continuation and maintenance therapies alone 
One continuation treatment study (Kocsis 2003) provided data on the comparison 
psychotherapy (CBASP, N = 88) versus combined treatment (nefazodone + CBASP, N = 
150), applying a non-randomized controlled trial (NRCT). 
Primary outcomes 
Rates of relapse/recurrence did not differ between participants receiving 
psychotherapy alone or in combination with medication (RR = 1.51, 95% CI = 0.57 to 4.01; 
participants = 234). 
Overall dropout rates at end of intervention did not differ between both treatment conditions 






No data on depression severity scales available. No data on quality of life available. 
No data on dropout due to adverse events available. No data on experiencing any adverse 
events available. No data on serious adverse events available. 
 
8 Comparison of different antidepressant medications (post hoc analyses) 
Two continuation treatment studies (both NRCTs) provided data on the comparison of 
two different antidepressant medications (Kocsis 1995; Koran 2001). Although we did not 
predefine this comparison as a main comparison of interest in the study protocol, we will 
report this additional data. 
8.1 Imipramine versus Desipramine 
One study (Kocsis 1995, N = 73) provided data on the comparison of two different 
tricyclic antidepressants (imipramine and desipramine). 
Primary outcomes 
8.1.1 Relapse/recurrence rates of depression 
No data on relapse/recurrence rates of depression available. Significantly more 
participants dropped out in the imipramine group (RR = 4.35, 95% CI = 1.19 to 15.87; 
participants = 73). This translates to a NNTB of five, that is, five participants must be treated 
with desipramine in order to maintain one additional participant in treatment.  
Secondary outcomes 
No data on depression severity scales available. No data on quality of life available.  
There were no significant differences between the dropout rates due to adverse events of the 
two groups (RR = 1.45, 95% CI = 0.26 to 8.09; participants = 73). No data on experiencing 





8.2 Imipramine versus Sertraline 
One study (Koran 2001, N = 386) compared a tricyclic antidepressant (imipramine) 
with a selective serotonine reuptake inhibitor (sertraline). 
Primary outcomes 
No significant differences between the relapse/recurrence rates of the two treatment 
arms occurred (RR = 1.27, 95% CI = 0.84 to 1.91; participants = 376). There were no 
significant differences between the overall dropout rates of the two groups (RR = 0.81, 95% 
CI = 0.48 to 1.38; participants = 386). 
Secondary outcomes 
The depression severity (measured with the HAM-D) at end of intervention did not 
differ significantly between imipramine and sertraline (MD = 0.40, 95% CI = -0.97 to 1.77; 
participants = 377). The degree of enjoyment and satisfaction in different areas of daily 
functioning (Q-LES-Q) at end of intervention was significantly higher in the sertraline group 
(MD = -4.30, 95% CI = -7.31 to -1.29; participants = 347). There were no significant 
differences between the dropout rates due to adverse events of the two groups (OR 1.99, 95% 
CI 0.60 to 6.65; participants = 386). 
8.2.6 Experiencing any adverse event 




We were not able to perform any of the a priori defined subgroup or meta-regression 







We could perform sensitivity analyses only for one comparison (pharmacological 
continuation and maintenance therapies versus placebo) as all other comparisons did not 
provide enough data. 
Excluding studies with a high or unclear risk of bias 
For each risk of bias domain, we planned to exclude the studies with high or unclear 
risk to compare these results with the results of the analysis including all studies. 
For the domains ‘random sequence generation’, ‘allocation concealment’, and ‘selective 
reporting’, none of the studies had a low risk of bias, thus these sensitivity analyses could not 
be performed. Concerning the domain ‘blinding of participants and personnel’, all of these 
studies had a low risk of bias. With regard to the domain ‘blinding of outcome assessment’, 
only the study of Gelenberg 2003 had a low risk of bias. When including only Gelenberg 
2003, the difference between medication and placebo concerning ‘relapse/recurrence’ did not 
reach significance (RR = 0.76, 95% CI 0.47 to 1.23, p = 0.27), whereas concerning ‘dropout 
any’, there appeared a significant difference (RR = 0.48, 95% CI 0.24 to 0.94, p = 0.03) 
favouring medication. With regard to ‘depression severity’ the difference between medication 
and placebo missed significance (MD = -2.10, 95% CI -5.08 to 0.88, p = 0.17) when including 
Gelenberg 2003 only. Referring to ‘dropout due to adverse event’, there was no significant 
difference between medication and placebo – consistent with the original results. 
Concerning the domain ‘incomplete outcome data’, we excluded the study of Keller 
1998 as it had a high risk in this domain. There was no change concerning the findings on the 
outcome measures ‘relapse/recurrence’ and ‘dropout any’ (except a lower rate of 
heterogeneity in the latter). Concerning ‘depression severity’, the heterogeneity increased 
when excluding Keller 1998. Medication was still superior to placebo but the differences 





Concerning ‘dropout due to adverse event’ the results did not change substantially when 
excluding Keller 1998. 
Regarding the domain ‘Other potential sources of bias’, the studies of Kocsis 1996 
and Miller 2001 (comparing desipramine with placebo) with the partially overlapping 
subgroup had a low risk of bias. Including only Kocsis 1996, the difference between 
medication and placebo regarding ‘relapse/recurrence’ remained significant. Regarding 
‘dropout any’ the difference between medication and placebo missed significance – 
corresponding to the original results. Concerning ‘depression severity’ and ‘dropout due to 
adverse event’ there were no data available for Kocsis 1996. 
Summarizing, the sensitivity analyses could only focus on three of the seven risk of 
bias domains and on the two primary outcomes (relapse/recurrence, dropout any) and on two 
secondary outcomes (depression severity, dropout due to adverse event). 
Exluding trials without a randomization on a personal level or without (re-)randomization 
before the continuation phase 
We could not perform these analyses as all studies providing data on the comparison 
pharmacological continuation and maintenance therapies versus placebo were RCTs with 
randomization on a personal level. 
Post hoc sensitivity analyses 
As there were two partially overlapping groups included (Kocsis 1996 and Miller 
2001) in our review regarding the comparison pharmacological continuation and maintenance 
therapies versus placebo, we decided to perform an a posteriori defined sensitivity analysis 
(including Miller 2001 instead of Kocsis 1996). Miller 2001 investigated the dysthymic 
subsample of Kocsis 1996 but also included additional dysthymic subjects. Miller 2001 only 
provided data on the outcome ‘relapse/recurrence’. The risk ratio was slightly lower (RR = 





heterogeneity (I² = 58%) when including Miller 2001 instead of Kocsis 1996. We consider 
these differences as clinically not meaningful (figure 13). 
 
Figure 13. Forest plot of comparison: Pharmacological continuation and maintenance therapies versus 
placebo, outcome: Relapse/recurrence. Sensitivity Analysis. 
 
 
4.1.6 Discussion   
Summary of main results   
This review is based on data from 10 studies, from which five studies investigated 
continuation treatments and five studies investigated maintenance treatments. All 
maintenance treatment studies and two continuations treatment studies applied a randomized-
controlled design (RCT). The remaining three continuation treatment studies used a non-
randomized-controlled design (NRCT). Five studies included comparisons of antidepressant 
medication versus pill placebo. Only three studies involved psychological treatment. Two of 
these three studies investigated the effect of CBASP (compared to antidepressant medication 
or their combination), or against assessment only, while the other study compared 
antidepressant medication with a combination of medication and group therapy. We also 
analyzed data for an a posteriori defined comparison as data of two studies were available, 
namely the direct comparison of two antidepressant medications. All 10 studies reported data 







Pharmacological continuation and maintenance therapies versus placebo  
Five studies compared continuation or maintenance antidepressant medication with 
pill placebo. The class of antidepressant medication varied between the included studies, 
selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, serotonin-
norepinephrine-dopamine reuptake inhibitors and tricyclic antidepressants were used. For the 
analyses, we excluded one study (Miller 2001) due to an overlapping group of patients with 
the study of Kocsis 1996. Our analysis based on four studies involving 383 participants 
revealed that participants taking antidepressant medication had significant less relapses or 
recurrences and a lower depressive symptom severity score compared to participants taking 
placebo at end of intervention. The results did not change significantly when replacing Kocsis 
1996 by Miller 2001. 
Continuation/maintenance antidepressant medication reduced risk of 
relapse/recurrence with an NNTB of six. Heterogeneity between studies was moderate. For 
the outcome relapse/recurrence, three studies (Keller 1998; Harrison 1986; Kocsis 1996) 
showed similar between-group effect sizes, although these studies varied largely regarding 
treatment duration and sample size. In comparison, in Gelenberg 2003, the effect favoring 
medication was smaller with a rather narrow CI. Miller 2001 showed a very strong effect 
favoring medication with a very large CI (due to small sample size). In the latter, solely 
dysthymic participants were treated over a period of 104 weeks, therefore the design and 
setting of this study is different from the other four studies. Besides, all studies used different 
antidepressants from varying classes, which could have been contributed to the moderate 
degree of heterogeneity. 
We found no significant differences between medication and placebo concerning the 
overall dropout rate. Heterogeneity was substantial (I² = 64%). In Harrison 1986 no 
participant in the placebo group dropped out, but they reported that all participants in the 





not possible by definition). Besides, two studies (Harrison 1986; Kocsis 1996) investigated 
rather small sample sizes, resulting in large CIs. 
Participants taking antidepressant medication had a significantly lower depressive 
symptom severity score compared to participants taking placebo at end of intervention (based 
on three RCTs). Two of these studies, both maintenance treatment studies (Keller 1998 and 
Gelenberg 2003) showed very similar results, both in means and SDs pre- and posttreatment 
and generally, in design of the study (maintenance phase, lasting 76 or 52 weeks, 
respectively). Treatment duration in the continuations treatment study of Harrison 1986 was 
26 weeks, and participants in the medication arm reported lower and participants in the 
placebo group higher symptom severity scores compared to the corresponding groups in the 
other two studies. These factors might have contributed to considerable heterogeneity 
between the three studies. Considering the results regarding relapse/recurrence and 
depression symptom severity, it can be assumed that continued and/or maintained 
pharmacotherapy is superior to pill placebo in persistent depressed participants. 
Three RCTs (Keller 1998; Harrison 1986; Gelenberg 2003) provided data on dropout 
due to adverse events at end of intervention and indicated no significant difference between 
medication and placebo. These three studies varied in sample size, dropout rates due to 
adverse events in general and also between treatment arms, potentially contributing to the 
moderate degree of heterogeneity. In the continuation treatment study of Harrison 1986, no 
participant in the placebo group dropped out due to adverse events, but all of these 
participants relapsed (before), and this study had a small sample size and rather short 
treatment duration compared to the other two studies. The maintenance treatment study of 
Keller 1998 showed considerable differences in dropout rates between the treatment arms, 
favoring placebo, and treatment lasted 76 weeks. In comparison to the other two studies, 
Gelenberg 2003 showed the smallest difference in dropout rates due to an adverse event 





unclear if participants actually took the medication throughout the entire maintenance phase 
as no laboratory tests were reported. This could possibly lead to less reporting of adverse 
events. One study (Keller 1998) provided quality of life measures, in which participants in the 
medication group benefitted compared to placebo. 
Sensitivity analyses predominantly revealed no relevant differences between original 
results and exclusion of all studies with high or unclear risk of bias in the single domains. 
There were two exceptions: Medication did not remain significantly superior to placebo 
concerning depression severity when excluding Keller 1998. When excluding all studies but 
Gelenberg 2003, the results changed with respect to relapse/recurrence and depression 
severity (the difference between medication and placebo missed significance) as well as 
overall dropout rate (there was a significantly lower dropout rate in the medication group). 
However, it remains unclear if these disparate results can be reduced to the potential risk of 
bias in the excluded studies or if they mainly can be explained by the specific study 
characteristics of Gelenberg 2003. 
Psychological continuation and maintenance therapies versus attention 
placebo/nonspecific control 
One maintenance treatment study with 52 weeks duration (Klein 2004), involving 82 
participants, provided data on this comparison. The study showed less relapses/recurrences 
and a lower depression severity score in the CBASP group compared to the assessment only 
group at end of intervention. Maintained CBASP treatment reduced the risk of 
relapse/recurrence with a NNTB of five. Overall dropout rates were similar in both treatment 
arms. It might be assumed that maintained active psychotherapy has a positive effect on 






Psychological continuation and maintenance therapies versus pharmacological 
continuation and maintenance therapies 
Only one study (Kocsis 2003) involving 179 participants provided data on the active 
comparison of psychotherapy with medication during the continuation treatment phase. 
Although participants receiving CBASP and those taking nefazodone did not differ regarding 
relapse/recurrence and overall dropout rate at end of intervention, a tendency favoring 
psychotherapeutic treatment was observable regarding dropout. 
Combined psychological and pharmacological continuation and maintenance therapies 
versus pharmacological continuation and maintenance therapies alone 
Three studies contributed data for this comparison. One continuation treatment study 
(Kocsis 2003) involving 238 participants provided relapse/recurrence rates and showed no 
statistical significant differences between the group taking nefazodone and the group 
receiving both CBASP and nefazodone. Two studies (Kocsis 2003; Hellerstein 2001) 
involving 280 participants provided overall dropout rates, showing no statistical significant 
differences between medication alone and the combined treatment. One study (Hellerstein 
2001) involving 39 participants reported a significant lower depression severity score for the 
combined group compared to medication alone at end of intervention. However, this effect 
did not remain at the 12 week follow-up. This same study provided quality of life measures, 
but found no differences between both treatment groups at end of intervention and follow-up. 
Combined psychological and pharmacological continuation and maintenance therapies 
versus psychotherapeutic continuation and maintenance therapies alone 
One continuation treatment study (Kocsis 2003) involving 238 participants provided 
relapse/recurrence and overall dropout rates for this comparison and showed no significant 






Comparison of different antidepressant medications (post hoc analyses) 
Two studies reported data on the direct comparison of two antidepressants. One 
continuation treatment study (Kocsis 1995) involving 73 participants compared two tricyclic 
antidepressants, whereby overall dropout rates were higher in the imipramine group 
compared to the desipramine group. Compared to imipramine, desipramine reduced the 
dropout risk with a NNTB of five. Dropout rates due to adverse events did not differ 
significantly between the two groups. The imipramine sample was relatively small (N = 23) 
and only half the size of the desipramine sample. The three dropouts in the desipramine group 
dropped out due to dissatisfaction with treatment response or due to side effects. In the 
imipramine group, one participant discontinued because of side effects, one participant had a 
dispute with the staff and four participants did not comply with the follow-up assessment. 
Data on relapse/recurrence rates were not provided in this comparison. 
The second study (Koran 2001), a continuation treatment study involving 386 
participants, compared a tricyclic antidepressant with a selective serotonine reuptake 
inhibitor, showing no significant differences between treatment arms regarding 
relapse/recurrence, overall dropout rate, dropout rate due to adverse events and depression 
severity at end of intervention. This study provided quality of life measures, in which 
participants of the SSRI group reported a significant higher quality of life at end of 
intervention. 
 
Overall completeness and applicability of evidence   
Only 10 studies were identified for inclusion in this review. Most of the searched 
studies could not be included into the review as they treated either solely participants with 
recurrent depression (with clear interepisode remission and an episode duration shorter than 
two years), they did not clearly assess the percentage of diagnostic subgroups of persistent 





are more studies on hand involving persistent depressed participants, but as no specific 
percentages were available from the publications or following contact with the authors, this 
data could not be considered for this review. Moreover, some long-term studies had to be 
excluded because they did not define clear response or remission criteria for entering the next 
treatment phase which we required for inclusion into the review as response or remission are 
considered as accurate criteria of continuation or maintenance treatments [8]. Overall, this 
resulted in a rather small body of evidence available for addressing the objectives of this 
review. 
Regarding the 10 included studies, for most comparisons only one or two studies 
provided data for the analyses, limiting the informative value of the presented results. For the 
comparison of antidepressant medication and placebo, five studies provided consistent data 
although different classes of medication were applied. Only three of the included studies 
involved psychological treatments, two of them applied in individual setting (CBASP), the 
other applied as a group therapy, both conducted in an outpatient setting in the US. More 
studies are required to evaluate the different forms of psychotherapy (e.g., Interpersonal 
Psychotherapy, Cognitive-Behavioral Therapy, CBASP, Mindfulness-Based Cognitive 
Therapy, Psychodynamic Therapy) in varying treatment settings (individual, group), cultures 
and health care systems. Moreover, just two studies investigated the combination of 
psychotherapy and antidepressant medication although guidelines already recommend the 
combined treatment for persistent depressive disorders [6]. Also, we expected to include 
comparisons with treatment as usual, investigating if long-lasting continuation and 
maintenance treatments are implemented in health care systems and evaluating these 
treatments under natural conditions. Unfortunately, no study using this comparator could be 
identified. 
From the 10 included studies, five were continuation studies, five maintenance studies. 





months), while the preceding continuation treatment studies were more similar in duration (16 
to 20 weeks). Per definition, participants remitted or at least partially responded during acute 
treatment should start continuation treatment within one year after terminating acute 
treatment. Then, maintenance treatments should be given during recovery, which is defined as 
remission lasting longer than six months [8, 45]. Three studies providing a continuation 
treatment phase defined a duration of 16 to 20 weeks treatment before participants entered a 
subsequent maintenance phase. This does not correspond to the recommended criterion of six 
months recovery before entering maintenance treatment. Still, we decided to include these 
studies into the review and followed the definition of the authors as they described reasonable 
criteria for participants being eligible entering the maintenance phase. We kept the term 
“maintenance treatment” for these treatments as they were longer than the examined 
continuation treatments, consistently. Due to the small amount of included studies we did not 
differentiate between effects of continuation versus maintenance treatments during the 
analyses, which would be valuable considering the distinct criteria of remission/recovery for 
both treatment phases. Especially in persistent depressive disorder with participants showing 
severe levels and duration of symptoms, clear criteria for receiving both treatments following 
acute therapy are required. Therefore, a consistent application of the terms continuation and 
maintenance treatment and corresponding implementation into research and health care is 
needed before definite conclusions about the effectiveness of such treatments can be drawn. 
For this review, the primary efficacy outcome was relapse or recurrence. Most of the 
studies applied rather strict criteria for participants to fulfil this outcome criterion at end of 
intervention, e.g., exceeding cut-offs during two or three consecutive sessions followed by a 
personal interview with a study investigator clarifying a potential diagnosis. Such procedures 
contribute to keeping participants longer in the study program and possibly underestimate 
absolute relapse and recurrence rates. Different definitions of this outcome between the 





examined treatments. Additionally, it must be kept in mind that two different target figures 
were mixed here: Relapse defines the return of symptoms before full remission is reached, 
while recurrence indicates a new episode after a full remission has been reached. 
The primary acceptance outcome was dropout due to any reason (other than 
relapse/recurrence), of which data were reported in nine of the 10 studies. Specific reasons for 
dropout were described rarely, instead more often side effects evolved in at least 10% of 
participants were mentioned. But, next to side effects, also other negative events as 
interpersonal problems (e.g., conflicts with others) might occur during or after treatment. 
Such adverse events were reported very rarely in the included studies of this review, but 
should be addressed clearly in future research [59]. Especially in long-term treatments as 
continuation and maintenance treatments, dropout is considered likely and should be assessed 
in more detail (e.g., if participants dropped out due to aspects of the intervention itself or due 
to other reasons). 
Another secondary outcome of interest of this review were quality of life measures. 
Only three of the 10 studies address this outcome although psychotherapeutic and 
pharmacological treatments are considered to improve quality of life in depressive disorders 
[163]. As persistent depressive disorders are characterized by a chronic course, an exclusive 
focus on improvement of depressive symptomatology over a long time might be too narrow to 
describe health status of participants completely. Including quality of life measures more 
frequently into studies is recommended. 
Moreover, we intended to analyze data at the time point ‘one year after the end of 
intervention’. Surprisingly, just one of the 10 studies provided follow-up data, and even this 
study addressed a short follow-up duration (12 weeks). Especially in persistent depressive 
disorder we consider the evaluation of long-term effects beyond termination of treatment as 
highly relevant and valuable information to provide recommendations on when therapy 





Another aspect regarding the applicability of evidence is date of publication. Studies 
included in this review were published between 1986 and 2004. The current practice 
including available medication and psychotherapy for treating patients with persistent forms 
of depression might have been different at that time. For example, the drug nefazodone used 
in two of the included studies (Kocsis 2003; Gelenberg 2003) was withdrawn from the market 
in 2003 respectively 2004 in some countries due to the rare incidence of hepatoxicity [74].  
 
Quality of the evidence   
For most of the planned comparisons only one or two studies provided data. Thus, we 
report a summary of findings table only for the comparison of pharmacological continuation 
and maintenance therapies versus placebo, referring to the quality of evidence of the primary 
outcomes relapse/recurrence and overall dropout (see table 2). 
Limitations in study design or execution (risk of bias) 
We included seven randomized controlled trials (RCTs) and three non-randomized 
controlled trials (NRCTs) involving 840 participants with persistent depressive disorder. Two 
of the three NRCTs were evaluated as having almost no risk of bias in the seven domains, 
while the other study was classified between moderate and serious risk for more than half of 
the domains. The seven included RCTs varied regarding risk of bias domains, and were rated 
mostly as low or unclear risk of bias, with one exception. One study (Hellerstein 2001) was 






Table 2 Summary of findings table 
Pharmacological continuation and maintenance treatment compared with placebo for persistent depressive disorder 
Patient or population: people with persistent depressive disorder 
Settings: outpatient treatment 
Intervention: pharmacological continuation or maintenance treatment (sertraline, phenelzine, nefazodone, desipramine) 
Comparison: pill placebo 

















(end of intervention) 
338 per 
1000 
139 per 10001 








The criteria of relapse/recurrence are provided in the "characteristics of 
studies"-tables of each included study. 
Dropout any 
(end of intervention) 
255 per 
1000 
230 per 10001 








"Dropout any" is defined as all reported dropouts due to other reasons 
than relapse/recurrence. 
One study (Kocsis 1996) only reports dropouts in the first month of the 
maintenance treatment phase. As the maintenance treatment lasts 24 
months, the dropout rate in this study is very likely to be 
underestimated. 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is 
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk Ratio 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
1 assumed risk calculated as the proportion of participants on placebo with the outcome (relapse/recurrence or dropout any) in the four included studies, multiplied by 1000. 
2 downgraded due to unexplained heterogeneity between studies (I²=64%). Due to the small number of included studies, subgroup or meta-regression analyses were not 
performed. In two studies, dropout rates were higher in the intervention group, in two studies they were lower. 






In general, allocation concealment and random sequence generation was addressed in 
none of the studies and therefore rated as unclear risk, and selective reporting was rated as 
unclear risk in five of these seven studies. One study (Kocsis 1996) with high risk of bias in 
the domain selective reporting analyzed data on dropout during the 104 week maintenance 
phase, but only the rates during the first month of treatment, probably underestimating the 
actual dropout rate over time.  
To separate the two primary outcomes (relapse/recurrence and overall dropout), we 
did not include the participants with relapse/recurrence in the overall dropout rates. This must 
be kept in mind when interpreting the absolute dropout rates. Additionally, as in one study 
(Harrison 1986) all participants in the placebo group relapsed and there is no information on 
the time of relapse, the dropout rate in this group is zero, possibly overestimating the 
acceptance of this treatment. If the participants relapsed early, there was „no chance“ for 
accepting or not-accepting the treatment. Incomplete outcome data was rated as high risk in 
two studies (Hellerstein 2001, Keller 1998) as they applied the Last Observation Carried 
Forward (LOCF) method for imputing missing values. In Keller 1998, 70% of the participants 
in the placebo group dropped out during the 76 week maintenance treatment, thus the missing 
data were replaced by the last available measure of the participant. Although this method is 
commonly used for analyzing longitudinal data, we consider this procedure inappropriate 
within the context of continuation/maintenance treatments as it potentially underestimates 
relapse and recurrence rates. As LOCF assumes that the missing data after the participant’s 
dropout stay the same as the last value observed for that participant [164], we assume that 
LOCF provides rather optimistic estimates instead of conservative estimates. This assumption 
of stability is rather unlikely for persistent depressive disorder over long periods of time 





Analyses regarding dropout rates for the comparison of antidepressant medication versus 
placebo resulted in serious heterogeneity between studies. Due to the small amount of studies 
we were not able to analyze these differences statistically. 
These circumstances in combination with the mentioned limitations of the studies 
contributed to downgrading the body of evidence for this comparison regarding the outcome 
dropout (other than relapse/recurrence) to low (see table 2, p. 97). However, for the 
comparison of relapse/recurrence rates in continued and maintained pharmacotherapy versus 
placebo treatment, four studies provided coherent data that involved 383 participants. The 
limitations in these studies were classified as existing but unlikely to produce significant 
change in effects, resulting in a rating of high quality of evidence (see table 2, p. 97). 
Consequently, we assume that persistent depressed participants benefit from long-lasting 
medication compared to pill placebo. 
Inconsistency of results 
Data were inconsistent in regard to overall dropout rates. Dropout rates varied between 
studies from 4% (Kocsis 1996) and 100% (Harrison 1986). This unexplained heterogeneity 
contributed to downgrading the quality of evidence to low regarding overall dropout rates in 
the comparison of antidepressant medication versus placebo. 
Indirectness of evidence 
All included studies directly addressed the objective of this review, namely the 









Imprecision of results 
Two of four studies addressing overall dropout rates in the comparison of 
antidepressant medication versus placebo showed wide confidence intervals (Harrison 1986; 
Kocsis 1996). This contributed to downgrading the quality of evidence to low. 
Publication bias 
Due to the small numbers of included studies, funnel plots were only applied for the 
comparison antidepressant medication versus pill placebo. Apparently, the funnel plot on 
relapse/recurrence seems asymmetrical (figure 14), with an overhang of small studies 
showing a large difference in favor of medication), while the funnel plot on dropout is 
symmetrical (figure 15). The application of statistical tests (e.g., Egger’s test) for funnel plot 
asymmetry was not conducted, as it is not advisable due to the small number of studies. The 
Cochrane Handbook [153] recommends these tests when there are at least 10 studies, 
otherwise the power is too low. 
 







Figure 15. Funnel plot of comparison: Medication versus placebo, outcome: Dropout any. 
 
Potential biases in the review process   
We used a broad search strategy for identifying all relevant studies regarding 
continuation and maintenance treatments in persistent depressive disorder (PDD). The main 
search was conducted in the specialized register of randomized controlled trials of the 
Cochrane Common Mental Disorders Group (CCMD-CTR) searching for study and reference 
records. Moreover, we searched other databases, grey literature, clinical trials register and 
contacted relevant authors in this field. We had to exclude a considerable amount of studies as 
most studies either did not include specifically participants with PDD or did not report the 
percentage of treated PDD participants. Although we were in email contact with the first 
authors of the included papers regarding this missing information, they either did not reply to 
our queries or simply had specific data no longer available due to conducting these studies a 





conducted with participants with PDD. But these studies did not solely (more than 80%) treat 
participants, which PDD and therefore did not meet our inclusion criteria. Screening of 
records, extracting and analyzing data was conducted by at least two review authors 
independently to prevent any severe bias in the used methods. 
However, there was marked clinical heterogeneity between the included studies, 
especially regarding sample size, subtype of persistent depression, kind of treatment (e.g., 
type of antidepressant medication), treatment duration and definition of relevant outcomes. 
Therefore, we are not reporting on a homogenous group of participants, manifesting in both 
studies investigating a specific subgroup (e.g., solely dysthymic participants) and studies 
investigating all four diagnostic subgroups of PDD, making it difficult to generalize the found 
results to PDD in general. This also applies to the type of treatment: Continuation and 
maintenance treatment with lengths between 16 weeks and two years were included, which 
allows no conclusion on continuation or maintenance treatment in general. 
Also, PDD is a rather severe form of depression with patients probably suffering from 
comorbid disorders, suicidality or psychotic symptoms, and who usually underwent several 
other treatments before entering a study, which in turn was an exclusion criterion in some of 
the included studies for this review. Such excluded participants are probably in more need of 
high quality treatment but without receiving it, especially regarding continued and maintained 
treatment. This raises the question what kind of participants joined the studies we included for 
this review – severe impaired ones or less impaired ones? We required the included studies to 
report on ICD or DSM diagnosis of PDD, neglecting total duration of illness or other potential 
indicators of impairment. But, as we required clear response or remission criteria for 
considering continuation or maintenance treatment studies for this review, symptom level of 
included participants is considered rather homogenous. Some of the included studies were 
funded by grants of pharmaceutical industry. Conducting long-term continuation and 





found results if covered by third parties. However, we considered risk of publication bias as 
low but the application of a statistical test was not advisable due to the small number of 
studies. Additionally, the required length of treatment – especially of maintenance studies – is 
possibly one reason for the lack of studies in this field. 
Another aspect of potential bias is the allowance or proscribing of concomitant 
treatments in addition to the treatment provided by the study. Two of the included studies 
investigating antidepressant medication reported that participants received ongoing 
psychotherapy. One study (Koran 2001) reported that 60% of the participants received 
ongoing psychotherapy while treated with sertraline or imipramine, yet no group differences 
were reported. In two studies, about 40% of the participants of both treatment groups 
(desipramine, placebo) were in stable long-term psychotherapy (Kocsis 1996, Miller 2001). 
Although parallel treatment is not necessarily considered biasing the results, especially when 
proportions are similar between treatment groups, the observed individual change is not solely 
based on study treatment but also on parallel treatment in the respective two studies. 
However, the other studies did not mention any information about parallel treatments or 
explicitly stated that no concomitant treatment was allowed. 
Despite the discussed conceptual and methodological concerns we consider 
conducting a meta-analysis appropriate, especially for the comparison of antidepressant 
medication versus pill placebo. Sensitivity analyses addressed differences in risk of bias 
between studies, although results did not change in the majority of cases. Heterogeneity was 
planned to be addressed through subgroup and meta-regression analyses but due to the little 
amount of studies included we were only able to discuss differences between studies on a 
descriptive level. In general, for the majority of comparisons we had to describe the results on 
basis of one single study, not being able to report pooled results. 
This review used two primary outcomes, rate of relapse/recurrence and rate of overall 





outcomes separately. Still, there is open discussion if both outcomes overlap conceptually in 
continuation and maintenance treatment studies. For example, in Harrison 1986 all 
participants of the placebo group relapsed, resulting in zero dropouts reported during 
treatment as participants simply had “no chance” for dropping out due to relapsing before, 
possibly overestimating the acceptance of placebo treatment. 
Continuation and maintenance treatment studies are usually performed as complex 
studies, i.e., studies with different treatment phases (acute, continuation and maintenance 
treatment). Criteria and procedures of transition from one into the next phase differed between 
studies: Some studies defined response, some remission as an eligibility criterion for the next 
phase, including different definitions of response and remission (see above). Some studies did 
not re-randomize participants when entering the new phase (especially concerning the 
transition from acute to continuation treatment). Other studies re-randomized responders from 
one treatment arm to a different treatment arm in the next phase, e.g., Klein 2004 randomized 
continuation phase responders of CBASP to CBASP or assessment only in the maintenance 
phase. These different procedures complicate the comparability between different studies. 
Moreover, studies mostly described different treatment phases, resulting in partly overlapping 
patient groups included in different analyses. 
As persistent depression is a chronic condition, relapses or recurrences are common in 
this population. Longer treatment durations (i.e., longer observation periods) probably 
increase the chance to observe relapses or recurrences, this must be kept in mind when 
comparing the results of different studies with varying treatment durations. 
Concerning data analysis, there is no widely accepted consensus on how to deal with 
missing data in meta-analysis when primary data is not available. In acute phase studies, 
researchers can replace missing values with methods like last observation carried forward 
(LOCF), if study authors do not report adequate ITT-analyses. However, in the case of 





instead of conservative estimates (see above) due to its concept of stability of measures over 
time [164]. Thus, we had to deal with the available data sets. However, percentages of 
missing data were low: Data on overall dropout rates were complete, the percentage of 
missing data concerning other outcomes ranged between zero and 10%. 
 
Agreements and disagreements with other studies or reviews   
To our knowledge, this is the first review evaluating the effectiveness of continuation 
and maintenance treatments in participants with persistent depressive disorder (PDD). A 
previous review investigated the efficacy and acceptability of acute treatments in PDD by 
applying network meta-analytic methods, showing that several antidepressant medications 
were superior to placebo, and that several evidence-based treatments exist [56]. Due to the 
small number of included studies in our review, comparisons between different 
antidepressants could not systematically be investigated. In line with the review of von Wolff 
and colleagues [58] on acute treatment in persistent depression, our review could also not 
provide a clear superiority of combined treatments compared to pharmacological 
monotherapy. 
Regarding continuation and maintenance studies, Wilkinson and Izmeth [165] 
evaluated treatments for older people with depressive disorders. This updated Cochrane 
review identified seven studies of which six compared continued or maintained antidepressant 
medication with placebo, favoring antidepressants regarding relapse/recurrence at 12 months, 
but showing no significant differences between treatment arms at six or 24 months follow-up. 
Although this result is in line with our result for this comparison and outcome, Wilkinson 
downgraded the level of evidence to low (GRADE) compared to the GRADE rating of high 
level evidence in our review. Like in our review, Wilkinson and Izmeth [165] included just 
two studies involving psychological treatment, and data reported on this as well as combined 





Regarding long-term effects of psychological treatments, Vittengl and colleagues [12] 
conducted a meta-analysis on effects of acute and continued cognitive–behavioral therapies 
(CT) in depression. They found high relapse and recurrence rates (29% within 1 year and 54% 
within 2 years) for participants discontinuing after acute CT. Those participants continuing 
CT had significantly less relapses and recurrences compared to active controls (e.g., receiving 
pharmacotherapy) at follow-up (10 to 255 weeks after end of continuation-phase treatment), 
with relapse/recurrence rates of 42% (continued CT) and 61% (active controls) over 114 
weeks on average. In comparison, rates of relapse/recurrence were similar at end of (20 to 52 
weeks) continuation phase for both CT and other active treatments, with relapse/recurrence 
rates of 10% (continued CT) and 22% (active controls) over 27 weeks on average. Although 
the results of Vittengl and colleagues [12] are encouraging to consider continued pharmaco- 
and/or psychotherapy in depression treatment, the analyses were based on only five to eight 
studies. 
Guidi and colleagues [166] conducted a meta-analysis on the sequential integration of 
pharmacotherapy and psychotherapy in major depressive disorder, i.e., participants received 
pharmacotherapy in the acute phase and psychotherapy in the residual phase. Receiving CBT 
during continuation of antidepressant drugs was superior to antidepressants alone or treatment 
as usual. Further, participants receiving CBT who had medication tapered and discontinued 
were significantly less likely to relapse compared to clinical management or continued 
pharmacotherapy. These analyses were based on 13 studies. 
 
Authors' conclusions   
Implications for practice   
This review comprises 10 studies and summarizes the current evidence of the 





(PDD). The comparison of antidepressant medication versus placebo showed coherent results 
based on five studies favoring pharmacotherapy as an effective continuation and maintenance 
treatment for participants with PDD compared to pill placebo regarding relapse/recurrence. 
On this basis, it can be concluded that continued and/or maintained pharmacotherapy with the 
reviewed antidepressant agents is a considerable treatment for preventing relapse and 
recurrence in patients suffering from PDD. As long-term follow-up data were not available in 
most of the studies, this review cannot draw any conclusions about an appropriate duration of 
antidepressant medication intake, or when to taper off or stop medication. In four of the five 
studies providing data on the comparison of medication versus pill placebo, medication in the 
placebo group was tapered down following an a priori defined scheme when starting a new 
treatment phase. Tapering down medication was predominantly used in the studies of this 
review, and is likely to be applied also in clinical practice instead of suddenly stopping 
medication. 
Moreover, in two of the five studies reporting a benefit from antidepressant 
medication compared to placebo about half of the sample size had ongoing psychotherapy 
next to study treatment. Thus, it is unclear if the individual course of the analyzed patients is 
only attributable to the medication provided by the study, or also to the parallel psychotherapy 
treatment. Additionally, interaction effects may occur: 1) The effect of antidepressant 
medication could be underestimated because the received psychotherapy makes an additional 
treatment (antidepressant medication) less meaningful or 2) receiving parallel psychotherapy 
itensifies the effect of medication or keeps the participant motivated to stay on medication. 
For all other planned comparisons the body of evidence with mostly just one or two studies 
providing data was too small to draw final conclusions about recommendations for other 
kinds of treatment. However, psychological treatments were addressed in four comparisons. 
The 52 week maintenance treatment study (RCT) of Klein 2004 found less 





CBASP compared to assessment only at end of treatment. Although just this one study 
addressed this comparison, we rated most of the domains as unclear or low risk of bias, 
indicating that psychotherapy in the maintenance phase is useful. One continuation treatment 
study (Kocsis 2003) found less dropouts in the group of participants receiving CBASP 
compared to participants receiving nefazodone. We evaluated the risk of bias of this NRCT as 
low, indicating that psychotherapy in the continuation phase might be better accepted by 
participants compared to medication. Both studies provided CBASP in the psychological 
treatment arm, it might be assumed that patients can benefit from this form of psychotherapy 
during the continuation and maintenance phase in clinical practice. 
Two studies addressed combined treatments. Hellerstein 2001 found a lower level of 
depressive symptoms in participants receiving medication combined with group therapy 
during the continuation phase compared with medication alone. We rated this RCT in all 
domains either with unclear or high risk of bias, questioning the implication for clinical 
practice. Kocsis 2003 compared CBASP with the combined treatment (CBAPS + nefazodone) 
and found no differences during the continuation phase. We evaluated the risk of bias of this 
NRCT as low, indicating that both psychotherapy and medication in the continuation phase 
might be effective interventions. 
For the type of antidepressant medication as well as distinct treatment options for 
specific patient populations (e.g. subtype of persistent depression) the reported data of the 
included studies was too small to draw final conclusions or recommendations. Even 
concerning the comparison of antidepressants versus placebo, meta-regression or subgroup 
analyses were not possible due to the small number of eligible studies. Also, all included 
studies were conducted in the US and were published between 1986 and 2004. Thus, 
differences between cultures and health care systems, as well as current developments 





this review. Conclusions and recommendations of this review should be interpreted on this 
background. 
Implications for research   
The above mentioned lack of studies on continuation and maintenance treatments in 
patients with persistent depression emphasizes the need for further primary studies – 
especially on psychological and combined treatments. The results of Vittengl and colleagues 
[12] suggest that long-term psychotherapy is effective in depression in general, emphasizing 
the need for verification the transferability of these results for the population of persistent 
depressive patients. Further studies should also assess health related quality of life as well as 
adverse events. Lack of reporting (consistently) on adverse events is a common problem in 
studies on acute treatment of persistent depressive disorder, especially in psychotherapeutic 
studies [59]. Generally, psychotherapeutic studies often fail to report on adverse events [60, 
61]. Additionally, further studies should address follow-up evaluations. Comparing 
continuing treatment to stopping treatment in the long run is necessary to draw conclusions on 
the recommendable duration of continuation and maintenance treatments. 
This review suggests the need for standardization of some terms and procedures. To 
compare study results among each other, standardized use of the terms “continuation” and 
“maintenance” as well as consistent definitions of relapse and recurrence are required. 
Different definitions for the transfer from one into the next treatment phase prevented the 
inclusion of further studies into this review as some studies evaluating long-term treatments 
included all participants (not only responders) or a clear separation of different treatment 
phases was lacking. Nevertheless, this probably reflects the clinical practice as it is likely that 
there is often no clear distinction between long-term acute treatment on one side and 





As there is broad evidence on depression treatments on the one hand and a lack of 
studies fulfilling the inclusion criteria of this review on the other hand, clear diagnostic 
procedures as well as clear reporting concerning the persistence of depressive symptoms is 
necessary. It is reasonable that several excluded studies also examined participants with 
persistent depressive disorder, which could have been analyzed here if data on this subgroup 
would have been reported. The lack of reporting on this specific diagnosis reflects the fact 
that chronic major depression and recurrent depression without full interepisode remission 
may be designated as “(recurrent) major depression” in DSM-IV and ICD-10, ignoring the 
persistence of depressive symptoms. However, the new category “persistent depressive 
disorder” implemented in DSM-5 (duration of at least two years) increases the likelihood of a 
precise diagnosis concerning persistent symptoms.  
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4.2 Maintaining patients' outcomes following psychotherapy by a 
telephone-based continuation therapy in recurrent and persistent 
depression: a mixed methods exploratory pilot study5 
4.2.1 Abstract 
Background. Persistent and recurrent depression are associated with a high risk of relapse 
indicating need for continued treatment to sustain remission in the long-term, but it is 
assumed that most patients receive inadequate or even no treatment. Delivering 
psychotherapy by telephone is considered valuable to provide many patients with treatment 
due to its low-intensity character, by ensuring personal contact within a flexible frame 
regarding location and time. Aim of the present study was to assess the feasibility of a six-
month telephone-based continuation therapy for patients who responded to previous acute 
treatment. 
Methods. Semi-structured interviews with participants and therapists were analyzed using 
qualitative content analysis. Depressive symptoms, depression-self-management and 
therapeutic alliance were assessed throughout therapy and at six-month follow-up. Using a 
mixed-methods approach we combined qualitative and quantitative data to obtain in-depth 
understanding of the intervention’s components. 
Results. Medium telephone was accepted, but relevance of an initial face-to-face meeting was 
reported if participant and therapist were unfamiliar. Low level of depressive symptoms and 
effective coping strategies were considered core conditions which need to be ensured before 
entering continuation therapy. A clear treatment plan implemented throughout therapy and 
prioritizing of contents within each session was required due to limited sessions and longer 
intervals between sessions. If one session per month was provided, fifty minutes was the 
preferred length of sessions. Reported benefit of intervention was associated with depressive 
                                                          





symptomatology and perceived fit with the participant’s needs and attitude towards content 
and format of continuation therapy. The intervention was perceived feasible and especially 
valuable in high risk patients to ensure continuous long-term monitoring and support. 
Conclusions. Continued psychotherapy delivered over telephone is assumed feasible if several 
preconditions as level of residual symptoms, coping strategies and fit between patient’s needs 
and intervention components are ensured. Based on results of this pilot study, a randomized 
controlled trial assessing the effectiveness of a telephone-based continuation therapy is 
ongoing to further contribute to long-term relapse prevention in high risk individuals.  




A substantial part of patients with a depressive disorder have a chronic or recurrent 
course [168] leading to persistent personal suffering, psychosocial impairment and also 
growing health expenditures. Chronic forms of depression include four diagnostic subgroups 
(dysthymia, chronic major depression, recurrent major depression with incomplete remission 
between episodes, double depression) [35] and are combined into one diagnosis referred to as 
persistent depressive disorder (PDD) according to the revision in the DSM-5 [13]. Whilst 
PDD is characterized by an illness duration of at least two years with persistent symptoms, 
recurrent depression with clear interepisode recovery is classified as an episodic form of 
major depressive disorder (MDD), indicated by a minimum of two episodes of MDD, which 
are separated by at least two months of normal functioning. Both PDD and recurrent 
depression are associated with severe impairments as increased loss of physical wellbeing, 





more hospitalizations, and longer treatment duration compared to non-chronic or non-
recurrent forms of depression [1, 17, 36, 37].  
As people suffering from PDD or recurrent depression are at high risk of relapse and 
recurrence even after successful pharmacological or psychological acute treatment [11, 38, 
169], continuation treatments should be provided to sustain remission in the long-term [6, 45].  
Whilst antidepressant medication (ADM) is often continued on the same dose leading 
to remission during the acute phase [6], psychotherapeutic continuation treatments are not 
considered a simple extension of acute therapy, but rather contain the consolidation of skills a 
patient acquired during acute treatment across daily routine situations [39]. Thus, continuation 
treatments should be only provided to patients who previously responded to or remitted 
during an acute treatment [8, 45], allowing a less frequent therapeutic setting, i.e., longer 
intervals between sessions are considered meaningful [6].  
Whilst the majority of studies address acute treatments in PDD and recurrent 
depression [12, 42, 56], considerable fewer studies focus on the efficacy and effectiveness of 
continuation therapies. Continued ADM is assumed effective in reducing relapse and 
recurrence as long as ADM is taken  [46, 62, 64, 68], and is associated with adverse events [9] 
and dropout rates up to 25% between acute and continuation treatment phase [68]. Although 
studies addressing psychological interventions are heterogeneous in regard to design, 
intervention, treatment duration, and quality, psychotherapy might have equal effects, a lower 
risk of side effects and better long-term effects regarding behavioral change compared to 
pharmacological treatments [10]. Thus, components of long-term psychotherapeutic 
interventions should be determined.  
A variety of long-term relapse preventive interventions were already investigated, 
mostly in individuals with non-chronic forms of depression [38], and mostly in cognitive-
behavioral therapies (CBT). The proposed mechanisms underlying patient’s change is usually 





assumed that change in negative content of beliefs might lead to reduced symptoms and 
prevention of relapse [170], and this change is expected to maintain or even improve with 
continued CBT [171]. Jarrett and colleagues provided recurrently depressed patients who 
responded to acute CBT with either continued CBT or assessment visits (symptom 
monitoring) [136]. Based on a treatment manual, patients received ten sessions of continued 
CBT over eight months which focused on maintaining skills acquired during acute therapy, 
anticipating critical situations, developing coping strategies and reviewing strategies to reduce 
symptoms, i.e., targeting prevention of relapse and recurrence and consolidation of skills [39]. 
Patients receiving continued CBT showed significantly less relapses and recurrences during 
treatment and follow-up compared to the control group, especially in higher risk patients 
[136]. This is in line with a meta-analysis showing that patients who continued CBT relapsed 
significantly less than patients without any active continuation treatment, at posttreatment and 
follow-up [12]. Although continued CBT did not differ from other active therapies (e.g., 
continued ADM) at posttreatment, it showed better outcomes (i.e., less relapses and 
recurrences) compared to other active treatments during two years of follow-up. Evidence 
regarding psychological interventions in PDD is low, which makes it difficult to draw definite 
conclusions on the effectiveness of continued psychotherapy in PDD, yet [122].  
Limited evidence in this field leaves open question if continued psychotherapy is not 
provided by mental health care, or if patients with PDD and recurrent depression are less 
likely to enter such treatment. By terminating acute therapy, patients report on better 
functioning, and thus, health insurances are probably less willing to cover the costs for 
treatment of an already remitted patient, and moreover, the patient might be eager to live 
without any therapeutic help at this point. Thus, patient’s symptom relief might hinder 
initiating and maintaining treatment, but also dissatisfaction with (previous) treatments might 
do [83]. Generally, dropout rates tend to vary between 30% and 50% in studies addressing 





CBT for unipolar depression in routine clinical practice [84]. Also time constraints were 
perceived as barriers to involve in psychotherapy, and predicted less attending of 
psychotherapy within a one-year follow-up [88]. As low level of mood, interest and energy 
are key symptoms of depression, the above mentioned challenges have to be taken into 
account when conceptualizing continuation treatments.  
One opportunity to meet these challenges is considered in low-intensity treatments, 
which are associated with fewer financial expenses due to less intense treatment and 
innovative delivery options increasing access to and maintenance of treatment [93]. Such 
treatments might include less or even no direct therapeutic involvement (compared to face-to-
face settings) by using technologies as internet or mobile devices, and might involve highly 
qualified mental health professionals (e.g., psychotherapists) or non-professions (e.g., peer 
supporters). In recent years, internet-based interventions became more popular due to rapidly 
progressing technical development, and is associated with less costs and shorter waiting times 
compared to traditional face-to-face settings [172]. Meta-analyses demonstrate that CBT 
provided over the internet (iCBT) is superior to control groups (waiting list, usual care) in 
reducing depressive symptoms [95, 96], and that iCBT seems to be equally effective to face-
to-face CBT in reducing depressive symptoms [100–102]. Meta-analyses also demonstrate 
that guided internet interventions lead to greater symptom reduction and less dropouts 
compared to unguided interventions [98, 99]. However, for some patients visual and auditory 
cues, which are missing in internet-based interventions, might be relevant for developing a 
sound therapeutic relationship [109], which in turn might enhance treatment outcomes [173].  
Thus, delivering psychotherapy by telephone might be another flexible and low-
threshold approach to provide many patients with mental health care, due to its low-intensity 
character in terms of low costs, overcoming barriers and practicability in everyday life [110]. 
While a personal contact between patient and therapist is guaranteed, delivering telephone 





to-face settings. Telephone therapy as a stand-alone treatment in depressive disorders has 
been investigated only within the field of acute depression so far, and is associated with 
reducing depressive symptoms compared to control groups [111], and shows comparable 
effectiveness (e.g., with regard to level of depressive symptoms) as well as lower dropout 
rates than face-to-face settings in CBT [112–114]. Moreover, therapeutic alliance in 
telephone-based CBT for acute depression was found to be not inferior to face-to-face CBT 
[115]. Studies also indicate a relative cost-effectiveness of telephone-based interventions, 
with 36% less costs per sessions compared to face-to-face settings [116].  
Delivering telephone-based therapy for individuals affected by PDD or recurrent 
depression might be an opportunity to provide adequate continuation treatment, which has a 
low-threshold access, is cost-effective and flexible in location and time, and is potentially 
reducing risk of relapse and recurrence in the long run. Thus, we piloted a telephone-based 
continuation psychotherapy provided over a period of six months among patients at high risk 
of relapse who responded to acute therapy previously. 
 
4.2.3 Methods 
Aim and objectives 
To assess feasibility and acceptance of a low-intensity telephone-based continuation 
treatment after successful termination of acute therapy in individuals with high risk of relapse. 
Primary study objective was to assess feasibility and acceptance of this intervention by 
qualitative interviews with both participants and therapists, focusing on the following 
components: implementation of the concept of the continuation therapy, acceptance of 
medium telephone including length and frequency of phone calls, unfamiliarity of participant 
and therapist, and reciprocal influence of these components. Moreover, we assessed 





alliance as quantitative measures to describe individual treatment courses. According to aims 
of pilot studies [174, 175] we used a mixed methods exploratory approach combining 
qualitative and quantitative measures to obtain in-depth understanding of this intervention 
including the new components, to later generate hypotheses for which individuals and under 
which circumstances this intervention might be adequate.  
Intervention 
This intervention is a low-intensity CBT-based continuation treatment provided for 
individuals who responded or remitted to a previous acute CBT, focusing on maintaining, 
reviewing and consolidation of skills acquired during this acute therapy, i.e., targeting 
prevention of relapse and recurrence. Thus, therapists were advised to discuss current 
concerns by reviewing skills the patient gained during acute psychotherapy and transfer and 
adapt these skills to the current situation in each session. Therapist procedures were supported 
by a manual which is based on guidelines in relapse prevention and continuation therapy in 
depression [39, 176, 177] and on a manual for telephone therapy in acute depressive disorder 
[178]. It contains a collection of strategies how to implement continuation treatment, keeping 
the participant motivated, strengthening his/her self-confidence and self-monitoring mood and 
behavior, formulated with specific reference to the medium telephone and persistent 
depressive disorder.  
Within our study, participants received eight psychotherapeutic sessions over six 
months, approximately one session every four weeks. The first session was conducted face-to-
face allowing room to form a sound relationship with the unfamiliar telephone therapist, to 
introduce the procedures of the next months, and to prepare a treatment plan. We chose 
employment of unfamiliar therapists accounting for flexibility which might be required for 
patients who received inpatient acute therapy by a therapist impossible to continue outpatient 





length of phone calls according to treatment condition (30minC-TT or 50minC-TT). Acute 
phase treatment sessions commonly last 50 minutes in German-speaking areas. We wondered 
if 30 minutes of continued telephone therapy (C-TT) might be sufficient during a continuation 
phase treatment due to the specific focus of intervention (i.e. transfer of already acquired 
skills). Phone calls were initiated by the therapist located in a therapeutic unit, and patients 
were advised to choose an adequate undisturbed place. Irrespective of treatment condition, 
every phone session followed a structured procedure. After a short monitoring of depressive 
symptoms (PHQ-9) and current medication, therapist and participant reviewed home-work 
(optional) and discussed the main topic of the ongoing session. After assigning new 
homework (optional), therapist and participant scheduled the next session.  
Psychotherapists were required to have a formal training in face-to-face CBT, 
permitted to treat patients in Switzerland. Monthly supervision for therapists was provided by 
the study team, to discuss treatment options and current health status of the included 
participants. Therapists followed a specific protocol to ensure safety in case of severe events, 
for example suicidality of a participant. 
Participants  
Subjects were considered eligible for participation if they aged 18 years or older, met 
criteria for persistent depressive disorder or recurrent depression according to DSM-5 [13], 
were currently in partial or full remission indicated by score of 9 or less on the Patient Health 
Questionnaire (PHQ-9), had completed a cognitive-behavioral oriented psychotherapy within 
the last six months before study enrolment, could speak and read Swiss-German or Standard 
German, and gave written informed consent. If subjects took antidepressant medication, long-
term and stable dosage (i.e., unchanged drug intake for three months at least) was demanded 
for study enrolment. If subjects showed deviations regarding level of depressive symptoms or 





case by case discussion with the whole study team. Subjects were excluded if they met 
diagnostic criteria for acute suicidality, psychotic symptoms, severe cognitive impairments, or 
intended to stop antidepressant medication within the time of study participation. If necessary 
information couldn’t be collected entirely within the screening interview, a research assistant 
contacted the subject’s prior therapist to complete information with the subject’s approval. If 
the participant’s symptoms worsened during the treatment period, the therapist initiated 
adequate crisis management including transfer to acute treatment if necessary.  
Setting and procedures 
Several in- and outpatient centers in northern Switzerland were recruited during winter 
2015, and requested to transfer patients to our psychotherapeutic unit who responded or 
remitted during acute therapy and were interested in continuation therapy. If individuals were 
considered eligible during a face-to-face screening interview, they were randomized to 
receive either 30minC-TT or 50minC-TT. Participants were kept uninformed that treatment 
conditions differed only in length of phone calls to avoid expectations that shorter contacts 
would be less effective. Following randomization a research assistant contacted the telephone 
therapist, providing all necessary information about the participant the therapist had to treat 
within the next six months. Face-to-face sessions were video-taped and therapeutic phone 
calls were audio-recorded.  
Instruments 
According to our primary study objective we assessed feasibility and acceptance with 
a semi-structured interview, using a guideline developed on previous work [179, 180]. 
Participants were interviewed after terminating treatment, and therapists were interviewed at 
the final phase of treating the last participant in the project. The guideline requested an open 
start into the interview, motivating the participant or therapist to describe general impressions 





guideline. The interview focused specifically on evaluation of new components of 
intervention: acceptance of medium telephone including length and frequency of phone calls 
in context of continuation treatment in individuals being at high risk for relapse, and with 
unfamiliarity of participant and therapist.  
According to reporting on individual treatment courses we assessed depression 
severity, depression-related self-management behavior and therapeutic alliance throughout 
therapy and at follow-up. Patient’s depression severity was measured with the German self-
report form of the nine item depression module of the Patient Health Questionnaire (PHQ-9) 
[181]. Participants are asked to complete the items in regard to the last two weeks (“How 
often have you been bothered by any of the following problems?”), rating the items on a four-
point Likert scale ranging from 0 (not at all) to 3 (nearly every day). Perceived self-efficacy 
for depression self-management (PSDM) was assessed on six items in which participants 
indicate their belief and ability to cope with depression (e.g., confidence regarding 
overcoming depression, recognizing early warning signs, looking for professional help in 
time) on a ten-point Likert scale ranging from 0 (not at all confident) to 10 (extremely 
confident) [182]. Therapeutic alliance was measured by the 12-item Working Alliance 
inventory – short revised (WAI-SR) [183]. The client’s form is rated on a five-point Likert 
scale ranging from 1 (rarely) to 5 (always), and assesses primary components of working 
alliance within three subscales: agreement of therapist and client on goals of treatment and 
how to reach treatment goals, and degree of confidence, trust and acceptance between client 
and therapist. All three instruments are considered reliable and valid measures in depressive 
disorders [182, 184, 185].  
Data analysis 
Semi-structured interviews of participants and therapists were audio-recorded and 





German). Transcripts were entered electronically, and analyzed with the qualitative content 
analyses by Mayring [186] using the software MAXQDA (version 12) which is recommended 
in qualitative, quantitative & mixed methods research. As we had specific study objectives to 
evaluate feasibility and acceptance of the intervention we first applied a deductive approach, 
i.e., categories were predefined and raw material (interview statements) were allocated to 
these categories [187]. In a second step, statements within one category were ordered into 
sub-categories inductively to generate more specific themes. For verification of allocation to 
categories and themes, 10% of the statements were independently double coded within three 
subsequent trials to improve accuracy. Ambiguous cases were discussed and allocation 
redefined, accordingly. To ensure anonymity, participants’ data are referred to as ‘P1-7’, and 
therapists’ statements are referred to as ‘T1/T2’. Quotes were translated into English by a 
non-native speaker. Quantitative data is reported in a descriptive manner displaying means 
and standard deviations, frequencies and percentages over time, comparatively in terms of 
treatment condition (30minC-TT or 50minC-TT) before and after treatment and at follow-up 
(six months posttreatment). Additionally, depression severity is presented graphically as the 
PHQ-9 was assessed during each therapeutic session. Applying an exploratory mixed-methods 
approach, we combined qualitative and quantitative measures during analyses to better 
understand interaction between perceptions of new intervention components and a patient’s 




Ten German-speaking participants contacted the study team or were referred by their 
prior (acute treatment) psychotherapists, respectively. Following the screening interview for 





preferring to join another study or not consenting videotapes and audio-recordings. We had to 
exclude one participant because previous psychotherapy had a vague orientation, and the 
previous therapist was not accessible by email or phone and no clinical report was available. 
Three of the remaining seven participants were randomized to receive 30min-C-TT while the 
other four participants received 50minC-TT. All seven participants completed the intervention 
with two exceptions: Mental health status of one participant receiving 30minC-TT worsened 
after the fourth phone call, requiring a referral to an acute treatment. During referral phase this 
participant received the remaining three phone calls until referral was completed. One other 
participant receiving 50minC-TT terminated treatment already after the fifth phone call 
because he declared not to need any more treatment due to feeling stable.  
Baseline socio-demographic and clinical characteristics of randomized participants are 
displayed in table 3, comparatively in terms of treatment condition. With respect to the small 
sample size balance between treatment conditions was not present. Most of the participants 
were single or divorced-separated, and varied regarding their employment status. Whilst three 
participants were referred to by their acute treatment therapist from inpatient psychiatry, the 
other four participants got informed about the study by public media and had prior outpatient 
acute treatment. Number of previous psychological treatments was nearly balanced between 
both conditions, and the majority of the participants took parallel antidepressant medication. 
All participants had either recurrent depression with incomplete remission between episodes 
or double depression (superimposition of a major depressive episode on antecedent 
dysthymia) before entering previous acute treatment, and an initial depression severity level 
indicating no symptoms (50minC-TT) or minimal symptoms (30minC-TT) on average [181]. 
All therapies were delivered by two female professional psychotherapists having eight years 






Table 3 Baseline characteristics of participants at baseline 
 30minC-TTa 
(N = 3) 
50minC-TTb 
(N = 4) 
Gender (female),  n 2 1 
Age, M (SD)c 43.7 (11.9) 54.8 (9.6) 
Marital status, n   
Single 0 2 
Married  1 0 
Divorced–separated  2 2 
Employment, n    
Full time  0 1 
Part time  1 1 
Unemployed  2 0 
Retired  0 1 
Supported  0 1 
Referral, n   
Psychologist/psychiatrist 1 2 
Media  2 2 
Number of previous psychological 
treatments, M (SD)c 
  
Inpatient  2.3 (2.5) 2.5 (1.7) 
Outpatient  1.7 (0.6) 2.5 (1.7) 
Last previous (acute) treatment, n   
Inpatient  1 2 
Outpatient  2 2 
Current antidepressant medication, n 2 4 
Diagnostic subgroup, n   
Pure dysthymia 0 0 
Chronic major depressive episode 0 0 
Double depression 2 2 
Recurrent depression, incomplete 
remission between episodes 
1 2 
Recurrent depression, complete 
remission between episodes 
0 0 
Depression severity (PHQ-9)d 8.3 (7.2) 4 (2.2) 
a Continued telephone therapy, 30 minutes phone calls 
b Continued telephone therapy, 50 minutes phone calls 
c Mean (M) and standard deviation (SD) 






Individual treatment courses 
Participants differed considerably in course of outcome measures during and following 
treatment, but already before entering continuation treatment (see table 4). With respect to 
individual development of depressive symptoms two participants improved (P3, P5), three 
remained more or less on their initial severity level (P2, P6, P7), and two others deteriorated 
(P1, P4) during treatment (see figure 16). Whilst most participants showed a slight to 
moderate increase of symptoms at six months follow-up, one participant (P4) showed less 
symptoms compared to posttreatment. During the subsequent report of qualitative analyses we 
will refer to data displayed in table 4 and figure 16, discussing potential associations between 
interview statements and quantitative data.  
 
Table 4 Quantitative measures of course of treatment compared across treatment conditions 














 n = 3 n = 4  n = 3 n = 4  n = 2 n = 3 
PHQ-9c 9.7 (8.5) 5.5 (2.5)  10.3 (2.1) 4.7 (5.7)  11.5 (2.1) 6.7 (1.5) 
PSDMd 36.0 (19.3) 41.3 (8.5)  22.0 (15.9) 46.0 (9.4)  28.5 (6.4) 39.0 (2.0) 
WAI-
Ce 
3.9 (1.2) 4.3 (0.4)  3.9 (0.8) 4.6 (0.4)  - - 
a Continued telephone therapy, 30 minutes phone calls 
b Continued telephone therapy, 50 minutes phone calls 
c Patient health questionnaire (sum scores ranging between 0 and 27)  
d Perceived self-efficacy for depression self-management (sum scores ranging from 0 to 60)  
e Working Alliance Inventory, client’s form, mean scores ranging from 1 to 5 







Figure 16. Course of depressive symptoms. 
Measured with the Patient Health Questionnaire (PHQ-9) during each session and at follow-up (six 
months posttreatment), displayed for the seven participants. Participants P1-P3 received 30minC-TT, 
participants P4-7 received 50minC-TT. 
 
Feasibility and acceptance of intervention components 
Five of seven participants agreed on conducting an interview after terminating 
treatment. One participant had to undergo surgery after terminating treatment, and was thus 
not able to join an interview. The other participant did not join an interview without stating 
reasons. Both therapists agreed on participating the interview. During analyses two main 
topics emerged: (1) Acceptance of medium telephone, and (2) Feasibility of the provided 
continuation therapy regarding aim of intervention, previous treatment, and length and 




















 (1) Acceptance of medium telephone 
Within this topic, two main themes emerged from the analysis. 
Alliance and communication 
Most participants and therapists were positively surprised that they could speak openly 
about anything on the phone with an unfamiliar person, perceiving telephone setting different 
but not worse compared to face-to-face settings: 
“The first phone calls required getting used to it. I never had this over the 
phone. During the first sessions, I did not contribute so much, because, 
especially during the first calls you do not know each other so well, you are 
approaching the other one. It takes quite a while until you open yourself, you 
are not starting right away. Approximately after the first two, three calls it 
went really well. We appreciated each other very well and had no holding 
backs. Yes, summarized, very positive.” (P3, 30minC-TT) 
However, development of a sound therapeutic relationship with an unfamiliar therapist 
was considered feasible only with an initial face-to-face session beforehand: 
“You should invest one or two hours. I mean, also for a therapist it is 
important to know where the patient got stuck, where does the patient needs 
support. I think that is important. And also to see the person. You need to 
establish a personal relationship, a bond of trust. I do not think, that this is 
possible entirely over the phone.” (P7, 50minC-TT) 
All therapists and participants noted that nonverbal signs were missing. For most 
participants it seemed to have no substantial influence on quality of trust or understanding, 
also reflected by high scores on the working alliance inventory (see table 4, p. 128), which are 
comparable to scores reported in face-to-face outpatient settings [185]. However, one 
participant perceived medium telephone as insufficient setting for fitting her needs, and this 
very participant showed moderate depressive symptoms throughout therapy and reported to 







“It was easy to keep a good therapeutic relationship over the entire therapy 
[over the phone], always allowing to intensify the relationship.” (T2) 
“In a face-to-face conversation, I see gestures and mimics of my therapist, 
her reactions, and I missed that on the phone … [I had the feeling] that she 
[the therapist] could less emphasize into my feelings. Maybe because she did 
not see me, just listened to what I told her … although telephone is actually 
a personal form of contact, I prefer [therapeutic] conversations with visual 
contact with the therapist” (P2, 30minC-TT)  
Also, having no facial contact was associated with a potential risk of being less present 
towards the patient. Another therapist tried to compensate missing cues by adapting language. 
„Still, I see the potential to make myself a bit more comfortable, isn’t it? As 
a therapist, I mean, the patient cannot see me. And it might happen that I am 
a bit less present. And I consider this a bigger risk compared to face-to-
face.“ (T1) 
 “I speak much slower and more precise compared to face-to-face. This is a 
rather mechanical aspect. But I have the impression, this generates attention 
if I speak slowly and understandable.” (T2) 
Location and time 
Participants associated telephone with an advantage of logistic flexibility in terms of 
choosing a suitable place, spending no time for journey or being independent from external 
factors, especially when living in rural areas. However, agreeing on day and time of the next 
session was perceived comparable to face-to-face settings, and therapists noted that employed 
participants preferred appointments pre- or after working hours. 
“Especially for me, I do not have a car, no driver’s license, and then, for me 
it always needs a bit more effort going anywhere. And now, I was just home, 
knowing that the phone would ring … interestingly, I talk differently when 
being home. I feel more save, familiar surroundings. I am the type of person 
who walks around the flat while phoning.” (P7, 50minC-TT) 
However, flexibility was not always considered an advantage compared to face-to-face 
settings. Although participants were advised to choose an undisturbed place, and most 
participants chose home or an empty office room for calling, daily circumstances (e.g., job or 





discuss the importance of a quiet and undisturbed therapeutic setting together with the patient 
before starting telephone therapy, and if and how such a setting can be ensured.  
“Once I called while sitting in the train because it did not work elsewhere. 
And sometimes I called from home, but I could not speak so well there 
either. For me, it would be better during evenings when my children are not 
around … yes, like here, a quiet neutral room like in a private praxis, where 
you are not distracted from other things … that’s better” (P2, 30minC-TT) 
 
(2) Feasibility of continuation therapy 
Within this topic, three main themes emerged from the analysis. 
Aim and focus of continuation therapy  
Most participants received aim and focus of continuation therapy as valuable and 
different from therapies they received before. They valued continued care in terms of longer 
and frequent support after terminating therapy and maintaining the gains of acute therapy by 
focusing on the future, especially regarding the persistent and recurrent character of 
depression.  
“Most notably, this [concept] was future-oriented, finding approaches to 
prevent relapse and to live with my illness instead of forcing to solve the past 
… and this concept of continued care was new for me … usually, you have to 
get along with it alone. But due to helping me maintaining strategies, I did 
not feel as lonely as following other therapies” (P5, 50minC-TT) 
“Also, to give myself time: can I manage that on my own? And if not, I have 
a lifeline which I can call or write to, who is there for me ... If I should 
stumble, this is ok because I have someone who helps me to get back on my 
feet. And then, I have to get along on my own again. I cannot rest on this. 
This illness is deceitful. I cannot rest until it became ingrained, as 
automatisms. I have to monitor myself every day. There is no other way.” 
(P7, 50minC-TT) 
These two participants started with low level of symptoms, maintained on that level or 
even improved during treatment, and received 50 minutes phone calls (see figure 16, p. 129). 
By contrast, one participant expressed her disappointment with the intervention. She 





received more frequent therapy in retrospect, indicating that concept of continuation therapy 
was probably not quite clear:  
“I think during this time [continuation therapy] other topics were relevant. 
And I think, not so much connection was made to previous [therapy]… I had 
expected to get support further on, for preventing. And if the therapist 
notices that there is more demand for action, to begin there …. Going more 
to the basis, what are triggers I am feeling exactly this way? Just, more 
digging into it.” (P2, 30minC-TT) 
This very participant entered continuation therapy with moderate levels of depressive 
symptoms, received 30 minutes phone calls, and additionally reported on difficult personal 
circumstances (unclear employment status, relationship issues). For this participant it might 
had been better to undergo further acute treatment because the combination of these 
conditions hampered implementation of effective continuation therapy, which we assume was 
amplified by medium telephone and an unfamiliar therapist. Another participant (P3) showed 
a similar course of depressive symptoms until the sixth’ session, received 30 minutes phone 
calls (see figure 16, p. 129), and also reported on difficult personal circumstances. However, 
this participant seemed to have adjusted to aim and context of the intervention and reported to 
have benefitted from the intervention, also shown by decreasing symptoms during the last two 
sessions:  
“I expected usual psychotherapeutic appointments, just shorter and over 
telephone ... and the first phone calls, I perceived them as too short, and I 
wondered: will this work? … we spoke a lot about what I had learned during 
previous therapy to manage similar situations. And I also learned some new 
good bets. It was a mix between previous and new insights, well done!” (P3, 
30minC-TT)   
To constantly focus on consolidating strategies requires an explicit therapy plan 
pursued throughout limited sessions of continuation therapy, and therapists perceived this as a 






“Yes, the challenge is the switch between acute and continuation phase. The 
challenge is, that you really do formulate therapy aims and a treatment plan 
right in the beginning. And having the focus on maintenance and 
stabilization that the patient can handle this on his/her own in the long-term. 
And that you organize each phone call in this regard. Because, there are 
some patients who speak about what happened, and so forth … you should 
prevent the patient of talking 15 minutes about any problem and then 
developing something on that … yes, it has to be clear, this is the treatment 
plan, stick to that.” (T1) 
Both participants and therapists would appreciate a formal integration of continuation 
therapy into the health care system to ensure that patients at high risk are actually monitored 
following acute therapy. Moreover, this might lower the threshold of contacting a therapist 
again, and by this, contributing to long-term stabilization: 
“I hope that this will find a way into daily treatment of patients that this idea 
of continued care will be a topic in therapists … because this was not a topic 
in my previous therapies. Of course, they told me that that I can call them if I 
should worsen. But then, I feel like a loser, if I call them.” (P5, 50minC-TT) 
“Because, of course, if acute therapy is terminated, the patient is usually not 
monitored anymore. Or the patient is not making contact again with a 
therapist if he/she gets worse. And for this, this concept is ideal … would be 
nice to have this offer that a patient can contact the therapist in such a 
formal frame. I think such a quick access to therapy could prevent … it 
might contribute that individuals get better, are stable in long-term.” (T2) 
 
Dependency on gains of precedent acute therapy 
As continuation therapy should be provided only to patients who at least responded to 
acute treatment, we allowed our participants to show minimal depressive symptoms as 
indicated by a PHQ-9 score less than 10 by study entry. However, two participants (P2, P3) 
showed higher scores (see figure 16, p. 129), but previous therapists affirmed stability of 
patients and eligibility for a continuation program. Although initial level of depressive 
symptoms seemed to influence course of continuation therapy in some way, therapists 
considered gains of acute therapy in terms of skills and tools a patient has as another 
important aspect for successful implementation of a continuation therapy. This might be 





set of strategies during the first session to the therapist, but proving whether they actually 
work and are considered helpful happens later during therapy, and therapists have to work 
with what the patient brings with him/her: 
“Practically, in my patients there was simply not that huge tool box you 
could use well-structured during all sessions. This was the crux. Often, we 
spoke about current concerns. And not in the light of how the patient learned 
to solve this, but rather that there was even no well-known strategy 
available. For instance, in this one patient [P2], she had so many “building 
sites”, that we focused on finding or developing strategies because she had 
no “portfolio of resources” she considered helpful… thus, it was rather a 
mix of acute and continuation therapy… I tried always to address 
“Remember, what was helpful last time? What did you do?” (T2) 
Moderate level of depressive symptoms of the mentioned participant (P2) remained 
rather stable during treatment (see figure 16, p. 129). At the same time, the participant 
reported on low level of self-efficacy for depression management at posttreatment (PSDM; 
see table 4, p. 128), which might have contributed to her perception to not have benefitted 
from the intervention at all. By contrast, in other participants continuation therapy worked 
very well, possibly supported by a short interval between acute and continuation therapy, 
which also enhances remembering strategies. Especially patients receiving 50minC-TT 
reported to have benefitted from the intervention, and showed higher levels of perceived self-
efficacy for depression self-management throughout therapy (see table 4, p. 128).  
“He (P7) really has a huge tool box. He not only has one, he is benefitting a 
lot, using it every day. We could focus on that during sessions. He completes 
these situational analyses. He always moves himself on the observer 
perspective, what does he need, and he claims his needs. This was really 
ever-present, all skills from acute therapy… In this patient, acute therapy 
was not that long ago as in the other patients.” (T1) 
“Maybe it would be good to have continuation therapy quite after acute 
therapy, if this is possible… This would be interesting because memory 
lowers… yes, that you remember what you actually spoke about [during 
acute therapy] … yes, you remember conversations roughly, but relatively 





The previous mentioned issues (patient’s skills, personal circumstances, functionality, 
needs, history of illness) might be best addressed by a continuous provider, as reported by 
both participants and therapists. However, working together with an unfamiliar therapist is 
assumed feasible due to aim and focus of continued care, which is considered in consolidating 
gains of previous therapy.  
“This was the good thing. I did not have to start again with Adam and Eva. 
Instead, it had a focus on the future … [in previous therapies] I had the 
feeling the first sessions had been only for the therapist, and after that, it 
was about me. And now, this could be omitted.” (P5, 50min) 
Frequency and length of sessions 
Whilst mean length of phone calls was around 33 minutes in 30minC-TT, mean length 
of phone calls was around 43 minutes in 50minC-TT. This is in line with impressions from the 
interviews as both therapists and participants received 30 minutes each month as definitely 
too short to benefit while 50 minutes was not always perceived a necessary length for each 
session. However, organizing own concerns within limited time was considered a challenge, 
and moreover an ability you have to acquire during continuation therapy: 
“You are just starting, you are getting into it, you know it is going on, and 
then “Hmm, we have to stop” …. And I looked strategically, what will have 
place within the next ten minutes, and what will have not? And then I just left 
out something. I had to learn to organize myself…. Because in the beginning 
we talk about my last month, how I felt. And if we would then also talk about 
what we discussed during the last session, there would be no time for things 
that concern me currently.” (P3, 30minC-TT) 
“30 minutes. For some people this might be too less. The question is, can I 
point out what is important for me? I mean, I could tell all my things from 
the last month, and then this will take three hours, approximately. This is the 
risk. You must have to point out, what is your topic today, what is important 
I want to speak about.” (P7, 50minC-TT) 
Phone sessions were conducted approximately each four weeks. There was a trend that 
participants receiving 30minC-TT (who showed higher levels of depressive symptoms already 
by study entry, see table 4, p. 128) perceived a one-month gap as too short compared to 





study). Moreover, participants mentioned that this gap requires prioritizing of your concerns, 
and that longer intervals between sessions is exactly the adequate setting needed for making 
the progress stepping from acute to continuation therapy: 
“Think, ok, we have just a few sessions, where do I want to emphasize? I 
have so many things we could speak about …. and yes, in the beginning of 
therapy I wished to have therapy more often. But then, later, I realized, it is 
continuation therapy. And this means, I have to get along with some things 
on my own now. I have to bite through until the next session” (P3, 30minC-
TT) 
“If you would go to the therapist every week, maybe there is no need for 
that, [because] then you would have again a dependency of relationship in 
which you can lean back and say ‘I will discuss this next week’… and really 
try to get along alone during this interval, without calling each time ‘please 
help me’ or ‘what shall I do?’, this is actually the crucial point, to learn to 
walk on your own.” (P7, 50minC-TT) 
Although participants perceived a one-month between phone calls as generally 
adequate they recommended entering continuation treatment with shorter intervals followed 
by extending these intervals, to have a “softer” transition from acute phase to continuation 
phase setting: 
“Yes, if one had finished [acute] therapy just recently, I imagine this might 
be too less. Maybe, once in two weeks, and later then, once a month, bit by 
bit. That intervals become longer. This would be desirable.” (P3, 30minC-
TT) 
This one-month interval between sessions was associated with perceived challenges in 
linking contents of these sessions, probably solved by making detailed notes about the past 
and prospective contents of sessions. Moreover, therapists discussed opportunities and 







“Yes, you lose linkage, remembering the last session is hard. You make 
notes, but it is still hard to remember the last conversation, to put yourself 
back there… you should write a protocol for yourself, regularly. This would 
be an option.” (P4, 50minC-TT) 
 “Nevertheless, I had the feeling some patients benefitted from writing me 
and I wrote back… an advantage is that it helps to keep alliance and to stay 
in the [therapeutic] process. A disadvantage is that this takes time, and that 





Aim of the study was to evaluate the feasibility and acceptance of a telephone-based 
continuation therapy for individuals at high risk for relapse into depression. We used an 
exploratory mixed-methods approach to obtain detailed understanding of this intervention 
including evaluation of the new components, i.e., medium telephone including length and 
frequency of phone calls in context of a continuation treatment with unfamiliarity of 
participant and therapist.  
We consider an effective implementation of the proposed intervention as feasible if 
several preconditions are ensured. First, the previous acute treatment has to be terminated 
successfully defined by a low or minimal level of depressive symptoms. Moreover, the patient 
had to acquire strategies to effectively cope with concerns or difficult circumstances 
independently. If both factors are ensured we consider likelihood of an effective continuation 
treatment including maintaining or improving mental health status as high. By contrast, for 
patients still showing moderate level of depressive symptoms by only a little range of 
effective coping strategies we consider the application of a low-intensity intervention as we 
provided as inadequate. Studies show that even after terminating depression treatment 30% to 
50% of individuals report on residual symptoms [188–191], and these are associated with 
enhanced likelihood for prompter relapse up to three times [188]. This might be even 





vulnerability, which is considered premorbid or has developed with accumulated depressive 
episodes [1]. Thus, even though patients might benefit from a low-intensity continuation 
intervention indicated by stable symptomatology/residual symptoms, superficial aim should 
be to further decrease level of depressive symptoms, which might be better addressed by a 
higher frequent acute therapy.  
Besides level of depressive symptoms, our therapists also highlighted the importance 
of available coping strategies. An acute-phase depression CBT study [113] investigated 
coping self-efficacy (using problem-focused coping, stopping unpleasant emotions and 
thoughts, getting support from others) [192], and found that moderate to high levels of coping 
self-efficacy significantly increased likelihood of responding to CBT, irrespective of 
treatment delivery (face-to-face vs telephone) [193]. In our study we assessed perceived self-
efficacy with depression management (PSDM), which shares aspects with coping self-
efficacy. We also observed in our participants with lower levels of depressive symptoms 
higher scores on the PSDM by entering continuation therapy, and even increasing PSDM 
scores by end of intervention, underlining the importance of coping strategies throughout 
treatment and across treatment phases.  
Second, a continuous provider enhances likelihood of valid assessment of patient’s 
response/remission status and coping strategies by terminating acute therapy. However, 
change of therapist between acute and continuation treatment phase is feasible if 
preconditions as outlined above are ensured and records on previous treatments are 
transferred to the new therapist. Change of providers is a common condition in health care 
systems in which funding of outpatient and inpatient treatment is covered by separate parties. 
Consequently, consistency of care between acute inpatient to continuation outpatient 
treatment might be impaired, and mistreatment or variation in prescribed medication can 
occur [194]. Several approaches as integration of general practitioners into both in- and 





standardized cover letters are discussed for improving communication between providers 
[194].  
Third, application of medium telephone was mostly addressed by well-known 
advantages as low-threshold access with personal contact, omission of drive to therapy (which 
is especially relevant for individuals living in rural areas or for those being physically 
impaired), and a more flexible integration of therapy into everyday life including job and 
family responsibilities [113, 117]. Those factors might enhance likelihood that high risk 
patients maintain in therapy even after successful acute treatment to sustain remission and 
recovery in the long-term. Also, telephone is recommended for treatments having a lower 
level of complexity by showing a medium level of comprehensiveness [110], and thus might 
especially qualify for mode of delivery of continuation treatments: Acute treatments intend to 
reduce patient’s symptoms and work towards understanding of development and maintenance 
of the patient’s depression. Whilst these processes are considered rather complex, 
continuation treatments aim to practice and intensify relapse prevention techniques already 
acquired during acute treatment, and telephone might be an adequate medium for this level of 
complexity. Our therapists mentioned two further issues to ensure when applying telephone: a 
stronger consideration of precise language, intonation and verbal cues [113], as well as a clear 
agreement with the patient on location for phone calls to avoid disturbed settings [178].  
Fourth, evaluation of length and frequency of sessions during the continuation 
treatment phase varied in regard to level of depressive symptoms and attitude towards the 
intervention concept. If participants showed moderate depressive symptoms and expected to 
receive high-intensity treatment, 30 minutes was perceived as inadequate and not fitting the 
participant’s needs. The ‘adequacy of fit’ between type of intervention, medium of delivery 
and patient’s concept of what a therapy represents is considered relevant to embark in therapy 
and benefit from it [117]. Both participants and therapists would have preferred the 50 





of symptom monitoring, reviewing home-work, discussing current concerns with regard to 
available strategies, and scheduling exercises and the next session. Other psychotherapeutic 
continuation interventions for recurrent or persistent depressed individuals apply a 50 or 60 
minutes setting [67, 137], even allowing an extension up to 90 minutes [136]. Moreover, 
those interventions usually start with biweekly sessions, passing over to one session per 
month.  
One of our therapists and one participant also recommended to determine only the 
number of sessions within a fixed time period, but allowing to choose frequency of sessions 
independently, including more frequent sessions directly after transition from acute to 
continuation treatment phase. However, three of our participants explicitly supported the 
application of a one-month interval between sessions to actually have time for practicing the 
consolidation of skills acquired during acute therapy. But this one-month gap was also 
associated with difficulties in making the link between the last and subsequent session. A 
stronger structure within a session and a clear treatment plan across the entire treatment 
period might help to prioritize contents of each session, and making a link between sessions. 
Also mandatory homework for reworking issues of the past session and reviewing the results 
of this homework at the next session could help to make a clear link between sessions over 
time, and in parallel, can contribute to increase of patient’s functioning [195].  
Fifth, we determined a six-month treatment period based on clinical guidelines who 
recommend a period between four and nine months [6, 45], and with regard to other 
psychotherapeutic continuation interventions who last between four and eight months [67, 
137]. The majority of our participants wished to have received longer continuation treatment, 
especially those who deteriorated during treatment or still showed moderate depressive 
symptoms by end of intervention. Four of five participants who provided follow-up data 
showed a slight to moderate increase in depressive symptoms after six month posttreatment. 





maintenance therapy might enhance relapse-preventive effects for individuals being at high 
risk even after successful acute and continuation treatment [6, 45].  
Long-term psychological and pharmacological maintenance treatments up to three 
years promise relapse-preventive effects in recurrent and persistent depressed individuals [62, 
65, 70, 169, 196, 197], and they usually provide the same treatment during all treatment 
phases. Sixth, there are interventions which provide remitted or recovered patients with 
continuation treatment irrespective of previous treatment(s). In recent years, the Mindfulness-
Based Cognitive Therapy (MBCT) [48] obtained attention in research and clinical practice, 
and is considered a promising approach in reducing relapse and recurrence in individuals, 
which experienced more than three depressive episodes [47]. MBCT is an eight-week 
intervention conducted as group therapy with weekly meetings and imparting strategies 
specific to the underlying theory of this intervention. Thus, this program differs from 
continuation treatments as explained above due to its rather short-term format and lack of 
explicit linking to previous treatments. Whilst our intervention is reliant on patient’s available 
strategies and rather immediate transition between acute and continuation treatment, MBCT 
has less restrictions and might provide a further or additional approach to sustain relapse and 
remission in the long-term.  
Finally, despite high demands, long-term psychotherapeutic continuation or 
maintenance interventions are currently not an integral part of standard mental health care [3]. 
This might be owed to progressively limited financial resources of the health care system, 
resulting in a lack of systematic and comprehensive networks of providers and treatment 
options. In outpatient settings therapists might offer ‘booster sessions’, which share 
components with continuation programs, as reviewing or reactivating the learned from 
therapy [198]. However, such booster sessions are commonly taking place only on the 
patient’s request and are not scheduled in advance. One of our participants mentioned that 





did not make use of booster sessions consequently. Later, by the time she deteriorated, she felt 
ashamed of contacting her therapist again. This highlights the value and need of a formal 
integration of continuation interventions into the health care system to ensure continuous 
long-term monitoring of patients being at high risk for relapse and recurrence.  
Strength and limitations of this study need to be considered when interpreting the 
found results. To our knowledge, this is the first study providing continued psychotherapeutic 
treatment to people with recurrent or persistent depressive disorder over telephone. Before 
effectiveness of an intervention can be evaluated it is recommended to assess quantitative as 
well as qualitative data within a feasibility trial to obtain detailed understanding of the 
intervention including aspects which already work well, but also problems in implementation 
[174, 175]. Hence, we conducted a pilot study to assess feasibility of this intervention 
evaluated by both participants and therapists using qualitative and quantitative methods, 
which we consider a key strength of this study as it investigated each new intervention 
component and interaction of these components. However, due its pilot character the study 
has some limitations. Findings are based on seven participants and two therapists who were 
motivated and engaged into this research project, raising question on the generalizability to 
routine care settings. The study was conducted in Switzerland and addressed characteristics 
specifically to the Swiss health care system, which might differ regarding format and funding 
of treatment from other countries. Moreover, we were not able to analyze quantitative 
measures on course of treatment statistically, and neither included an untreated control group. 
Hence, we do not know if and how our intervention accounts for changes we observed in 
participants. Also, not all participants completed all measures and two participants did not 
join the interview, probably biasing the results considering the small sample size.  
Findings of this pilot study have important implications for further development of 
continued psychotherapy for depressed individuals at high risk for relapse and recurrence. 





preventive effects in high risk individuals. At the same time, patients report on severe side-
effects resulting in discontinuing antidepressant medication without the doctor’s agreement, 
which in turn increases likelihood of relapse. Psychological long-term interventions can meet 
this condition by focusing on enduring behavioral change which might be less associated with 
adverse events. Moreover, as individuals with recurrent or persistent depression commonly 
take antidepressant medication, psychotherapy might support relevance and continuous intake 
of drugs. Barriers on several levels (patient, provider, health care system) do hamper access to 
treatment, and telephone is considered a promising approach to provide more patients with 
low-threshold care by showing characteristics similar to face-to-face settings. However, this 
pilot study cannot draw any conclusions on the effectiveness of this intervention due to 
discussed limitations. But, findings of this project influenced further development of the 
intervention, and is going to be investigated for its effectiveness within an ongoing multi-
center randomized controlled trial organized by our department, comparing the telephone-
based continuation therapy against treatment as usual (NCT03219879). 
 
Conclusion 
The present findings provide in-depth insight to opportunities and boundaries of a 
telephone-based psychotherapeutic continuation program for people with recurrent or 
persistent depressive disorder. While participants and therapists evaluated the concept and 
aim of this intervention as feasible, and considered telephone as an adequate medium for this 
treatment phase, there are factors which need to be taken into account for deciding which 
individuals might benefit from this intervention. Low level of residual symptoms and 
available effective coping strategies are core conditions which need to be ensured before 
terminating acute and entering continuation therapy. A clear treatment plan implemented 
throughout therapy and prioritizing of contents within each session is required by both 





aspects are fulfilled, medium telephone is considered feasible and moreover, might facilitate 






4.3  Identifying relapse prevention elements during psychological 
treatment of depression: Development of an observer-based rating6 
instrument 
4.3.1 Abstract 
Background. Although observer-rated instruments assessing therapist’s adherence to relapse-
preventive treatments are available, they do not adequately cover specific relapse-preventive 
elements that focus on implementation of strategies after terminating treatment. This study 
describes the development of the KERI-D (Kodierbogen zur Erfassung 
Rückfallprophylaktischer Interventionen bei Depression/Coding System to Assess 
Interventions of Relapse Prevention in Depression). The KERI-D is a new observer-based 
rating tool for acute or continuation/maintenance-phase sessions and assesses relapse-
prevention elements including implementation into patient’s daily routines. 
Methods. The development of the KERI-D included iterative steps referring to theoretical, 
clinical and empirical sources. It consists of 19 content items within four categories (self-care, 
early warning signs, triggering events/situations, termination of therapy) and one global item. 
For empirical analyses, videotaped psychotherapy sessions of 36 psychotherapies were rated 
by three independent observers and analyzed for their psychometric properties. 
Results. Most items showed moderate to good inter-rater reliability (median ICC = .80) and 
retest reliability (median ICC = .93). Principal-axis factor analysis revealed three subscales, 
and first evidence of content validity was demonstrated. No associations with clinical follow-
up data were found. 
Limitations. Analysis was limited to a relatively small sample of selected psychotherapy 
sessions. Evaluation of predictive validity is a desirable next step to further examine 
applicability and scope of the instrument. 
                                                          





Conclusions. The KERI-D is the first observer-based rating instrument measuring specific 
relapse-prevention strategies in psychotherapy for depression. It may help to identify elements 
that prove effective in reducing relapse/recurrence in the long-term and thereby help to 
optimize effect duration of depression treatment. 
 
4.3.2 Background 
Psychotherapy research on the effective prevention of relapse and recurrence after 
acute depression treatments has mostly investigated cognitive behavioral interventions, both 
alone and in combination with antidepressants [12, 137, 200]. However, after a terminated 
acute phase of cognitive behavioral therapy (CBT), relapse/recurrence rates were found to be 
29% in the first year and 54% in the second year [12]. Even with continued/maintained 
psychotherapy or pharmacotherapy, relapse and recurrence rates are still found to be high 
[12]. Considering generally high relapse rates in depression, it is essential to identify 
potentially underlying processes of relapse prevention, followed by an investigation of their 
effectiveness and related mechanisms of action. Although treatment manuals recommend a 
variety of relapse-prevention elements, available measures assessing therapists’ treatment 
adherence and competence only marginally target relapse-preventive aspects beyond core 
cognitive treatment elements (e.g., CT techniques). 
Three types of psychological interventions target the prevention of recurrence of 
depressive symptoms [38]: 1. Interventions during acute treatment aiming to maintain 
reduced symptoms also beyond termination. 2. Continuation and/or 3. Maintenance treatment, 
both provided after terminating acute treatment. Whilst continuation treatments are provided 
to currently remitted patients or to patients that previously responded to treatment, 
maintenance treatments are given during recovery defined as remission lasting longer than six 





relapse (return of depressive symptoms before full remission has been achieved) or recurrence 
(appearance of another new episode of depression after full remission) [8].  
Established treatment manuals for cognitive and interpersonal therapies [176, 201–
204] include specific recommendations for relapse prevention techniques being mostly 
assigned to the final phase of therapy. More specifically, elements to rehearse in this 
treatment phase include: early detection of depressive symptoms, anticipating critical 
situations and adequate coping skills, maintaining antidepressant activities, reinforcing helpful 
cognitions, planning the future, sensitizing the patient to potential relapses, and preparing 
transition from therapy to time after therapy termination. Although a variety of relapse 
prevention strategies seem to be recommended and commonly used in clinical practice, 
instruments measuring the quantity and quality of specific relapse-prevention elements have 
not yet been developed. More specifically, available scales assessing adherence and 
competence during psychotherapy do not fully cover the adequate implementation of relapse-
prevention techniques beyond core treatment elements (e.g., central cognitions in CT). 
In psychotherapy research, treatment integrity is defined by adherence and competence 
[77]. Adherence is defined as the degree a therapist provides interventions as determined in 
the treatment manual, whereas competence is defined as the extent to which a therapist 
implements such techniques in a skillful manner. A variety of reliable and validated 
instruments assessing therapist’s adherence and competence during psychotherapy are 
available. The most influential adherence scale is the Collaborative Study Psychotherapy 
Rating Scale [CSPRS; 80], developed to assess treatment integrity in CBT, interpersonal 
therapy, and psychiatric clinical management, including also particular CBT techniques (e.g., 
recognizing cognitive errors) observed in-session [205]. Referring specifically to relapse 
prevention after terminated acute treatment in individual setting, only one scale is available: 
The Cognitive-Behavioral Maintenance Therapy—Adherence Scale (CBMT-AS) was 





adherence to the manual of relapse-prevention therapy for recurrent depressive disorder [206]. 
Besides global evaluations (“management of time”) and cognitive-behavioral contents 
(“Encouragement of self-monitoring”), also one “relapse prevention” item is included. 
However, this single item was not used in further analyses because it was considered to be 
insufficiently assessable during therapy sessions [206].  
The most influential competence scale is the validated and frequently applied 
Cognitive Therapy Scale [CTS; 81]. It is an observer-based rating instrument containing items 
on general competencies (e.g., use of feedback and summaries), specific competencies (e.g., 
focus on central cognitions), and one global item (overall rating of competence). Evidence for 
associations of competence and adherence measures with clinical outcomes in cognitive 
treatments for depression is equivocal. The meta-analysis of Webb and colleagues [79] found 
no significant associations, which the authors attributed to the variety of applied methods 
(rating instrument, number of rated sessions, etc.), or to little influence of therapists’ 
adherence and competence on patients’ symptom change. 
The mentioned instruments target relapse-preventive elements only to a marginal 
degree, i.e., items such as ‘Encouragement of self-monitoring’ or ‘relapse prevention’ [e.g., 
CBMT-AS; 206], and these instruments focus rather on the application of certain behaviors 
during treatment than preparing for their application after discontinuing treatment. Thus, there 
is a need for an instrument assessing specific relapse-preventive elements initiated by the 
therapist which focus on the patient’s implementation of strategies after termination of 
treatment, such as anticipating critical situations or sensitizing the patient to potential relapses 
and recurrences in the long-term.  
Aim of the present study was to create a rating instrument to systematically assess 
relapse-preventive elements during CBT for depression. For this, we developed the KERI-D 
(Kodierbogen zur Erfassung Rückfallprophylaktischer Interventionen bei Depression/Coding 





rating instrument to be applied in videotaped psychotherapy sessions during acute and 
continued/maintained depression treatment. The KERI-D assesses relapse-preventive 
elements that include both quantitative and qualitative aspects of the related 
psychotherapeutic process. The main objectives were to 1) assess the reliability of the KERI-
D on an item level, 2) determine whether the KERI-D is able to identify relapse-preventive 
interventions occurring during psychotherapy, 3) explore the factorial structure of content 
items, 4) investigate associations with clinical outcome data, and 5) assess content validity of 
the KERI-D as measured by expert ratings. 
 
4.3.3 Methods 
Developing the rating material 
Developmental steps. The KERI-D was developed by means of the following iterative 
steps: First, literature was screened for information on relapse-preventive strategies 
recommended in manuals for clinical practitioners [e.g., 39, 203]. Existing treatment integrity 
scales were screened [80, 206, 207, e.g., 208]. In addition, experienced psychotherapists were 
interviewed on how they define relapse prevention and how they implement such strategies in 
their daily routines [209]. Second, major categories and corresponding items of relapse 
prevention were derived from theory  [39, 176]. By screening six videotaped psychotherapy 
sessions additional aspects of relapse prevention not yet derived by previous steps were 
elicited. For this step, the last three sessions of two psychotherapies had been selected 
randomly from all available videotaped psychotherapies (see section “Assessing the reliability 
of the KERI-D”). This process resulted in six categories with 183 items. After conceptually 
overlapping items were condensed and re-reviewed regarding their relevance for relapse-
preventive efforts, a preliminary version with five categories and 39 items was prepared.  
Third, this preliminary version of the rating scheme was used for pilot ratings by three 





how to adapt and optimize the rating scheme. All decisions were made by consensus. Each 
revised version was used in multiple rating trials. Agreement between raters was assessed 
frequently to ensure reliability of the instrument. Highly discordant ratings were discussed by 
all raters, and the rating manual was revised accordingly and finalized. This process resulted 
in four categories and 20 items, presented as the KERI-D (Kodierbogen zur Erfassung 
Rückfallprophylaktischer Interventionen bei Depression/Coding System to Assess 
Interventions of Relapse Prevention in Depression) [210]. (A more detailed report in German 
on the instrument development can be requested from the last author.) 
Content of the KERI-D. The four main categories, their corresponding items, the 
transfer item, and rating procedures are described below. Items of category A to C cover the 
patient’s individual concerns of the past and the future, the implementation of specific 
interventions and strategies, and potential problems in transforming those in daily routine. 
Category D contains elements referring explicitly to the end of treatment and to the 
preparation of the post-treatment phase. Since items in these four categories relate to specific 
contents covered in the therapies, they are referred to below as “content items”. In contrast, 
the transfer item refers to an overall rating of the whole therapy session and describes how the 
therapist facilitates the translation from therapy to the patient’s daily life after terminating 
therapy. For the complete rating sheet including all items, see Appendix C and D, p. 210.  
Self-care (A). Five items assess the extent to which the patient’s individual positive activities 
and resources are addressed. Sample item: “Specific opportunities and resources for 
practicing self-care are discussed.” 
Early warning signs (B). Four items assess to what extent the patient’s symptoms are 
addressed, in terms of recognizing depressive mood adequately when it develops. Sample 





Triggering events and situations (C). Four items assess to what extent potentially triggering 
events and situations that may contribute to a relapse are addressed. Sample item: “Specific 
strategies to prepare for potentially triggering events and situations are discussed.” 
Termination of therapy and planning next steps (D). Six items assess whether the following 
issues are discussed: most important findings in therapy, goals in life, continuation treatment 
options, plans for the future, importance of relapse prevention strategies. Sample item: “The 
patient’s most important findings during therapy and/or achievements are discussed.” 
Transfer item: This global item measures the extent to which the therapist addresses issues (of 
categories A to D) in a way that encourages the patient to implement and sustain the skills, 
knowledge or competences gained in therapy in their daily routine, and continue these efforts 
over the long-term.  
Assessing the reliability of the KERI-D 
Psychotherapy sessions. Data were provided by a study conducted in Zurich, 
Switzerland (NCT01012856), comparing the effectiveness of (CBT) and Exposure-Based 
Cognitive Therapy (EBCT-R) in patients suffering from an acute episode of unipolar major 
depressive disorder [211]. The study included 144 outpatients and 28 therapists. Each 
therapist provided both CBT and EBCT-R. Whereas both treatments had separate treatment 
manuals, the relapse-preventive section of both manuals was identical. All patients were 
offered 22 sessions of either CBT or EBCT-R. The therapy sessions analyzed for the current 
article were selected using the following criteria: Videotapes of the patient’s final two therapy 
sessions (21 and 22) were available in good audio-visual quality. Sessions 21 and 22 were 
selected because relapse-preventive elements were to be expected in the terminating phase of 
therapy. To achieve a maximal variance in the implementation of relapse prevention elements, 





Raters and rater training. Three students at Master’s level in clinical psychology 
served for the final rating of 72 therapy sessions. Each rater underwent a one-day training 
session focused on familiarization with the rating manual and the instrument, followed by 
independently rating the same four videotaped psychotherapy sessions. The raters achieved a 
median ICC(2,1) of .70 over all items between each of the three pairs of raters (ICCpair 1= .88 
ICCpair 2= .70; ICCpair 3= .67). 
Allocation of psychotherapy sessions to raters. We used a balanced incomplete block 
design [212] for allocating the 72 sessions. Each session was rated by two out of the three 
available raters in order to determine inter-rater reliability, and each rater coded the same 
number of sessions with each of the other two raters [205]. Furthermore, the sessions were 
stratified by an equal number of sessions 21 and 22 as well as CBT and EBCT-R sessions in 
order to minimize bias of therapy sessions between raters. This resulted in a total of 72 rated 
sessions from 36 therapies provided by 22 therapists. The mean length of sessions was 55 
minutes (session 21) and 54 minutes (session 22). 
Rating process7. All items are rated on a five-point Likert scale for how much the rater 
would agree (not at all … thoroughly) that a therapist’s behavior was shown during an entire 
therapy session [213, 214]. For each item, sample dialogues between patient and therapist 
illustrate the highest possible rating (thoroughly). While watching the therapy session on 
videotape, the rater is encouraged to take notes, as the final rating is conducted after stopping 
the video.  
Content Validity Index 
Content validity of the items was assessed by five content experts determining the 
Content Validity Index on item level [I-CVI; 215, 216]. Experts were chosen on basis of their 
                                                          
7 A detailed description of each item and of the rating instructions can be found in the rating manual (in German 





experience with research and clinical practice in depression treatment. They had an average of 
14 years’ experience in research and clinical work. They were asked to rate each item in terms 
of its relevance to relapse prevention in general and in terms of the item’s relevance to each of 
the four categories (A to D). Relevance was assessed on a four-point ordinal rating scale (1 = 
not relevant; 2 = major revision needed to be relevant; 3 = relevant and minor alterations 
needed; 4 = highly relevant). 
Analyses 
Inter-rater and retest reliabilities were examined by calculating intra-class correlations 
(ICCs) in a two-way random model (ICC2,2), testing for absolute agreement between the two 
raters or within one rater, respectively. Each rater rated 10% of sessions six months after 
finishing the first rating [217]. For determining an item’s frequency, it was first rated using a 
five-point Likert scale from 0 (not at all) to 4 (thoroughly). Subsequently, the ratings were 
dichotomized into “0 = Item did not occur” (formerly “not at all”) and “1 = Item occurred” 
(including the manifestations 1–4 on the former Likert scale). Two-sided t-tests on 5%-alpha 
level were calculated to examine differences between mean scores of items in sessions 21 
versus 22. We thus averaged the corresponding two scores for each session and item [207], 
and most of the items achieved moderate to good ICCs. To estimate a factor structure of items 
in categories A, B and C, we first merged the scores of sessions 21 and 22, using the higher 
score of either session 21 or 22. This approach accounts for the fact that some relapse-
preventive elements may emerge during session 21, others in the final therapy session, or in 
both. Then, we determined the number of components by using parallel analysis and the 
Velicer’s Minimum Average Partial (MAP) Test [218]. As both approaches revealed three 
components for our data set, we specified three factors in the statistic software package SPSS 
and ran a principal axis analysis (oblimin rotation) to examine factor loadings. As a measure 





Bivariate associations between KERI-D subscales and clinical outcome data (retrieved 
from the original trial) were determined by calculating Spearman correlations. One analyzed 
outcome was the self-reported level of depressive symptoms as measured by the Beck 
Depression Inventory [BDI-II; 144, 219] at posttreatment and at 12-month-follow-up. An 
additional outcome was diagnosis of a major depressive episode (MDE) at posttreatment, and 
whether at least one MDE occurred during the 12-month-follow-up. To assess diagnosis of an 
MDE, we conducted the clinician-rated Structured Clinical Interview [220] at 3-, 6- and 12-
month follow-up, and generated a dichotomous variable measuring the occurrence vs non-
occurrence of an MDE. Therapeutic alliance as measured by a modified version of the Bern 
Post-Session Report-Patient Form [221] was analyzed for session 21 and 22. To determine 
content validity we calculated the content validity index [I-CVI; 215], dividing the number of 
experts providing a rating of either 3 or 4 by the total number of experts. With five experts or 




Reliability of the KERI-D 
Table 5 shows the median ICC across all three pairs for each pair of raters. The 
median ICCs ranged from 0 to .95, with a mean of .69 and a median of .80. The items varied 
substantially in terms of inter-rater reliability, particularly for the items that occurred 
infrequently (see table 7). Table 6 shows retest reliabilities for each rater and the median score 
over all three raters. Median ICCs ranged from 0 to 1, with a mean of .85 and a median of .93. 
We did not determine a median score for items A2c and B2a since just one rater provided a 
reliability score (see table 6). For the majority of items the correlations indicate sufficient 














Category A: Self-care 
A1a (self-care activities) .79 .90 .88 .88 
A1b (patient resources) .92 .73 .79 .79 
A2a (opportunities practicing self-care) .55 .85 .35 .55 
A2b (difficulties in practicing and maintaining) .81 .84 .55 .81 
A2c (options for monitoring/evaluation) .00 .72 .00 .00 
Category B: Early warning signs 
B1a (early warning signs) .74 .89 .93 .89 
B2a (methods to monitor and recognize) (-) .35 .00 .18 
B2b (strategies for dealing with it) .80 .89 .93 .89 
B2c (difficulties in implementing) .00 .62 .26 .26 
Category C: Triggering events and situations 
C1a (triggering events and situations) .94 .81 .88 .88 
C2a (strategies to prepare) .62 .44 .75 .62 
C2b (difficulties in implementing) .54 .65 .53 .54 
C2c (symptoms of relapse, emergency kit/plan) .71 .92 .85 .85 
Category D: Termination of therapy and planning next steps 
D1a (findings during therapy/achievements) .75 .63 .85 .75 
D1b (life goals) .72 .81 .60 .72 
D1c (emotions and cognitions on terminating therapy) .94 .86 .85 .86 
D2a (options for contacting therapist after terminating therapy) .85 .90 .91 .90 
D2b (continuing treatment) .86 .95 .97 .95 
D3a (chance of a relapse, significance of relapse prevention) .46 .77 .64 .64 
Transfer item  
(extent the therapist encourages patient to implement and sustain 
skills, knowledge, and competencies gained in therapy in daily 
routine and in the long term) 
.60 .80 .85 .80 
(-) … ICC could not be calculated as there was no variance between the raters. Each pair of raters 
coded the same N = 24 sessions; the intra-class correlations should therefore be interpreted with 






Table 6 Retest reliabilities for each rater and overall (median) 







Category A: Self-care 
A1a (self-care activities) .93 .91 .80 .91 
A1b (patient resources) .94 .46 0 .46 
A2a (opportunities practicing self-care) .98 1 .59 .98 
A2b (difficulties in practicing and maintaining) .92 .97 0 .92 
A2c (options for monitoring/evaluation) (-) 1 (-) - a 
Category B: Early warning signs 
B1a (early warning signs) .98 .95 .96 .96 
B2a (methods to monitor and recognize) (-) (-) (-) - a 
B2b (strategies for dealing with it) 1 .70 .88 .88 
B2c (difficulties in implementing) 1 1 0 1 
Category C: Triggering events and situations 
C1a (triggering events and situations) .93 .96 .95 .95 
C2a (strategies to prepare) .96 0 .91 .91 
C2b (difficulties in implementing) 1 0 .98 .98 
C2c (symptoms of relapse, emergency kit/plan) 1 .89 1 1 
Category D: Termination of therapy and planning next steps 
D1a (findings during therapy/achievements) .94 .93 .91 .93 
D1b (life goals) .98 .89 .98 .98 
D1c (emotions and cognitions on terminating therapy) .89 .75 (-) .82 
D2a (options for contacting therapist after terminating therapy) 0 0 .47 0 
D2b (continuing treatment) 1 .82 .85 .85 
D3a (chance of a relapse, significance of relapse prevention) .78 0 .86 .78 
Transfer item  
(extent the therapist encourages patient to implement and sustain skills, 
knowledge or competences gained in therapy into his/her daily routine 
and in the long run) 
.95 .71 .96 .95 
 (-) … ICC could not be calculated as there was no variance between the rated scores. a… no median 








Table 7 shows relative frequency rated by each rater individually and the median 
frequency over all three raters. The median occurrence of items ranged from 2% to 96%, with 
a mean of 45.8% and a median of 47%. Item frequency ranged widely, with some items being 
rated to occur in almost every session (e.g., transfer item) and others almost never (e.g., A2c: 
options for monitoring).  
Comparison of sessions 21 and 22 
The mean scores ranged from 0.07 to 1.93 in session 21, and from 0.03 to 2.65 in 
session 22. Four items showed significant differences between the two sessions, with all four 
session 22 items achieving a higher rating in comparison to 21 (C2c: t(70) = -2.57, p < .05; 
D1a: t(70) = -3.07, p < .01; D1c: t(70) = -3.00, p < .01; D2a: t(70) = -3.54, p < .01). As the 
majority of items did not differ between the two sessions we merged the scores of sessions 21 
and 22, yielding a mean of 2.56 and a median of 2.58 for these maximum scores. Figure 17 
(see p. 160) shows the frequencies of each possible rating category (0…4) for each of the 20 
items and the mean of each item on the Likert scale. At least three of five rating categories 
were coded by the raters in all 20 items, in 17 of 20 items all of the five rating categories were 
coded, and in 19 of 20 items the highest possible rating (4 = thoroughly) was coded. This 
resulted in a considerable variety regarding the total amount of the five different rating 
categories coded. Also the mean scores of items varied largely, with a minimum of .18 (item 














Category A: Self-care 
A1a (self-care activities) 75 65 65 65 
A1b (patient resources) 65 65 60 65 
A2a (opportunities practicing self-care) 63 19 46 46 
A2b (difficulties in practicing and maintaining) 50 27 33 33 
A2c (options for monitoring/evaluation) 2 2 10 2 
Category B: Early warning signs 
B1a (early warning signs) 54 60 60 60 
B2a (methods to monitor and recognize) 2 2 15 2 
B2b (strategies for dealing with it) 48 46 56 48 
B2c (difficulties in implementing) 21 10 31 21 
Category C: Triggering events and situations 
C1a (triggering events and situations) 46 71 79 71 
C2a (strategies to prepare) 17 44 56 44 
C2b (difficulties in implementing) 8 10 27 10 
C2c (symptoms of relapse, emergency kit/plan) 25 29 31 29 
Category D: Termination of therapy and planning next steps 
D1a (findings during therapy/achievements) 96 79 77 79 
D1b (life goals) 46 48 56 48 
D1c (emotions and cognitions on terminating therapy) 33 29 23 29 
D2a (options for contacting therapist after terminating therapy) 33 67 65 65 
D2b (continuing treatment) 40 42 31 40 
D3a (chance of a relapse, significance of relapse prevention) 79 50 63 63 
Transfer item  
(extent the therapist encourages patient to implement and sustain skills, 
knowledge or competences gained in therapy into his/her daily routine 
and in the long run) 
96 79 96 96 
Each rater coded N = 48 sessions; the frequency of occurrence should therefore be interpreted with 
respect to these 48 sessions. Example: Rater 1 coded item A1a in 75% of the 48 sessions. Item A1a 








Figure 17. Frequencies and means of KERI-D ratings aggregated over the final two therapy sessions of N = 36 therapies. 
Frequencies (x-axis) indicate how often each of the five possible rating categories (Likert scale ranging from 0 to 4 with 0 = not at all and 
4 = thoroughly)) was observed for each of the 20 items. Merged scores of both sessions 21 and 22 were used. Numbers above each bar indicate 






First examination of a factor structure 
The principal axis analysis revealed factor loadings that corresponded broadly to our 
theoretical assumptions about three categories (see table 8). All category A items (self-care) 
loaded on one factor. In addition, items in category B (early warning signs) and C (triggering 
events and situations) loaded on the assumed factors with one exception. Item C2c (symptoms 
of relapse, “emergency kit”) loaded on the factor composed of category B items. However, all 
three factors demonstrated good internal consistency in this data set (see table 8), with scores 
ranging from .75 to .85.  
 
Table 8 Results of principal axis analysis and internal consistency (N = 36) 
 Factor loadings 
Items I II III 
B2b (strategies for dealing with it) .96   
B2c (difficulties in implementing) .75   
B1a (early warning signs) .74   
C2c (symptoms of relapse, emergency kit/plan) .69   
B2a (methods to monitor and recognize) .52   
A2a (opportunities practicing self-care)  .88  
A2b (difficulties in practicing and maintaining)  .80  
A1a (self-care activities)  .73  
A2c (options for monitoring/evaluation)  .39  
A1b (patient resources)  .29  
C2a (strategies to prepare)   .92 
C2b (difficulties in implementing)   .65 
C1a (triggering events and situations)   .54 
Cronbach’s alpha .75 .85 .76 





The KERI-D subscales and clinical outcome data 
Based on results of factor analysis, we integrated item C2c into subscale B, and 
associated subscales A to C as well as the global Transfer item with clinical outcome data (see 
table 9). Significant associations between the single KERI-D items were: Higher scores in 
triggering events/situations were positively associated with higher scores in self-care and 
early warning signs, and self-care was positively associated with the global item Transfer. 
Relating KERI-D to the therapeutic alliance in the last session, a better alliance was 
associated with higher scores in early warning signs and triggering events/situations. As 
expected, higher levels of depressive symptoms at posttreatment and during 12-month-follow-
up were associated with occurrence of a major depressive episode (MDE) at both times. No 
associations between KERI-D subscales and depressive symptoms at posttreatment or during 
follow-up were found. 
Content validity 
Thirteen of 19 items had the highest possible CVI rating of 1.00 (i.e., all experts rated 
an item as relevant); the other six items had a CVI of .80 (i.e., four out of five experts rated an 
item as relevant). Five of these six items received a rating of 2 (‘major revision needed to be 
relevant’) on the 4-point ordinal scale. One item (D1c; emotions, cognitions on terminating 
therapy) was rated by one expert as not relevant at all. However, the other five experts rated 






Table 9 Bivariate associations between scales of the KERI-D and clinical outcome data (n = 25-36) 
 1 2 3 4 5 6 7 8 9 10 
1. Subscale A (self-care) 1 .20 .36* .35* .12 .09 .04 .07 .19 .06 
2. Subscale B (early warning signs)  1 .41* .33 .06 .10 .08 .25 .23 .45** 
3. Subscale C (triggering events/situations)   1 .27 -.15 .03 -.27 .00 .28 .39* 
4. Transfer (global item)    1 -.23 -.22 -.26 .08 .33 .28 
5. BDI-II (post)     1 .71** .66** .56** -.23 -.22 
6. BDI-II (FU)      1 .46* .67** -.37 -.21 
7. Major depressive episode (post)       1 .56** -.33 -.33 
8. Major depressive episode (FU)        1 -.44* -.25 
9. Therapeutic alliance (session 21)         1 .88** 
10. Therapeutic alliance (session 22)          1 







Aim of this study was to identify a comprehensive collection of explicit relapse-
preventive elements during psychological treatment of depression and, on this basis, to 
develop an observer-based rating instrument called the KERI-D (Kodierbogen zur Erfassung 
Rückfallprophylaktischer Interventionen bei Depression/Coding System to Assess 
Interventions of Relapse Prevention in Depression). 17 of 20 items showed moderate to good 
inter-rater reliability, as well as moderate to very good stabilities on retest after six months. 
Whereas most of the assessed items occurred during the final two sessions of acute therapy, 
the maximum intensity of the coded behaviors shown by therapists was not very high, 
indicated by an average of 2.56 of 4 points for maximum scores. Factor analysis revealed 
three distinct factors (self-care, early warning signs, and triggering events/situations) that 
corresponded largely with theoretical assumptions noted in relevant treatment manuals for 
relapse prevention. We did not find any associations of KERI-D subscales with depressive 
symptoms or the diagnosis of a depressive episode during a 12-month-follow-up. However, 
better therapeutic alliance during the last session was associated with higher scores in two 
KERI-D subscales (early warning signs, triggering events/situations). Finally, experts rated 
the content validity of the majority of items and categories as clinically and scientifically 
relevant for relapse prevention.  
Category D items and the transfer item were not included in the factor analysis, but 
served to explore further elements of relapse prevention. Category D items specifically target 
the discussion of the termination of therapy, assessing both aspects related to the therapy itself 
(e.g., accomplishments in therapy) and aspects of the post-treatment phase and patient’s future 
(e.g., life goals). Three of these six items occurred more often in the very last session than the 





therapists considered these topics highly relevant at the end of therapy. Overall and compared 
to the content items, the transfer item received rather high ratings, demonstrating that 
therapists did indeed emphasize the importance of implementing according strategies and of 
transferring therapy gains to life after ending therapy.  
The KERI-D was developed on the basis of theoretical knowledge, clinical 
conceptions as well as videotaped therapy sessions during cognitive behavioral treatment 
[211]. Reviewing and stabilizing modified cognitions during treatment can be considered core 
prognostic factors reducing risk of relapse also after terminating treatment [38], and can be 
assessed by validated and reliable adherence [e.g., CSPRS; 80] and competence rating scales 
[e.g., CTS; 81]. In addition to existing measures, the KERI-D has an explicit focus on relapse 
prevention interventions that aim to prepare the implementation of strategies after terminating 
treatment. As we consider leading the therapy session towards transferring therapy contents 
and gains into daily routines mainly as tasks and achievements of the therapist, the KERI-D 
primarily evaluates therapist behavior, comparable to observer-based instruments assessing 
treatment integrity [222]. However, it is important to note that so far, the rating of the KERI-
D items neither represents a distinct adherence or competence measure [77] for the following 
reasons:  
1) The treatment manual used in the study providing the videotaped psychotherapy 
sessions to be analyzed [211] did not include recommendations for relapse prevention that 
were as detailed as we later specified them in the KERI-D. Thus, therapists could not be 
adherent to the study-specific treatment manual regarding several relapse prevention elements 
as defined by the KERI-D. However, the current KERI-D intends to address a therapist’s 
adherence regarding the implementation of specific relapse-preventive efforts beyond a 
specific manual given that several forms of psychotherapy recommend the application of such 





2) Therapist’s competence is defined by the way techniques are implemented in a 
skillful manner [77]. For example, the Cognitive Therapy Scale [CTS; 81] contains two 
subscales ‘general competencies’ and ‘specific competencies’, whereby the latter one includes 
such aspects as the choice of adequate strategies and adequate implementation of techniques. 
These aspects are close to the KERI-D ratings given that higher scores on the KERI-D items 
imply better implementation of the content the item addresses. However, in the KERI-D the 
quality of implementation towards sustainability is rated with regard to specific contents (e.g., 
difficulties in implementing strategies for dealing with early warning signs) and also with 
regard to time after terminating therapy. This procedure differs from competence rating scales 
such as the CTS, which focus on the implementation of general techniques during the session 
(as clarity of communication, resource activation) without focusing on the time after therapy. 
However, the KERI-D currently includes one global item (‘Overall impression of the whole 
session: Transfer’), which could be considered comparable to the global item of the CTS 
(‘overall rating of competence’).  
Strengths 
We developed an observer-based rating instrument using qualitative and quantitative 
techniques with additional support from scientific and clinical experts. As relapse prevention 
is recommended in several forms of psychotherapy [176, e.g., 203] and because the contents 
of its items is not CBT-specific, the KERI-D may also be used for analyzing therapy sessions 
from other therapies than CBT. Moreover, the KERI-D can be applied for ratings of end-
phase sessions of acute treatment preparing patients for life after terminating therapy, but can 
also be used for ratings of sessions within continuation and maintenance treatments, which 
explicitly target the long-term prevention of relapse or recurrence [6]. During the 
development of the KERI-D, up to six raters rated videotaped psychotherapy sessions. Having 





therapist self-reports of the accuracy of delivering the treatment [82] and can be considered a 
strength of the proposed rating instrument. Furthermore, as 22 therapists contributed data, our 
analysis covers a wide range of relapse-preventive behaviors. As the psychotherapy sessions 
used for our ratings originate from a study not explicitly focusing on relapse prevention, 
therapists could not know that they would be evaluated for relapse-preventive efforts 
increasing external validity of the instrument and clinical representativity [223].  
Limitations 
Although the KERI-D showed satisfactory reliability and content validity in its first 
application, the analyses were based on a small and particular sample of selected 
psychotherapy sessions. Together with the chosen statistical methods (e.g., explorative factor 
analysis), only limited conclusions can be drawn. A next step would be to analyze further 
psychometric properties of the KERI-D referring to a larger sample size, including 
confirmatory factor analysis and further validation with clinical outcome measures and other 
(rating) instruments [224]. Generalizability of the reported results may also be limited because 
the psychotherapies were videotaped as part of an experimental trial with a maximum session 
number of 22. The resulting characteristics of the sampled psychotherapies could have biased 
the results with respect to occurrence and intensity of observed behaviors in comparison to 
therapies in other settings (e.g., time unlimited therapies or therapies focusing specifically on 
relapse prevention). Furthermore, the three raters of the final rating were also involved in the 
development of the KERI-D, and were thus familiar with the manual before the official rater 
training. Consequently, more extensive rater training might be required to validate the 
instrument by other researchers, considering that the amount of time invested in rater training 







Implications for research and practice 
The inclusion of relapse-prevention elements in the last sessions of a psychotherapy is 
meant to help the patient prepare for the transition from therapy to life post therapy in ways 
that may reduce the likelihood of relapses. Yet, we found no correlative associations between 
the current KERI-D subscales and clinical follow-up data (i.e., depressive symptoms or major 
depressive episode during a 12-month follow-up phase). Investigating longitudinal 
associations of relapse-prevention elements as assessed by the KERI-D with clinical outcomes 
in larger samples would promise to give more detailed information about the relevance of 
particular elements, and may suggest which elements may be integrated into future treatment 
recommendations. Besides assessing predictive validity of the scale [226], we recommend 
further studies to address the following issues: First, applying the KERI-D also in 
continuation and maintenance treatments, as they specifically aim at preventing relapse in the 
long-run (DGPPN 2015). Second, assessing construct validity [226] by associating the KERI-
D with instruments for the assessment of relapse-preventive processes [e.g., CBMT-AS; 206]. 
Third, investigating the KERI-D with clinical experts as observers [77].  
Conclusion 
To our knowledge, this is the first instrument that measures specific relapse-prevention 
elements in psychotherapy by observer ratings. Considering the high relapse rates of formerly 
depressed patients after a successful acute treatment, an effective relapse prevention is 
important to maintain gains of therapy. The development of the KERI-D is a first step in 
defining specific relapse-prevention elements during psychotherapy against depression by 
providing an instrument that assesses the occurrence and intensity of these elements above 
and beyond cognitive elements. By this, the KERI-D could make a significant contribution to 





5 General discussion 
This thesis addresses relapse-preventive efforts of treatments in depressive disorders 
to sustain remission and recovery in the long-term. As acute treatments are widely 
investigated already, this thesis set its focus on long-term treatments in terms of continuation 
and maintenance interventions in individuals being at high risk for relapse and recurrence. It 
is of further interest whether and to which degree therapists apply relapse-preventive efforts 
during psychotherapy, which might enhance transfer of therapy gains throughout and beyond 
depression treatment.  
The next chapter will shortly summarize and discuss the main results of each study, 
alongside with clinical and methodological issues regarding conductance of the study and 
evaluation and scope of the found results. The subsequent chapters will discuss overall 
findings gained from this thesis as well as recommendations for future research. 
 
5.1 Summary and discussion of study results 
5.1.1 There is limited evidence on continued and maintained pharmacological and 
psychological treatments for individuals with persistent depression (study 1) 
Despite the recommendation of continuation and maintenance treatments for 
individuals being at high risk of relapse and recurrence of their depression we were able to 
include only ten studies addressing these treatment phases in persistently depressed patients 
into the systematic review and meta-analysis. The only result we consistently found was that 
antidepressant medication (ADM) is superior to placebo regarding the reduction of 
relapse/recurrence, comparable to results regarding the acute treatment phase in PDD [56, 57]. 
However, none of these studies provided follow-up data, leaving questions open on long-term 





studies reported that concomitant treatment was allowed, and that 40% to 60% of their 
participants received ongoing psychotherapy (in both the ADM and the placebo group). Even 
though parallel treatment is not necessarily considered biasing the results, the observed 
individual change is most likely not solely based on ADM (i.e., the study treatment) but also 
on psychotherapy (i.e., non-study treatment) in the respective two studies. This may highlight 
the relevance of combined psychological and pharmacological long-term treatment in 
persistently depressed individuals. Only three studies provided data on psychotherapeutic 
treatments, and these studies differed markedly in frequency and form of provided 
psychotherapy, and also in analyzed outcomes. However, we assume that individuals with 
PDD might benefit from continued and/or maintained psychotherapy, but due to the limited 
amount of analyzed studies this assumption cannot be confirmed meta-analytically.  
Several methodological issues arose during conducting this meta-analysis, which 
might be considered for prospective reviews and meta-analyses focusing on relapse-
preventive efforts and long-term treatments. First of all, some studies addressed the problem 
of missing data with the LOCF (last observation carrying forward) method, which assumes 
stability of data over time [164]. With respect to high relapse and recurrence rates in 
depressive disorders [1] we consider this method inadequate and potentially overestimating 
the proposed long-term effectiveness of treatments. The CONSORT guidelines recommend 
using more than one imputation analysis set for studies in which non-compliance (e.g., loss to 
follow-up) is an issue [227]. This means that different approaches for imputing missing data 
in long-term trials should be applied and presented in publications in order to assess the 
influence on effectiveness outcomes of each imputation method [228]. 
Second, for the majority of addressed comparisons we found marked heterogeneity 
between trials, which raises the question if meta-analysis is the adequate method for 
summarizing data originating from studies which differ greatly in kind and quality of applied 





can hardly correct for low quality of primary studies, resulting in low quality of overall effects 
computed by meta-analyses. By applying sensitivity analyses we accounted for differences in 
trials excluding those with high risk of bias in one or several domains. However, due to the 
generally limited number of included studies this method was somewhat obsolete for our 
analyses, as it sometimes resulted in only one remaining study of high quality. Improving the 
significance of a meta-analyses implies improvement in conducting primary studies [230], 
which can be supported by guidelines as the CONSORT statement [231], which define a clear 
reporting procedure when conducting randomized-controlled trials (RCTs).  
Third, we defined rather strict criteria for including relevant studies. More specifically, 
we required the studies to apply clear response and remission criteria for the patients who are 
considered eligible for entering continuation and maintenance treatment, and we included 
only studies treating PDD patients or reporting data on that population. Consequently, we 
excluded studies [139, 197, 200, 232, 233] that address long-term interventions for 
individuals who had been suffering from depression for many years because the studies failed 
to clearly report on required data as explained above. Thus, we recommend a consistent use 
and implementation of definitions (e.g., response, remission, continuation, maintenance) in 
further studies to better specify treatment options and to better estimate treatment effects.  
Fourth, this leads to the discussion if there is actually a need for this clear 
differentiation between acute, continuation and maintenance treatments, and also between 
PDD and recurrent depression with full inter-episode recovery. Do therapists treat recurrently 
depressed individuals, who have been affected for ten years differently from those individuals 
who have been suffering from PDD for ten years? And is it more reasonable for all 
individuals being at high risk to receive long-term care, or for reception of a specific care to 
depend on response and remission status? Even though expressed quite offhand, this shall 
illustrate that strict definitions in research might not always address the needs of complex 





recommend to include studies addressing long-term interventions for depressed individuals 
being at high risk for relapse and recurrence, followed by several subgroup analyses targeting 
the above mentioned issues (e.g., diagnostic subgroup, treatment phase, response/remission 
status).  
Fifth, meta-analyses usually target specific stand-alone interventions because 
likelihood of homogenous trials increases, and consequently, it is possible to draw clear 
conclusions on direction and causes of effects. With respect to individuals suffering from 
chronic mental illness, it might be questioned if a complex treatment concept including 
several providers and treatment options might be preferred over single approaches [234]. 
Unfortunately, such integrative treatment concepts for chronic conditions [235, 236] are rarely 
investigated as testing the effectiveness of complex interventions including various treatment 
components and providers is associated with methodological challenges [237]. For instance, 
domains as ‘random sequence generation’, ‘allocation concealment’, ‘blinding of participants 
and personnel’, ‘incomplete outcome data’, implementation of which is required for a well-
done RCT [153], can hardly be managed within complex interventions. Additionally, clinical 
heterogeneity regarding population, intervention and implementation hamper a meaningful 
and valid synthesis of data [238]. Thus, studies addressing such concepts might be more often 
excluded by reviews/meta-analyses, although mental health care provided by a team of 
practitioners including several treatment concepts might increase likelihood that individuals 
being at high risk are constantly monitored and treated in the long-term. 
Regarding the aim of this thesis we assume that persistently depressed patients benefit 
from continued and maintained ADM, and that they might benefit from psychotherapy as 
well. However, the effectiveness of the examined treatments can be ascertained for as long as 
these treatments are provided. Conclusions on long-term effectiveness after termination of 
continuation and maintenance treatments cannot be drawn, and studies are advised to collect 





conducting studies addressing long-term care for PDD patients, especially targeting 
psychological interventions and their combination with ADM. Several methodological and 
clinical issues might be considered for further studies to improve number and quality of 
investigations, and to consequently widen the scope of study results. With respect to the 
limited number of long-term psychotherapy studies investigating high-risk individuals, we 
developed a low-intensity telephone-based continuation therapy for recurrently and 
persistently depressed individuals who had responded to acute psychotherapy. Within a pilot 
study we assessed feasibility and acceptance of the new components of this intervention to 
evaluate which components need improvement, and to later run a larger randomized-
controlled trial addressing the effectiveness of this intervention. 
 
5.1.2 A telephone-based continuation psychotherapy for depressed individuals at high 
risk for relapse is feasible under specific conditions (study 2) 
Use of the medium telephone was predominantly associated with well-known 
advantages as low-threshold access with personal contact, omission of journey to therapy 
(which is especially relevant for individuals living in rural areas or for those being physically 
impaired), and a more flexible integration of therapy into everyday life including job and 
family responsibilities [113, 117]. Moreover, both patients and therapists perceived the 
development and maintenance of a sound therapeutic relationship comparable to face-to-face 
settings, as has also been described in other studies [115, 185]. The most relevant issue 
discussed during the interviews was the implementation of a continuation therapy concept, 
which was considered to be dependent on several preconditions including success of previous 
acute therapy, time frame of sessions and a clear treatment plan, especially if patient and 
therapist are unfamiliar at the beginning of continuation therapy. The decision of whether or 





symptoms as well as availability of effective coping strategies. Although a 30 minutes phone 
session each month was perceived feasible if both participant and therapist applied a high 
level of prioritizing of concerns, a 50 minutes setting was selected as first choice. Longer 
intervals between sessions (e.g., one month) were perceived as challenging (compared to 
acute phase settings), but also valued by participants, as this encouraged them to cope with 
everyday life on their own again. In summary, we assume that the above mentioned 
preconditions should be ensured in the first instance, and that the medium telephone might 
facilitate access to this intervention. 
However, whether change in health status of our participants can be attributed to 
elements of the intervention or other factors remains unclear due to lack of a control group 
and a small sample size. A randomized-controlled trial (RCT) organized by the same 
department which conducted this pilot study investigates the effectiveness of the telephone-
based continuation therapy compared to treatment as usual (‘Natel’; NCT03219879), 
optimized and adapted based on results of this pilot study. For the ongoing RCT the following 
setting was implemented: eight phone sessions lasting approximately 50 minutes within six 
months, the acute phase therapist ideally provides continuation therapy as well, each session 
and the entire treatment are more structured in terms of using working sheets, stronger focus 
on patient’s skills and a constant reference to these skills throughout therapy.  
Besides recommendations regarding this specific intervention, the following sections 
will discuss overall issues, which might be considered when providing relapse-preventive 
long-term treatments for high-risk individuals. RCTs enable researchers to estimate the effect 
of one intervention compared to other interventions or no intervention at all. However, most 
studies do not account for a possible misfit between needs and expectations of a patient and 
the provided intervention [117]. For instance, we had one participant in the pilot study who 
reported to not have benefitted from our intervention at all. During the interview, it emerged 





preferably in a face-to-face setting. Moreover, this participant reported to have had actually no 
time for a therapy due to family and job responsibilities, which resulted in phone sessions 
occasionally conducted while on the train. It is understandable that this participant did not 
benefit from this intervention because her expectations regarding the intervention could not be 
met by the intervention we intended to provide. As a consequence, we recommend to clearly 
discuss opportunities and boundaries of a continuation therapy, as well as differences and 
common features between face-to-face and telephone settings. Additionally, motivation of a 
patient to continue treatment even though remission has been achieved should be enquired.  
Motivational aspects influencing entering therapy and will to change are already focus 
of scientific inquiry and known to predict therapy outcome [239]. Motivational and other 
processes (within the patient, but also in the environment), which might influence whether 
chronic patients continue psychotherapy or not, are unknown, yet. This might be of clinical 
relevance as chronic conditions are likely to need long-term or even lifetime treatment, and 
sometimes without expectation of entire cure. In clinical routine care, motivational 
interviewing and psycho-educational interventions are implemented trying to improve 
adherence to treatment, especially to taking medication [240]. Most research focuses on 
adherence to medication because pharmacological treatments of severe psychiatric disorders 
are, depending on the specific diagnosis, commonly first choice treatment. Unfortunately, the 
WHO reported that even in developed countries only 50% of individuals suffering from 
chronic diseases (including depression) adhere to treatment recommendations regarding long-
term therapy [241]. Even though the mechanisms of why depressed patients do not follow 
treatment advice are still unclear and might be related to the illness itself [242], it is assumed 
that patients make their decision by balancing perceived risks against benefits based on 
available information [243]. Although patients tend to associate medication with harms [32], 
there is still limited research if psychological interventions might lead to any harms [244]. 





beliefs regarding such negative outcomes could be focus of future research, in combination 
with testing the impact on continuing or quitting long-term therapy.   
Our therapists mentioned that participating patients had been probably more motivated 
compared to patients in common routine care settings. Also, the two therapists themselves had 
an affiliation to the conducting department, and might have been more motivated compared to 
routine care therapists. Both aspects reflect that the population investigated in controlled study 
settings and routine health care settings differ [245]. Participating in a RCT is usually 
associated with receiving therapy free of any charges, and therapists receive time, money and 
frequent supervision from the study team. By contrast, routine care therapists adhere to the 
system they work in, e.g., treatment options and procedures are clearly defined by the hospital 
or praxis. Providing or organizing care, which exceeds the care provided by the system 
requires individual motivation and belief in other treatment concepts. Our pilot study was a 
mixture of settings in some way. We intended for routine care providers to refer eligible 
patients to our study, so that they could receive continuation therapy, which was provided by 
our study therapists who had a scientific affiliation. Unfortunately, we had difficulties 
recruiting eligible patients as only one hospital referred patients to our intervention. Although 
recruiting is a common problem in community-based mental health research [246], we can 
only speculate about why the majority of providers who had previously agreed to participate, 
did not participate in the end. 
Mason and colleagues [246] identified several barriers including concern about 
protecting the patient and impact on the relationship between therapist and patient. We 
received feedback from providers that they do not believe that their patients would continue 
psychotherapy over telephone with an unfamiliar therapist. Thus, it is likely that such 
providers did not offer our intervention to their patients, as their own clinical attitude did not 
correspond with the format of our intervention. The ongoing RCT did incorporate this 





ensuring continuous therapists. However, there might be other barriers regarding recruitment, 
which could be addressed by further research. With respect to our pilot study, knowing about 
specific barriers would help to optimize elements associated with treatment delivery, i.e., 
which elements should be included that patients actually have access to and participate in a 
study or routine care intervention in a specific health care system: What kind of patient needs 
this intervention? Is this system (insurances, hospitals, therapists) able and willing to provide 
this intervention? Who covers the costs for this intervention?  
Regarding the aim of this thesis we assume that a telephone-based continuation 
therapy for depressed individuals at high risk for relapse might contribute to sustained 
remission in the long-term. However, this assumption is based on results of a small pilot study 
so far, and needs further investigation. Moreover, encouraging providers and patients to 
participate in this intervention was challenging, and further investigation of the reasons for 
these recruiting difficulties is needed. Exploring factors as motivation and beliefs regarding 
long-term treatment would be a valuable research issue to test a potential impact on a patient’s 
decision on continuing or quitting therapy. Besides motivation and beliefs there are further 
treatment elements, which are discussed to have an impact on treatment outcomes, as level of 
depressive symptoms and dropout rates. Whilst the majority of studies investigated cognitive 
processes as possible mechanisms in relapse prevention so far, we were interested in whether 
or not further relapse-preventive efforts are observable during psychotherapy. We developed 
an observer-based rating instrument, which targets the transition of therapy gains into the 
patient’s everyday life throughout and beyond termination of treatment, and analyzed this new 








5.1.3 Therapists show relapse-preventive efforts during psychotherapy which exceed 
core concepts of cognitive-behavioral therapies (study 3) 
We could show that therapists apply relapse-preventive efforts during the end of acute 
psychotherapy, which exceed elements covered by existing adherence and competence scales. 
Items of the newly developed “KERI-D” (Kodierbogen zur Erfassung 
Rückfallprophylaktischer Interventionen bei Depression/Coding System to Assess 
Interventions of Relapse Prevention in Depression) show moderate to good inter-rater and 
retest reliabilities, and three subscales emerged during analyses. First evidence on content 
validity could also be demonstrated. However, the KERI-D showed no correlative 
associations with clinical outcome data (depressive symptoms; occurrence of a depressive 
episode) during a 12-month-follow-up. Thus, the proposed instrument contributes to defining 
relapse-preventive efforts during psychotherapy, but needs further conceptual development 
and, moreover, statistical investigation by applying longitudinal models to explore whether 
such relapse-preventive elements actually predict relapse and recurrence in the long-term. 
These findings have to be interpreted taking several methodological and clinical issues into 
account:  
First, the observed therapists were not trained specifically in relapse-preventive efforts 
but rather focused on being adherent to the treatment manual. This might be a strength of this 
study as it allowed us to observe relapse-preventive efforts which a therapist might also show 
in routine care settings. As a consequence we might get a deeper understanding of what 
relapse prevention actually is, or, in other words, what elements the concept of relapse 
prevention is composed of. Although ‘relapse prevention’ is a common term used in clinical 
practice, there is no measure or common guideline available, which clearly defines elements 





Second, trials investigating relapse prevention consider the core concepts of the 
delivered treatment to be the mechanism that lead to patient change, e.g., change in 
dysfunctional beliefs during CBT might lead to a decrease of depressive symptoms [101]. 
However, such processes are measured within the treatment period and it remains unclear 
how enduring such change in core concepts is, and how the patient manages to sustain such 
therapy achievements also beyond the termination of therapy. The KERI-D tries to assess how 
therapists encourage the patient to sustain therapy gains throughout and beyond therapy. 
However, we only assessed the therapist’s perspective. As clinical outcome data such as rates 
of relapse and recurrence are usually applied as indicators for predictive validity, it would be 
valuable to assess what kind of strategies and elements of therapy patients can specify by the 
end of therapy. By measuring only the therapist’s behavior we do not know what relapse-
preventive components the patient actually mastered or internalized. The patient´s level of 
achievement or internalization might be another factor for predicting relapse (compared to 
therapist’s initiations of relapse-preventive efforts), for instance with the help of a self-report 
questionnaire measuring the patient’s extent of available relapse-preventive strategies and 
their usefulness, importance and practicability in everyday life. Moreover, the association 
between therapist’s initiation of relapse-preventive efforts and patient’s level of relapse-
preventive achievements would be of high interest for exploring the therapist’s influence on 
relapse prevention, which in turn would have influence on a possible integration of relapse-
preventive elements into treatment manuals.  
Third, the extent to which the KERI-D overlaps with existing adherence and 
competence scales is of interest for further development of the KERI-D. For instance, the 
Cognitive-Behavioral Maintenance Therapy—Adherence Scale (CBMT-AS) [206] is applied 
during a psychotherapeutic maintenance therapy intending to prevent relapse and recurrence 
in the long-term. Whilst the CBMT-AS mostly contains items regarding core mechanisms of 





elements are already covered by existing instruments as the CBMT-AS). Thus, a combination 
of both cognitive elements (‘reviewing dysfunctional beliefs’) and more general relapse-
preventive efforts (‘strategies to prepare for triggering events and situations’) might enrich a 
tool to broadly cover the concept of relapse prevention, especially if applied in cognitive-
behavioral interventions. On the other hand, the KERI-D might differ from existing adherence 
and competence scales as it does not rely on or refer to a specific orientation in 
psychotherapy. The KERI-D in its current form may be applied in all forms of psychotherapy 
as it tries to assess elements, which focus on the transfer from therapy achievements to time 
after therapy, irrespective of contents of these achievements. And we consider this focus to be 
highly relevant in depressive disorders, as therapy should not only intend to decrease 
depressive symptoms in the short-term, but moreover to enable the patient to frequently and 
independently use and adapt achieved strategies to maintain well-being in the long-term. In 
other words, one part of relapse prevention differs between psychotherapy orientations, 
namely the proposed mechanisms that lead to symptom change (which are usually defined by 
the core theoretical concept of this orientation). The other part, which is intended to be 
covered by the KERI-D, might be considered a more universal approach to relapse 
prevention, as it focuses on the process and transfer of therapy gains, and should therefore be 
relevant to all forms of psychotherapy.  
Fourth, we introduced the KERI-D to be applicable in all three treatment phases. 
However, initial development and investigation of psychometric properties as presented in 
study 3 were conducted with videotaped psychotherapy sessions retrieved from last sessions 
of acute phase therapy. In a next step validation with data from continuation and maintenance 
therapies would be of interest for possible extension of the current KERI-D including aspects, 
which were not apparent within previous developmental steps.  
Finally, the KERI-D aims to assess relapse-preventive interventions as declared by its 





occurrence of a depressive episode) during a 12-month-follow-up, yet. There are several 
methodological issues conceivable for this result. We analyzed a rather small sample of 
psychotherapy sessions (N = 36) of the availa ble data pool (N = 144), and we did not 
randomize these sessions but selected video material with regard to structural circumstances 
(e.g., availability of sessions 21 and 22 in good quality). Additionally, clinical outcome data at 
12-month-follow-up was not available from all 36 participants. The combination of these 
circumstances might diminish likelihood of meaningful results.  
On the other hand, one could discuss whether the KERI-D should be actually able to 
predict change in depressive symptoms or occurrence of a depressive episode during follow-
up. We do not assume that elements measured with the KERI-D are the only responsible 
therapy elements for improvement or deterioration of mental health status. Elements such as 
working on dysfunctional attitudes and negative (automatic) thoughts, mindfulness skills, 
attributional style, rumination, and therapeutic alliance were found to have an influence on 
patient’s symptom change [53]. Moreover, as outlined above, the KERI-D assesses therapist’s 
initiation of relapse-preventive efforts. A measure, which assesses internalized relapse-
preventive strategies, which are actually implemented by the patient, might be a better 
indicator for predicting relapse during follow-up. Despite several research attempts, previous 
evidence regarding proposed mechanisms of change is evaluated as weak due to 
methodological issues [53]. Moreover, also studies addressing the association between 
reliable and valid adherence and competence scales and clinical outcome data cannot present 
conclusive results [79]. Thus, in future analyses the individual influence of each of these 
elements as well as the combination of all of these proposed mechanisms could be 
investigated with regard to change in patient’s health status during and beyond treatment.  
Regarding the aim of this thesis we conclude that therapists do encourage patients to 
transfer therapy gains to life after termination of treatment, and that therapists differ in the 





actually relapse-preventive could not be established in this study and needs further 
investigation by applying longitudinal models in larger samples. Moreover, assessing the 
patient’s perspective on relapse-preventive achievements might give deeper insight into the 
therapeutic concept of relapse prevention. This study made an attempt to define the concept 
and elements of relapse prevention that target other components beyond core mechanisms of 
therapy orientations. We consider this approach meaningful as research of the last decades 
showed that psychotherapy of any form is effective, but relapse rates tend to be high, in all 
forms of psychotherapy. Thus, therapy elements, irrespective of the specific form of 
psychotherapy, might help to define how therapists can enhance the implementation of 
therapy gains into the patient’s everyday life, and by this, reduce risk for relapse and 
recurrence in the long-term.  
 
5.2 Overall discussion 
Previous research developed and investigated several psychological and 
pharmacological interventions for individuals suffering from depressive disorders. Despite 
these efforts, relapse and recurrence rates tend to be high, especially in recurrently and 
persistently depressed individuals. This thesis addresses this situation by conducting three 
studies that focus on long-term effectiveness of interventions in different treatment phases for 
high-risk individuals. The systematic review/meta-analysis (study 1) showed that continued 
and maintained antidepressant medication is effective in persistently depressed individuals for 
as long as medication is provided, that psychological interventions might be effective, and 
that further studies addressing long-term psychotherapy are needed. Study 2 showed that 
continued psychotherapy delivered by telephone is feasible and accepted in high-risk 
individuals if several preconditions, such as level of depressive symptoms, availability of 





elements of psychotherapy that might be relapse-preventive throughout and beyond treatment 
were analyzed in study 3, showing that therapists try to enhance the transfer of therapy gains 
into the patients’ everyday life.   
Regarding relapse-preventive efforts to sustain long-term remission, this thesis 
concludes that research provides several attempts to avoid relapse and recurrence, but that 
conclusive evidence on the effectiveness of these interventions is limited. We outlined that 
acute phase treatments are effective, but rather in the short-term. Follow-up data exceeding 
one year post-treatment are rarely reported, which is considered inadequate as studies show 
that relapse and recurrence rates rise up to 54% within two years following acute treatment 
[12]. Everyone (patient, provider, system) wishes a short-term therapy to be effective and that 
the patient quickly returns to a functional level. But facing high relapse and recurrence rates 
even after successful acute therapy, long-term or even lifetime treatments might be a 
pessimistic approach, but maybe also the more realistic one for severe depression. The 
“revolving-door-patient” is an observed phenomenon describing that patients with chronic 
severe mental illness are discharged from the hospital after acute therapy to be admitted to 
hospital again sooner or later, multiple times [247]. Whether those patients do not receive 
adequate inpatient treatment, or if they receive no adequate care following inpatient treatment, 
is unclear. This thesis sets a strong focus on the latter explanation, especially when referring 
to persistently or recurrently depressed patients. Whilst providing several short-term 
treatments with intervals of (more or less) well-being in-between is one way of care, the 
question is whether this treatment concept corresponds to the needs of a chronically impaired 
patient. This thesis assumes that long-term care in terms of continuation and maintenance 
treatments might be the more appropriate way of approaching the recurrent and persistent 
character of depressive disorders. Such treatments involve continuous monitoring of the 





This concept of care might be able to recognize a patient’s deterioration before a full 
depressive episode occurs, potentially minimizing rates of re-hospitalizations.  
This thesis shows that well-investigated continuation and maintenance treatment 
studies for persistent depressed individuals are rare, and that psychological interventions are 
overshadowed by research on antidepressants. It can be assumed that this situation in research 
reflects the current routine care situation, in regard to preference of medication but also in 
regard to a preference for providing short-term treatments. As the body of previous research 
found high relapse and recurrence rates even after successful acute therapy, researchers and 
health care systems might reconsider their current treatment concepts, and considering a long-
term treatment perspective for future research. Piloting a telephone-based continuation 
therapy for high-risk individuals aimed at contributing to this long-term perspective, offering 
patients who had previously terminated acute therapy a further six months of support. Patients 
highlighted the value of such a continuation therapy to get further support following acute 
therapy, underlining the patients’ needs and wishes for low-intensity continued care. The 
effectiveness of this intervention is under current scientific investigation within a RCT 
conducted in Switzerland and Germany, contributing to the currently limited evidence 
regarding long-term treatments. With respect to addressing depressed individuals who are at 
high risk for relapse and recurrence, one could discuss whether six months of continued care 
including eight therapeutic contacts is sufficient. The dose-effect relationship in 
psychotherapy mostly refers to the number of sessions needed to observe clinically relevant 
change in patients, combined with the frequency in which the sessions are provided. Whilst 
there is still open discussion if number of sessions is a relevant factor, evidence suggests that 
a higher frequency is associated with steeper recovery curves (e.g., two sessions per week is 
more effective than one session per week) [4, 248]. Previous evidence is based on acute phase 





for patients, providers and policy makers. This thesis addresses this topic, but cannot present 
any conclusive long-term results beyond treatment termination.  
This thesis also explored in more detail which elements of psychotherapy might 
enhance therapy achievements in terms of relapse prevention. We were able to observe a 
variety of therapist-initiated efforts, which we consider relevant for long-term relapse 
prevention from a theoretical and clinical perspective. However, we could not prove any 
statistical associations between observed relapse-preventive efforts and course of depressive 
symptoms during a one-year-follow-up, yet. Thus, this thesis contributes to the perspective 
that therapists should continuously make a link between therapy achievements in-session and 
their transfer into everyday life, potentially enhancing the durability of therapy gains.  
Results from the presented studies indicate that psychotherapeutic long-term relapse-
preventive interventions for high-risk patients are rarely investigated or reported, and might 
also be less often provided in clinical practice compared to acute treatments. Whilst 
pharmacological interventions are often prescribed as long-term therapy and much more 
frequently investigated in studies, especially patients with chronic conditions tend to quit 
medication [241]. It remains unclear why, compared to pharmacological studies, only few 
studies address psychological long-term interventions, even though they are preferred by 
patients [32]. Pharmacological studies might be funded more often due to connections to the 
pharmaceutical industry, and providing antidepressant medication is probably less time-
intensive for both therapist and patient. By contrast, conducting psychotherapy research itself 
might be more cost-intensive, and involving in psychotherapy requires a patient’s motivation 
and time, and moreover, his/her will to change behavior. Moreover, whilst medication is 
commonly covered by health insurances, psychotherapy is often limited in coverage, and 
sometimes even not reimbursed at all by insurances. This situation is alarming with respect to 
reported long-term cost-effectiveness of psychotherapy, especially in patients with severe 





Besides discussions about the system’s financial resources we should also focus on 
facilitating access to treatment. Even though clinical guidelines include detailed 
recommendations of state-of-the art treatments for individuals with severe mental health 
problems, only between 25% and 40% receive specific mental health care [250, 251]. One 
part of this thesis tried to address a potential improvement of access by delivering a 
psychotherapeutic intervention over telephone. This mode of delivery is associated with a 
low-threshold and flexible access [110] to treatment which shows comparable effects to face-
to-face acute treatments [113]. Both participants and therapists of our study perceived this 
medium as especially adequate for the continuation treatment phase, as reasons for the 
development and maintenance of their depression were already discussed in detail during the 
acute phase treatment. Continued monitoring within a less frequent setting was assumed to be 
feasible by telephone, including advantages as outlined above. Whether or not this 
intervention is effective and whether or not the medium telephone can improve access to 
long-term treatment cannot be answered by this thesis, and needs further investigation. But, 
including remote technologies (e.g., internet, telephone, mobile phone) into mental health care 
in times of their general availability might facilitate access to psychotherapy for individuals 
showing preference for such type of treatment delivery.   
Summarized, the long-term effectiveness of relapse-preventive efforts for the 
treatment of depressive disorders is inconclusive especially with regard to psychological 
interventions. Kind and ‘dose’ of intervention as well as mechanisms that lead to long-lasting 
effects remain unclear even though several research attempts exist. One recent work 
summarizes the achievements of four decades of psychotherapy research in adult depression 
[4], and concludes that future research should not develop any new psychotherapies for 
depression. Instead, research should aim to reduce burden of disease by focusing more on 
relapse prevention and optimizing treatments for chronic and treatment-resistant depression 





investigating the long-term effectiveness of treatments for individuals at high risk for relapse 
and recurrence. The following chapter will outline several aspects of current research practice, 
discussing potential adaptations and recommendations for future research.  
 
5.3  Outlook and concluding remarks 
This thesis outlined the need for relapse-preventive efforts for depressed individuals 
with a high risk of relapse and recurrence, and the limited availability of studies addressing 
this topic comprehensively. These available studies on long-term care and its effectiveness 
vary in applied methods and results, leaving open the question whether or not one method or 
intervention is ‘better’ than another, and consequently, in which way long-term studies should 
be ideally conducted. First of all, in research we are confronted with several terms and 
definitions specifying the population we can treat, observe and analyze. For instance, patients 
should only enter a continuation treatment phase in case of partial response or remission [8]. 
In this regard, three aspects are meaningful to discuss. 1) The range between responding to a 
treatment and remitting with treatment is large, questioning the precision of indication for a 
continuation treatment. 2) To assess response and remission requires pre-/post data of a 
patient, and the regular use of psychometric scales in clinical routine care is considered an 
exception [252]. 3) Usually, studies define a specific number of sessions a patient receives 
during a specific time frame (e.g., 16 sessions of CBT during 16 weeks of acute treatment), 
and only those patients responding or remitting during this period enter continuation treatment 
and only that data is reported. Which patients do improve within 16 weeks and which not, i.e., 
whose data is reported? 
Summarized, even though a clear definition of which patients should enter continued 
care is available, the consistent implementation of this definition is in question. Studies 





fewer relapses/recurrences, lower risk of a chronic course of their disease) compared to 
patients who ‘only’ responded to treatment [252]. Thus, research might take this into account 
by requiring remission by the end of acute treatment to ensure that patients are able to 
continue treatment in another setting. This also indicates that studies might consider not only 
to predefine a specific number of sessions, but by contrast, to treat until remission. Then, 
whether or not a patient needs 16 or 30 sessions of CBT to remit could be considered within 
further analyses. Such a procedure would allow to treat the variety of depressed subjects 
(especially those with severe forms of depression), and to take the individual course of the 
disease and needs of a specific patient into account. Obviously, the same applies for the health 
care system: funding treatment as long as it is needed might be a better approach than funding 
a defined maximum of sessions. This requires a consistent and feasible application of rating 
scales to measure remission status. Several reliable and validated clinician-rated and self-
report instruments exist (e.g., Hamilton-Rating-Scale, Beck Depression Inventory) [253], but 
their use in clinical routine care is often associated with limited time to administer those 
instruments properly [252]. Research might respond to this situation by investigating 
strategies and systems to better implement such instruments into clinical routine care.  
Response, remission, relapse, and recurrence are typical outcomes of interest in 
depression studies, and although studies and routine care differ in applying and measuring 
these outcomes, they are state-of-the-art in research. However, besides level of depression 
severity other outcomes should be acknowledged. We highlighted the relevance of coping 
skills and depression self-management, which could be further indicators for whether 
continuation and maintenance treatment is indicated or not, and for whether a patient is 
prepared to handle critical concerns on his own. Although self-report instruments assessing 
level of coping during and after treatment exist [182, 192, 193], they are rarely used (or 





By contrast, assessing quality of life is far more integrated into current studies as a 
secondary outcome, and underlines that patients benefit from psychotherapy not only in terms 
of a reduction of symptoms, but also in terms of additional outcomes such as quality of 
personal and work-related relationships, level of comfort and engagement in activities [254]. 
Especially for severe forms of depression, in which absence or low- levels of depression 
might not be achieved over lifetime, interventions which increase quality of life might be 
relevant and beneficial. With respect to quality of life and well-being, some researchers 
address so-called ‘well and unwell weeks’ during follow-up periods [255]. Such continuous 
measures account for fluctuation of symptoms over time, which do not have to lead to relapse 
or recurrence, but give insight into the health status of an individual. Such long-term measures 
can be facilitated by use of remote technologies, e.g., monitoring of symptoms with the help 
of mobile phones to enhance relapse prevention [256].  
To conclude, this thesis reported on current evidence regarding relapse-preventive 
efforts for depressive disorders, underlining the need for continuous long-term care for 
individuals being at high risk for relapse and recurrence, and the need for enhancing the 
transfer of therapy gains into the patient’s everyday life. Although several attempts had been 
made during the last decades, prevalence and burden of depression remain high, persistent and 
recurrent conditions receive little attention, long-term effectiveness of available treatments is 
questionable, and in addition to this, a greater part of affected people have no access to 
adequate mental health care. Relapse-preventive efforts can be realized in different forms and 
during several treatment phases, by enhancing transfer from therapy to time after therapy, and 
by providing continuation and maintenance treatments. Whether or not these attempts prove 
effective in reducing relapse and recurrence in the long-term should be focus of future 
research. Moreover, including remote technologies as telephone, mobile phones and the 
Internet can enhance access to treatment and might increase likelihood that individuals 





should be applied, several aspects have to be taken into account, such as level of impairment, 
attitude towards delivery options and further personal circumstances of a patient.  
Researchers as well as stakeholders within the health care system should reconsider 
their perspectives on available treatment concepts. Stand-alone short-term interventions might 
be straightforward to investigate and might be affordable at first glance, but might also lead to 
increasing numbers of “revolving-door-patients” and repeated treatments. Continuous long-
term care, which includes frequent monitoring and reviewing of relapse prevention tools over 
a specific (yet undefined) time span, might appear cost-intensive. On the other side, it may 
prevent relapse and recurrence by early detection of deterioration and adequate intervening, 
potentially minimizing burden of disease and enhancing (guided) self-management of 
depression. Those processes should be implemented with respect to the patient’s everyday life 
circumstances, enhancing transfer from therapy to life after therapy.  
The terms ‘long-term care’ or ‘chronic conditions’ might imply that depressed 
individuals at high risk are treatment resistant or need lifetime care, which is accurate in some 
cases. For the majority of affected individuals it implies that more and longer treatment might 
be needed, and that the health care system should encourage such individuals to involve in 
and remain in treatment and to integrate therapy achievements into their lives. Researchers are 
encouraged to take over this perspective by investigating interventions that prevent relapse 











A – Search syntax of electronic searches 
1. Description of the Cochrane Common Mental Disorders Specialized Register (CCMD-
CTR) 
The Cochrane Common Mental Disorders Group maintains a specialized register of 
randomized controlled trials the CCMD-CTR. This register contains over 39,000 reference 
records (reports of RCTs) for depression, anxiety and other common mental disorders. A 
percentage of the reference records have been tagged to 12,500 individual, PICO coded study 
records (with coding based on the EU-Psi coding manual). Reports of trials for inclusion in 
the register are collated from (weekly), generic searches of MEDLINE, EMBASE and 
PsycINFO, quarterly searches of the Cochrane Central Register of Controlled Trials 
(CENTRAL) and review specific searches of additional databases. Reports of trials are also 
sourced from international trial registries, drug companies, the hand-searching of key 
journals, conference proceedings and other (non-Cochrane) systematic reviews and meta-
analyses. Details of CCMD's core search strategies can be found on the Group's website. 
 
2. OVID PsycINFO will be searched using the following terms: 
[Condition] 
1. (chronic* depress*).ti,ab,id. 
2. (double depress*).ti,ab,id. 
3. DYSTHYMIC DISORDER/ 
4. MAJOR DEPRESSION/ and (“CHRONICITY (Disorders)”/ or CHRONIC ILLNESS/) 
5. (dysthymi*).ti,ab,id. 
6. RECURRENT DEPRESSION/ 
7. (depress* adj2 recurr*).ti,ab,id. 
8. persistent depressive disorder.ti,ab,id. 
9. or/1-8 
[Maintenance] 
10. MAINTENANCE THERAPY/ 
11. (maintenance or maintained).ti,ab,id. 
12. continuation.ti,ab,id. 
13. (stable or stabilise*1).ab. 
14. RELAPSE PREVENTION/ 






[Controlled Trials Filter] 
17. exp EXPERIMENTAL DESIGN/ 
18. TREATMENT EFFECTIVENESS EVALUATION/ 
19. MENTAL HEALTH PROGRAM EVALUATION/ 
20. (empirical study or longitudinal study or prospective study or quantitative study).md. 
21. “2000”.md. [treatment outcome/clinical study] 
22. RETROSPECTIVE STUDIES/ 
23. EVIDENCE BASED PRACTICE/ 
24. (study or trial or treatment* or intervention or therap* or psychotherap*).ti. 
25. (control* adj3 (group*1 or study or trial)).ti,ab,id. 




29. (RCT or random*).ti,ab,id. 
30. (crossover* or cross over*).ti,ab,id. 
31. (quasi experimental).ti,ab,id. 
32. (longitudinal or cohort).ti,ab,id. 
33. (case adj (control or report or series)).ti,ab,id. 
34. (cross-sectional).ti,ab,id. 
35. (experimental or quantitative or pilot).ti,ab,id. 
36. or/17-35 
37. (9 and 16 and 36) 
[Psychotherapies] 
38. exp PSYCHOTHERAPY/ 
39. exp PSYCHOTHERAPEUTIC TECHNIQUES/ 
40. exp COGNITIVE TECHNIQUES/ 
41. exp COUNSELING/ 
42. 3300.cc. [Classification Code: Health & Mental Health Treatment & Prevention] 
43. 3310.cc. [Classification Code: Psychotherapy & Psychotherapeutic Counseling] 
44. 3311.cc. [Classification Code: Cognitive Therapies] 
45. 3312.cc. [Classification Code: Behavior Therapy & Behavior Modification] 
46. 3313.cc. [Classification Code: Group & Family Therapy] 
47. 3314.cc. [Classification Code: Interpersonal & Client Centered & Humanistic Therapy] 
48. 3315.cc. [Classification Code: Psychoanalytic Therapy] 
49. (CBT or c-CBT or iCBT or coping skills or counsel?ing or mindfulness or psychoanal* or 
psychotherap* or rehabilitat*).ti,ab,id. 
50. ((psychologic* or psychodynamic or behavio?r or cognitive) adj3 (intervent* or therap* or 
treat* or manag*)).ti,ab,id. 
51. (Abreaction or Acting Out or Adlerian or Adolescent Psychotherap* or Age Regression or 
Analytical Psychotherap* or Anger Control or Anger Management or Art Therap* or 
Assertive* Training or Autogenic Training or Autosuggestion or Aversion Therap* or Balint 
Group or Behavio?r Contracting or Behavio?r Modification or Behavio?r Therap* or 
Bibliotherap* or Biofeedback or Body Psychotherap* or Brief Psychotherap* or Caregiver 
Support or Child Psychotherap* or Client Cent* Therapy or Cognitive Behavio?r Therap* or 
Cognitive Behavio?ral Stress Management or Cognitive Rehabilitation or Cognitive 
Restructuring or Cognitive Therap* or Colo?r Therap* or Conjoint Therap* or Contingency 
Management or Conversion Therap* or Conversational Therap* or Countertransference or 
Couples Therap* or Covert Sensitization or Crisis Intervention).ti,ab,id,de. 





Psychotherap* or Eclectic Therap* or Emotion* Focus* Therap* or Emotional Freedom 
Technique or Encounter Group Therap* or Existential Therap* or Experiential Psychotherap* 
or Exposure Therap* or Expressive Psychotherap* or Eye Movement Desensiti#ation or 
Family Therap* or Free Association or Geriatric Psychotherap* or Gestalt Therap* or 
Griefwork or Group Psychotherap* or Group Therap* or Guided Image* or Holistic 
Psychotherap* or Humanistic Psychotherap* or Hypnosis or Hypnotherapy or 
Hypnoti#zability or Implosive Therap* or Individual Psychotherap* or Insight Therap* or 
Integrative Psychotherap* or Integrative Therap* or Interpersonal Psychotherap*).ti,ab,id,de. 
53. (Logotherap* or Marathon Group Therap* or Marital Therap* or Meditation or Mental 
Healing or Metacognitive Therap* or Milieu Therap* or Mind train* or Morita Therap* or 
Music Therap* or Narrative Therap* or Nondirective Therap* or Personal Construct Therap* 
or Person Cent* Therap* or Persuasion Therap* or Pet Therap* or Play Therap* or Primal 
Therap* or Problem Solving Therap* or Psychoanalysis or Psychoanalytic Therap* or 
Psychodrama or Psychodynamic Psychotherapy or Psychotherapeutic Counsel* or 
Psychotherapeutic Processes or Psychotherapeutic Training or (Psychotherap* adj3 Rational-
Emotive)) .ti,ab,id,de. 
54. (Rational Emotive Behavio?r Therap* or Reality Therap* or Reciprocal Inhibition 
Therap* or Relationship Therap* or Relaxation Stress Management or Relaxation Technique* 
or Relaxation Therap* or Relaxation Training or Reminiscence Therap* or Role Playing or 
Self Analys* or Self Esteem Building or Sensitivity Training Group* or Sex Therap* or Sleep 
Phase Chronotherap* or Socioenvironmental Therap* or Sociotherap* or Solution Focused 
Therap* or Support Group* or (Support adj3 Psycho*) or Systematic Desensiti#ation or 
Therapeutic Communit* or Transactional Analysis or Validation Therap*).ti,ab,id,de. 
55. or/38-54 
[Antidepressants] 
56. PSYCHOPHARMACOLOGY/ or NEUROPSYCHOPHARMACOLOGY/ 
57. 3340.cc. [Classification Code: Clinical Psychopharmacology] 
58. exp ANTIDEPRESSANT DRUGS/ 
59. NEUROTRANSMITTER UPTAKE INHIBITORS/ or exp SEROTONIN 
NOREPINEPHERINE REUPTAKE INHIBITORS/ or exp SEROTONIN REUPTAKE 
INHIBITORS/ 
60. exp MONOAMINE OXIDASE INHIBITORS/ 
61. exp TRICYCLIC ANTIDEPRESSANT DRUGS/ 
62. (antidepress* or anti depress* or MAOI* or monoamine oxidase inhibit* or ((serotonin or 
norepinephrine or noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or 
dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti 
adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or 
heterocyclic*).ti,ab,id,de. 
63. (Agomelatine or Alnespirone or Amoxapine or Amfebutamone or Amiflamine or 
Amineptine or Amitriptylin* or Amitriptylinoxide or Amoxapine or (Atomoxetine or 
Tomoxetine) or Benactyzine or Brofaromine or Bupropion or Butriptylin* or Cianopramine or 
Cilobamine or Citalopram or (Chlorimipramin* or Clomipramin* or Chlomipramin* or 
Clorimipramine) or Clorgyline or Clovoxamine or (CX157 or Tyrima) or Dapoxetine or 
Deanol or Dibenzepin* or Demexiptilin* or Deprenyl or Desipramine or Desvenlafaxine or 
Dibenzepin or Dimetacrin* or (Dosulepin or Dothiepin) or Doxepin or Duloxetine or DVS-
233 or Enilospirone or Eptapirone or Escitalopram or Etoperidone or Femoxetine or 
Fluotracen or Fluoxetine or Fluparoxan or Furazolidone or Fluvoxamine or Harmaline or 
Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or Imipramin* or Iprindole 
or Iproniazid* or Ipsapirone or Imipraminoxide or Isocarboxazid* or Lesopitron or 
Levomilnacipran or Lithium or Lofepramin* or (Lu AA21004 or Vortioxetine) or Lu 





Mianserin or Milnacipran or Minaprine or Mirtazapine or Moclobemide or Nefazodone or 
Nialamide or Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptyline or 
Noxiptilin* or Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or 
Pipofezin* or Pirandamine or Piribedil or Pirlindole or Pivagabine or Pizotyline or 
Propizepine or (Protriptylin* or Pertofrane) or Quinupramine or Quipazine or Reboxetine or 
Ritanserin or Rolipram or Scopolamine or Selegiline or Sertraline or (Setiptiline or 
Teciptiline) or Tandospirone or Tetrindole or Thiazesim or Thozalinone or Tianeptin* or 
Toloxatone or Tranylcypromine or Trazodone or Trimipramine or 5-Hydroxytryptophan or 5-
HT or Tryptophan or Hydroxytryptophan or Venlafaxine or Viloxazine or Vilazodone or 
Viqualine or Zalospirone or Zimeldine or (Alaproclate or Caroxazone or Diclofensine or 
Fenfluramine)) .ti,ab,id,de. 
64. or/56-63 
[Mood Stabilisers or Antipsychotics] 
65. MOOD STABILIZERS/ 
66. exp ANTICONVULSIVE DRUGS/ 
67. exp NEUROLEPTIC DRUGS/ 
68. ((mood stabili?er*1 or lithium or eslicarbazepine or licarbazepine or valnoctamide or 
carbamazepine or valproate or valproic acid or divalpro* or ziprasidone or gabapentin or 
lamotrigine or topiramate) or (antipsychotic*1 or amisulpride or aripiprazole or asenapine or 
cariprazine or clozapine or haloperidol or iloperidone or lurasidone or olanzapine or 
quetiapin* or paliperidone or prosulpride or risperidone)).ti,ab,id,de. 
69. or/65-68 
70. (9 and (55 or 64 or 69) and 36) 





B – Characteristics of included studies 
 
Gelenberg 2003   
Methods Design: RCT 
Phases: acute (12 weeks), continuation (16 weeks), maintenance (52 weeks) 
Comparison groups: nefadozodone versus placebo 
Funded by: Bristol-Myers Squibb 
Participants Number of participants randomized (NRCT: number of participants 
included): 160 
Criteria for relapse/recurrence: “If depressive symptoms began to emerge, as 
evidenced by a HAM-D-24 score of 16 or greater, another evaluation was 
scheduled within 2 weeks. Evaluations continued every 2 weeks until either 
the symptoms subsided or recurrence criteria were met. Recurrence was 
defined as a HAM-D-24 score of 16 or greater, together with a diagnosis of 
MDD as determined from a DSM-IV MDD checklist administered by the 
independent evaluator, on two consecutive visits. At the second of these 
visits, the recurrence also needed confirmation by each site’s senior 
investigator based on a clinical interview. In addition, because some patients 
had elevated HAM-D-24 scores but did not meet MDD criteria, or 
discontinued before the confirmatory visit, a committee of senior 
investigators conducted a blinded review of all patient data at the end of the 
study. Recurrence was declared if there was consensus among the committee 
that an episode of MDD had occurred. The committee also indicated the date 
of onset of the recurrence. The final definition of time-to-recurrence was 
based on the first recurrence declared by either one of the two methods to 
define recurrence.” (p. 809) 
Age distribution in sample M(SD): nefazodone: 44.4(11.1), placebo: 
44.1(8.4) 
Sex distribution in sample (% female): nefazodone 69.7; placebo 65.5 
Diagnoses in sample: nefazodone: 34.2% chronic major depressive disorder, 
36.8% double depression, 29.0% recurrent depressive disorder without 
complete remission between episodes; placebo: 28.6% chronic major 
depressive disorder, 42.9% double depression, 28.6% recurrent depressive 
disorder without complete remission between episodes 
Depression severity at continuation/maintenance baseline M(SD): HAM-D-
24 nefazodone: 5.9(4.4); placebo: 5.6(4.0) 
Mean age of onset M(SD): nefazodone: 24.1(13.3); placebo: 27.7(12.7) 






Interventions Maintenance treatment (52 weeks) 
Nefazodone (N = 76) 
Name (class and type): nefazodone (SNDRI) 
Planned number of sessions or dosage of drug: 300 to600mg/day 
Number of sessions or dosage of drug M(SD): 485.9(115.6)mg/day 
Placebo (N = 84) 
Name (class and type): placebo 
Planned number of sessions or dosage of drug: / 
Number of sessions or dosage of drug M(SD): 504.0(115.9)mg/day 
Notes: For all medication visits, any formal psychotherapeutic interventions 
were proscribed. Participants in the placebo arm received identical (but 
inactive) tablets without any tapering down between continuation and 
maintenance phase. 
Outcomes 1. Relapse/Recurrence 
2. HAMD-24 mean 
3. Dropout any 
4. Dropout due to adverse events 
Notes Probably conflict of interest because of funding. 
 
 Harrison 1986   
Methods Design: RCT 
Phases: continuation treatment (26.1 weeks) after response to phenelzine 
treatment 
Comparison groups: phenelzine versus placebo 
Funded by: probably internal funding of the authors institution, no 
information given 
Participants Number of participants randomized (NRCT: number of participants 
included): 12 
Criteria for relapse/recurrence: “Patients were considered to have relapsed 
and were withdrawn from the protocol if they scored 3 or more on the CGI 
for 2 consecutive weeks. Patients received a score of 3 on the CGI only if 





Age distribution in sample M(SD): unclear 
Sex distribution in sample (% female): 83.3 
Diagnoses in sample: phenelzine: 20.0% dysthymia, 80.0% double 
depression; placebo: 58.0% dysthymia, 42.0% double depression 
Depression severity at continuation/maintenance baseline M(SD): HAM-D 
phenelzine: 1.8(1.3); placebo: 4.4(3.9) 
Mean age of onset M(SD): unclear 
Length current/last major episode in months M(SD): unclear 
Interventions Continuation treatment (26.1 weeks) 
Phenelzine (N = 5) 
Name (class and type): phenelzine (MOI) 
Planned number of sessions or dosage of drug: unclear 
Number of sessions or dosage of drug M(SD): 51.0(7.4)mg/day 
Placebo (N = 7) 
Name (class and type): pill placebo 
Planned number of sessions or dosage of drug: / 
Number of sessions or dosage of drug M(SD): / 
Notes: The placebo group discontinued phenelzine treatment over a period of 
14 days by tapering the daily dose by 15mg every 2 to 3 days according to a 
predetermined schedule. No information about concomitant treatments. 
Outcomes 1. Relapse/Recurrence 
2. HAM-D mean 
3. Dropout any 
4. Dropout due to adverse event 
5. Experiencing any adverse event (no data available for the placebo group) 
6. Serious adverse events (no data available for the placebo group) 










Hellerstein 2001   
Methods Design: RCT 
Phases: acute (8 weeks), continuation (16 weeks) 
Comparison groups: fluoxetine versus fluoxetine + group psychotherapy 
Funded by: this study was supported by a grant from the Eli Lilly Company. 
Participants Number of participants randomized (NRCT: number of participants 
included): 40 
Criteria for relapse/recurrence: not available 
Age distribution in sample M(SD): 45.1(9.8) 
Sex distribution in sample (% female): 50.0 
Diagnoses in sample: 100% dysthymia 
Depression severity at continuation/maintenance baseline M(SD): HAM-D 21 
fluoxetine: 7.8(4.7); combination: 6.2(4.9) 
Mean age of onset M(SD): unclear 
Length current/last major episode in months M(SD): unclear 
Interventions Continuation treatment (16 weeks) 
Fluoxetine (N = 18) 
Name (class and type): fluoxetine (SSRI) 
Planned number of sessions or dosage of drug: 20 to 80mg/day 
Number of sessions or dosage of drug M(SD): 38.8(18.9) mg/day 
Combination (N = 19) 
Name (class and type): fluoxetine (SSRI) + group psychotherapy (CT/IPT) 
Planned number of sessions or dosage of drug: 20-80mg/day + 16 sessions 
Number of sessions or dosage of drug M(SD): 37.4(17.3) mg/day 
Notes: Participants were not allowed to currently undergo another 
psychotherapy. In the medication group, psychiatrists were instructed not to 
engage in psychotherapy, counseling, or supportive interventions. 
Outcomes 1. HAM-D-21 mean (end of intervention and follow-up) 
2. Dropout any 
3. SWLS (end of intervention and follow-up) 
Notes Possibly conflict of interest (funded by Eli Lilly); discrepant information 
given in text vs. tables; sometimes also unclear/discrepant: information given 







Keller 1998   
Methods Design: RCT 
Phases: acute (12 weeks), continuation (16 weeks), maintenance (76 weeks) 
Comparison groups: sertraline versus placebo 
Funded by: grant from Pfizer (NY) 
Participants Number of participants randomized (NRCT: number of participants 
included): 161 
Criteria for relapse/recurrence: recurrence: DSM-III-R criteria for major 
depression for at least three weeks; CGI severity score of four or more (at 
least moderate severity); CGI improvement score of three or more (minimally 
improved or less); and an increase in HAM-D score of four or more points 
higher than the maintenance baseline; next visit one week later --> in total at 
least four weeks of clinical worsening; additionally: senior investigator 
supporting diagnosis/recurrence (p. 1666/1667) 
Age distribution in sample M(SD): sertraline: 40.8(9.0); placebo: 42.4(9.7) 
Sex distribution in sample (% female): sertraline: 62.3; placebo: 69.0 
Diagnoses in sample: sertraline: 52.0% chronic major depressive disorder, 
48.0% double depression; placebo: 43.0% chronic major depressive disorder, 
57.0% double depression 
Depression severity at continuation/maintenance baseline M(SD): sertraline: 
5.5(4.2); Placebo: 6.3(3.7) 
Mean age of onset M(SD): sertraline: 24.9(11.2); placebo: 25.7(12.5) 
Length current/last major episode in months M(SD): sertraline: 88.2(121.7) 
placebo: 54.9(80.8) 
Interventions Maintenance treatment (76 weeks) 
Sertraline (N = 77) 
Name (class and type): sertraline (SSRI) 
Planned number of sessions or dosage of drug: 50 to 200mg/day 
Number of sessions or dosage of drug M(SD): 146.1mg/day 
Placebo (N = 84) 
Name (class and type): placebo pills 
Planned number of sessions or dosage of drug: unclear 





Notes: Participants in the placebo arm tapered sertraline by 50mg reduction 
per week as placebo substitution. No information about concomitant 
treatments. 
Outcomes 1. Relapse/recurrence 
2. HAM-D-24 mean 
3. Dropout any 
4. SF-36 
5. Dropout due to adverse event 
6. Experiencing any adverse event 
Notes Probably conflict of interest because of funding. 
They used 2 different criteria for relapse/recurrence, we extracted the stricter 
one --> therefore, maybe less relapse observed than actual happened, in 
combination with lots of dropouts --> bias of results? 
“Patients meeting recurrence criteria could continue in the study if both 
patient and study physician agreed that no change in the study medication 
was indicated at that time. Instead, an increase in daily dose was undertaken 
at a rate of 50mg/week up to the maximum daily dose of 200mg of sertraline 
hydrochloride. A similar double-blind titration was also used for patients 
receiving placebo treatment.” (further details see p. 1667) 
 
 Klein 2004   
Methods Design: RCT 
Phases: acute (12 weeks), continuation (16 weeks), maintenance (52 weeks) 
Comparison groups: CBASP versus assessment only 
Funded by: Bristol-Myers Squibb 
Participants Number of participants randomized (NRCT: number of participants 
included): 82 
Criteria for relapse/recurrence: “Recurrence was defined in the protocol as a 
HRSD-24 score of 16 or greater on two consecutive visits and a diagnosis of 
MDD as determined from a DSM–IV MDD checklist administered by the 
independent evaluator. At the second of these visits, the recurrence also 
needed confirmation by the site’s senior investigator on the basis of a clinical 
interview” (p. 683) 






Sex distribution in sample (% female): CBASP: 81.0; assessment only: 52.5 
Diagnoses in sample: CBASP: 50.0% chronic major depressive disorder, 
26.2% double depression, 23.8% recurrent depressive disorder with 
incomplete remission between episodes; assessment only: 60.0% chronic 
major depressive disorder, 20.0% double depression, 20.0% recurrent 
depressive disorder with incomplete remission between episodes 
Depression severity at continuation/maintenance baseline M(SD): HRSD-24 
CBASP: 6.6(3.8); assessment only: 6.2(4.4) 
Mean age of onset M(SD): CBASP: 27.0(12.4); assessment only: 29.5(13.5) 
Length current/last major episode in months M(SD): CBASP: 92.4(115.2); 
assessment only: 85.2(122.4) 
Interventions Maintenance treatment (52 weeks) 
Name (class and type): CBASP 
Planned number of sessions or dosage of drug: 13 
Number of sessions or dosage of drug M(SD): 11.1(3.8) 
Name (class and type): assessment only 
Planned number of sessions or dosage of drug: 13 
Number of sessions or dosage of drug M(SD): unclear 
Notes: “In both conditions, all psychotropic medication and nonprotocol 
psychotherapy were prohibited.” (p. 683) 
Outcomes 1. Relapse/recurrence 
2. HRSD-24 mean 
3. Dropout any 
Notes Probably conflict of interest because of funding. 
 
 Kocsis 1995   
Methods Design: NRCT 
Phases: acute (6 to10 weeks), continuation (16 to 20 weeks), maintenance 
(104,4 weeks) 
Comparison groups: imipramine versus desipramine 
Funded by: no information 
Participants Number of participants randomized (NRCT: number of participants included): 
73 






Age distribution in sample M(SD): 36.0(10.0) 
Sex distribution in sample (% female): 64.1 
Diagnoses in sample: 37.0% dysthymia, 63.0% double depression 
Depression severity at continuation/maintenance baseline M(SD): unclear 
Mean age of onset M(SD): unclear 
Length current/last major episode in months M(SD): unclear 
Interventions Continuation treatment (16 to 20 weeks) 
Impipramine (N = 23) 
Name (class and type): imipramine (TCA) 
Planned number of sessions or dosage of drug: 300mg/day 
Number of sessions or dosage of drug M(SD): unclear 
Sertraline (N = 50) 
Name (class and type): desipramine (TCA) 
Planned number of sessions or dosage of drug: 200mg/day 
Number of sessions or dosage of drug M(SD): 232(72) mg/day 
Notes: “Patients were allowed to remain in stable long-term psychotherapy 
during the study but were not allowed to enter into new psychotherapy 
arrangements.” (p. 214) No data provided about the percentage of participants 
receiving parallel psychotherapy. “Concomitant psychotropic medications 
were proscribed.“ (p. 214) 
Outcomes 1. Dropout any 
2. Dropout due to adverse event 
Notes There were three different treatment arms in the acute treatment, but it is 
unclear how participants were allocated to the different treatment arms, for 
example if there were randomized. Additionally, the rationale of the acute 
treatment is unclear (for example some participants received medication on a 











 Kocsis 1996   
Methods Design: RCT 
Phases: acute (10 weeks), continuation (16 weeks), maintenance (104.4 weeks) 
Comparison groups: desipramine versus placebo 
Funded by: grant from the National Institute of Mental Health 
Participants Number of participants randomized (NRCT: number of participants included): 
53 
Criteria for relapse/recurrence: “Suspected relapse occurred when a HAM-D 
score rose above 12 during the maintenance phase. Clinicians discussed and 
encouraged compliance and obtained a plasma drug level, which was reviewed 
by a nonblind observer who was not involved in the treatment. The nonblind 
observer gave instructions or dummy instructions for dosage adjustments. 
Relapse was defined as HAM-D scores greater than 12 and GAS scores below 
60 on three successive ratings over a period of 4 weeks or at least one rating 
meeting these criteria and an urgent need for alternative treatment for a 
depressive syndrome.” (p. 771) 
Age distribution in sample M(SD): 36.9(9.6) 
Sex distribution in sample (% female): 57.4 
Diagnoses in sample: 10.9% chronic major depressive disorder, 39.5% 
dysthymia, 49.6% double depression 
Depression severity at continuation/maintenance baseline M(SD): unclear 
Mean age of onset M(SD): 12.6(6.9) 
Length current/last major episode in months M(SD): unclear 
Interventions Maintenance treatment (104.4 weeks) 
Desipramine (N = 28) 
Name (class and type): desipramine (TCA) 
Planned number of sessions or dosage of drug: 75 to 350mg/day 
Number of sessions or dosage of drug M(SD): unclear 
Placebo (N = 25) 
Name (class and type): placebo 
Planned number of sessions or dosage of drug: subjects in the placebo group 
were tapered by approximately 25% per week over the month and then 
received identical placebo at the same dose equivalent for the next 23 months 
or until relapse. 
Number of sessions or dosage of drug M(SD): unclear 





during the first month of maintenance treatment followed by receiving 
identical placebo pills. Stable psychotherapeutic treatment was allowed during 
the study, 39% of participants from the desipramine group and 40% of 
participants from the placebo group were in stable psychotherapeutic treatment 
during the study. 
Outcomes 1. Relapse/recurrence 
2. Dropout any 
Notes Desipramine (norpramine) and matching placebo were provided by Marion 
Merrill Dow Inc., Kansas City, Mo. 
 
 Kocsis 2003   
Methods Design: NRCT 
Phases: acute (12 weeks), continuation (16 weeks), maintenance (52 weeks) 
Comparison groups: nefazodone versus CBASP versus combination 
Funded by: Bristol-Myers Squibb 
Participants Number of participants randomized (NRCT: number of participants included): 
329 
Criteria for relapse/recurrence: “Two definitions of relapse were utilized. Any 
patient who scored higher than 15 on the HAM-D was considered at risk for a 
relapse of MDD. In all such cases, an independent evaluator completed the 
DSM-IV criteria checklist for MDD, and if the patient met DSM-IV symptom 
criteria, the treating clinician was notified. A confirmatory visit was scheduled 
within 14 days and the HAM-D and MDD criteria checklist assessment were 
repeated. Patients meeting MDD criteria were evaluated by an independent 
senior investigator to confirm relapse. In addition, an investigator could 
declare a relapse on de facto grounds in the case of an exacerbation of 
depressive symptomatology with marked incapacity and clinically significant 
suicidal ideation, including psychiatric hospitalizations resulting from such 
exacerbations. Patients not meeting relapse criteria but continuing to score 
higher than 15 on the HAM-D were followed every other week until their 
outcome was clarified.” (p. 77) 
Age distribution in sample M(SD): nefazodone: 43.1(9.7); CBASP: 
44.0(10.8); combination: 44.6(9.4) 
Sex distribution in sample (% female): nefazodone: 58.7; CBASP: 66.3; 
combination: 67.8 
Diagnoses in sample: nefazodone: 32.6% chronic major depressive disorder, 
41.3% double depression, 26.1% recurrent depressive disorder with 
incomplete remission between episodes; CBASP: 33.7% chronic major 





disorder with incomplete remission between episodes; combination: 32.2% 
chronic major depressive disorder, 42.1% double depression, 26.6% recurrent 
depressive disorder with incomplete remission between episodes 
Depression severity at continuation/maintenance baseline M(SD): unclear 
Mean age of onset M(SD): nefazodone: 26.3(13.1); CBASP: 28.1(13.5); 
combination: 27.0(12.9) 
Length current/last major episode in months M(SD): nefazodone: 92.4(114.0); 
CBASP: 105.6(144.0); combination: 99.6(120.0) 
Interventions Continuation treatment (16 weeks) 
Nefazodone (N = 91) 
Name (class and type): nefazodone (SNDRI) 
Planned number of sessions or dosage of drug: 300-600mg/day 
Number of sessions or dosage of drug M(SD): 499(115)mg/day 
CBASP (N = 88) 
Name (class and type): CBASP 
Planned number of sessions or dosage of drug: 6 sessions 
Number of sessions or dosage of drug M(SD): 6(1) sessions 
Combination (N = 150) 
Name (class and type): combination (SNDRI+CBASP) 
Planned number of sessions or dosage of drug: 300-600mg/day + 6 sessions 
Number of sessions or dosage of drug M(SD): 479(108)mg/day + 5.9(1.1) 
sessions 
Notes: “Pharmacotherapists were directed not to provide any 
psychotherapeutic interventions.” (p. 76) 
Outcomes 1. Relapse/recurrence 
2. Dropout any 
Notes Probably conflict of interest because of funding and conncection of the authors 











 Koran 2001   
Methods Design: NRCT 
Phases: acute (12 weeks), continuation (16 weeks), maintenance (76 weeks) 
Comparison groups: sertraline versus imipramine 
Funded by: grant from Pfizer (NY) 
Participants Number of participants randomized (NRCT: number of participants included): 
386 
Criteria for relapse/recurrence: “A full remission of depression was defined as 
a CGI improvement score (CGI-I) (Guy, 1976) of 1 or 2 (very much or much 
improved) and a Hamilton Depression Rating Scale score (HRSD) (Hamilton, 
1960) ≤ 7. A satisfactory therapeutic response (partial remission) was defined 
as a CGI-I ≥2, a HRSD ≤ 15 with a ≥ 50% decrease from baseline, and a CGI 
severity score (CGI-S) ≤ 3 (i.e. no more than mild depression). A patient 
whose scores dropped below a ‘satisfactory therapeutic response’ for a 4-week 
period was considered relapsed.” (p. 29) 
Age distribution in sample M(SD): sertraline: 40.2(9.7); imipramine: 43.1(9.6) 
Sex distribution in sample (% female): sertraline: 68.2; imipramine: 57.1 
Diagnoses in sample: sertraline: 49.0% chronic major depressive disorder, 
51.0% double depression; imipramine: 45.0% chronic major depressive 
disorder, 55.0% double depression 
Depression severity at continuation/maintenance baseline M(SD): sertraline: 
6.7(3.7); impramine: 6.9(3.5) 
Mean age of onset M(SD): unclear 
Length current/last major episode in months M(SD): sertraline: 73.2(98.4); 
imipramine: 76.8(114.0) 
Interventions Continuation treatment (16 weeks) 
Sertraline (N = 239) 
Name (class and type): sertraline (SSRI) 
Planned number of sessions or dosage of drug: 50 to 200mg/day 
Number of sessions or dosage of drug: 149(55)mg/day 
Imipramine (N = 147) 
Name (class and type): imipramine (TCA) 
Planned number of sessions or dosage of drug: 50 to 300mg/day 
Number of sessions or dosage of drug: 227(73)mg/day 
Notes: “Psychotherapy was not allowed during the study unless it had started 





all stages of the study without change.” (p. 28) 60% of the participants 
received ongoing psychotherapy during the continuation phase. 
Outcomes 1. Relapse/recurrence 
2. HAM-D-24 mean 
3. Dropout any 
4. Q-LES-Q score 
5. Dropout due to adverse event 
Notes Probably conflict of interest because of funding (authors = members of 
industry who financed study). 
Further randomized comparison on maintenance treatment of the sertraline 
group with placebo in the publication of Keller (1998). 
 
 Miller 2001   
Methods Design: RCT 
Phases: acute (10 to 12 weeks), continuation (16 weeks), maintenance (104.4 
weeks) 
Comparison groups: desipramine versus placebo 
Funded by: Supported by grant R01-MH37103 from the National Institute of 
Mental Health and from a fund established in the New York Community 
Trust by DeWitt-Wallace. 
Participants Number of participants randomized (NRCT: number of participants 
included): 27 
Criteria for relapse/recurrence: “Recurrence was defined as HAM-D scores > 
12 and GAS scores < 60 on three successive ratings over a period of 4 weeks 
or at least one rating meeting theses criteria and an urgent need for alternative 
treatment for recurrence of depressive symptoms.” (p. 233) 
Age distribution in sample M(SD): desipramine: 34.4(9.6), placebo: 
39.0(11.2) 
Sex distribution in sample (% female): desipramine: 43.0, placebo: 46.0 
Diagnoses in sample: 100% dysthymia 
Depression severity at continuation/maintenance baseline M(SD): 
desipramine: 3.1(2.5), placebo: 3.9(5.2) 
Mean age of onset M(SD): desipramine: 14.5(10.4), placebo: 12.3(8.0) 





Interventions Maintenance treatment (104.4 weeks) 
Desipramine (N = 14) 
Name (class and type): desipramine (TCA) 
Planned number of sessions or dosage of drug: unclear 
Number of sessions or dosage of drug M(SD): 223(90)mg/day 
Placebo (N = 13) 
Name (class and type): placebo 
Planned number of sessions or dosage of drug: unclear 
Number of sessions or dosage of drug M(SD): 240(60)mg/day (dummy 
dosage) 
Notes: Participants in the placebo arm were tapered down by 25% per week 
during the first month of maintenance treatment followed by receiving 
identical placebo pills. 43% of participants from the DMI group and 38% of 
participants from the placebo group were in stable long-term psychotherapy 
during the study, a nonsignificant difference. 
Outcomes 1. Relapse/recurrence 
Notes Analysis of the dysthymic subgroup of Kocsis et al 1996 and some additional 









 Coding system to assess interventions of relapse prevention in depression 
 
 
Date _________________________________                       Name of rater _________________________ 
 
 
Mark/number of the video ___________________             Therapy session__________________________ 
 
 
Quality of sound:                       
 
                                   The therapist could be heard clearly                                                         ☐             ☐            ☐     
 
 
                                   The patient could be heard clearly                                                           ☐             ☐            ☐     
 





1. Aspects of self-care 
 
a. Individual self-care activities are discussed 
 
 
b. Individual patient resources are discussed 
 
 
☐    ☐     ☐     ☐     ☐ 
 
☐    ☐     ☐     ☐     ☐ 
 
2. Implementation of self-care 
 
 




b. Specific difficulties in practicing and maintaining self-care are discussed 
 
 
c. Specific options for monitoring/evaluating self-care are discussed 
☐    ☐     ☐     ☐     ☐ 
 
   
☐    ☐     ☐     ☐     ☐ 
 
  
☐    ☐     ☐     ☐     ☐ 
   
 
 
B. Early warning signs 
 
1. Aspects of early warning signs  
a. Individual early warning signs (Cognition, Emotion, Somatization, Behavior) are 
discussed 
☐    ☐     ☐     ☐     ☐ 
     
2. Dealing with early warning signs  
a. Specific methods to monitor and recognize early warning signs are discussed 
 
 
b. Specific strategies for dealing with early warning signs are discussed 
 
 
c. Specific difficulties in implementing the strategies are discussed 
☐    ☐     ☐     ☐     ☐ 
☐    ☐     ☐     ☐     ☐ 
  







A little Moderately Considerably Thoroughly Not at all 






C. Triggering events and situations 
 
 
1. Aspects of triggering events and situations  
a. Individual triggering events and situations are discussed ☐    ☐     ☐     ☐     ☐ 
 
 
2. Dealing with triggering events and situations  
 
a. Specific strategies to prepare for triggering events and situations are discussed 
 
 
b. Specific difficulties in implementing the strategies are discussed 
 
 
c. Individual symptoms of a relapse and/or an emergency kit/plan for reacting to a relapse 
are discussed  
 
 
☐    ☐     ☐     ☐     ☐ 
 
 
☐    ☐     ☐     ☐     ☐ 
 




D. Termination of therapy and planning next steps 
 
1. Aspects of termination of therapy  
 
 
a. The patient’s most important findings during therapy and/or achievements are discussed 
 
b. The patient’s personal life goals are discussed 
 
c. The patient’s emotions and cognitions on terminating therapy are discussed 
 
☐    ☐     ☐     ☐     ☐ 
 
☐    ☐     ☐     ☐     ☐ 
 
☐    ☐     ☐     ☐     ☐ 
 
 
2. Dealing with the termination of therapy 
 
 
a. Options for contacting the therapist after terminating therapy are discussed 
 
b. Concrete options for continuing treatment are discussed 
☐    ☐     ☐     ☐     ☐ 
☐    ☐     ☐     ☐     ☐ 
 
 
3. Importance of dealing with potential relapse(s) 
 
 
a. The chance of a relapse and/or the significance of relapse prevention are discussed ☐    ☐     ☐     ☐     ☐ 
                
  
 
 Overall impression of the whole session: Transfer  
 
From the therapist: The extent to which the therapist discusses (category A to D) topics in such 
a way that the patient is encouraged to implement and sustain skills, knowledge or 
competences gained in therapy into their daily routine and in the long run. 
 
☐    ☐     ☐     ☐     ☐ 
                









Kodierbogen zur Erfassung Rückfallprophylaktischer Interventionen bei Depression – KERI-D 
 
 
Datum _________________________________                       Name des Raters_________________________ 
 
 
Kennzeichen des Videos ___________________                      Therapiesitzung__________________________ 
 
 
Tonqualität:                       
 
                                   Der Therapeut war akustisch gut  zu verstehen                                  ☐             ☐            ☐     
 
 
                                   Der Patient war  akustisch gut  zu verstehen                                       ☐             ☐            ☐     
 





3. Aspekte von Selbstfürsorge 
 
c. Es werden individuelle Aktivitäten zur Selbstfürsorge intensiv thematisiert. 
 
 
d. Es werden individuelle Ressourcen des Patienten intensiv thematisiert. 
 
 
☐    ☐     ☐     ☐     ☐ 
 
☐    ☐     ☐     ☐     ☐ 
 
4. Durchführung von Selbstfürsorge 
 
 
d. Es werden konkrete Rahmenbedingungen oder Hilfsmittel zur Durchführung der 
Selbstfürsorge intensiv thematisiert.   
 
e. Es werden konkrete Schwierigkeiten bei der Durchführung und Aufrechterhaltung der 
Selbstfürsorge intensiv thematisiert.  
 
f. Es werden konkrete Möglichkeiten der Evaluation von Selbstfürsorge intensiv 
thematisiert. 
☐    ☐     ☐     ☐     ☐ 
 
   
☐    ☐     ☐     ☐     ☐ 
 
  
☐    ☐     ☐     ☐     ☐ 





3. Aspekte der Frühwarnsignale  
b. Es werden individuelle Frühwarnsignale (Kog., Emo., Som., Ver.) intensiv thematisiert.  ☐    ☐     ☐     ☐     ☐ 
     
4. Umgang mit Frühwarnsignalen  
d. Es werden konkrete Methoden intensiv thematisiert, wie Frühwarnsignale beobachtet 
und erkannt werden können. 
 
e. Es werden konkrete Strategien zum Umgang mit Frühwarnsignalen intensiv thematisiert. 
 
 
f. Es werden konkrete Schwierigkeiten bei der Anwendung der Strategien intensiv 
thematisiert. 
☐    ☐     ☐     ☐     ☐ 
   
  
☐    ☐     ☐     ☐     ☐ 
  







nicht  zu 
Trifft  









nicht  zu 
Trifft  
















C. Depressionsauslösende Ereignisse und Situationen 
 
 
3. Aspekte depressionsauslösender Ereignisse und Situationen  
b. Es werden individuelle depressionsauslösende Ereignisse und Situationen intensiv 
thematisiert. 
☐    ☐     ☐     ☐     ☐ 
 
 
4. Umgang mit depressionsauslösenden Ereignissen und Situationen  
 
d. Es werden konkrete Strategien zur Vorbereitung auf depressionsauslösende Ereignisse 
und Situationen intensiv thematisiert. 
 
e. Es werden konkrete Schwierigkeiten bei der Anwendung der Strategien intensiv 
thematisiert. 
 
f. Es werden individuelle Merkmale eines Rückfalls und / oder der Notfallplan, als 
Hilfsmittel zur Reaktion auf einen Rückfall, intensiv thematisiert. 
 
 
☐    ☐     ☐     ☐     ☐ 
 
 
☐    ☐     ☐     ☐     ☐ 
 




D. Therapieabschluss und Zukunftsperspektive 
 
4. Aspekte des Therapieabschlusses  
 
 
d. Die wichtigsten persönlichen Erkenntnisse der Therapie und / oder Erfolge des Patienten 
werden intensiv thematisiert. 
 
e. Persönliche Lebensziele des Patienten werden intensiv thematisiert. 
 
f. Mit dem Therapieabschluss verbundene Emotionen oder Kognitionen des Patienten 
werden intensiv thematisiert. 
 
☐    ☐     ☐     ☐     ☐ 
 
☐    ☐     ☐     ☐     ☐ 
 
☐    ☐     ☐     ☐     ☐ 
 
 
5. Umgang mit Therapieabschluss 
 
 
c. Die Möglichkeit des Kontaktes zum Therapeuten nach Therapieende wird konkret 
thematisiert. 
 
d. Es werden konkrete weiterführende Angebote intensiv thematisiert. 
☐    ☐     ☐     ☐     ☐ 
   
 
☐    ☐     ☐     ☐     ☐ 
 
 
6. Relevanz der Auseinandersetzung mit der Zukunft 
 
 
b. Die Möglichkeit eines Rückfalls und / oder die Bedeutsamkeit der Rückfallprophylaxe 
wird intensiv thematisiert. 
☐    ☐     ☐     ☐     ☐ 
                
  
 
 Gesamteindruck: Transfer & Langfristigkeit 
 
Therapeutenangebot: Der Therapeut bearbeitet die Inhalte der Therapiesitzung in einer 
Weise, dass ein Transfer von der Therapie in den Alltag des Patienten nach Therapieende 
ermöglicht wird und gleichzeitig auch auf eine langfristige Wirkung abgezielt wird.  
 
☐    ☐     ☐     ☐     ☐ 
                
Trifft  









nicht  zu 
Trifft  
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